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 Abstract 
Nanotechnology offers exciting options for the site-selective delivery of chemotherapeutics 
and diagnostic agents using nanoparticles. Varieties of organic and inorganic nanomaterials have 
been explored extensively as a delivery system either in the form of drug carriers or imaging agents. 
Successful stories include the clinical translation of anticancer nanomedicines such as PEGylated 
liposomal doxorubicin (DOXIL®), albumin-bound paclitaxel (Abraxane®), and polymeric micelle 
loaded paclitaxel (Genexol®), which are currently used in the clinic as one of the first lines for cancer 
chemotherapies. These conventional nanomedicines rely on passive-drug targeting taking advantage 
of leaky tumor vasculature, called the Enhanced Permeability and Retention (EPR) effect. However, 
delivering biologically active components selectively to the diseased cell, for example, cancer, is 
highly challenging due to the biological barriers in the body including blood pool cells/proteins, 
heterogeneous microenvironment, and intracellular degradation. Therefore, the goal of this 
dissertation is to develop nanoplatforms that can deliver the agents of interest in targeted fashion to 
cancer while bypassing or collaborating with the biological barriers. The design consideration of 
these nanoplatforms centralizes on using simple chemical reactions and cell biology to engineer 
nanoparticles. The presented nanoparticles were extensively studied and evaluated for their 
biological functions using in vitro and in vivo models. These nanoconstructs described herein address 
current limitations of conventional nanomedicine such as (1) the lack of understanding of the 
interaction of nanoparticle and biological system, and (2) the lack of an effective targeting strategy 
to deliver drugs to the cancer cell in the tumors. The significant findings of each system will be 
highlighted and discussed throughout this dissertation.  Results obtained highlight key findings such 
as nanoparticle intracellular fate, maximized tumor accumulation, and unique pharmacokinetics 
could open the avenues for systemic investigations for personalized medicine and lay the foundation 
for nanomedicine design to accelerate clinical translation.  
 Engineering nanoparticles using chemical and biological approaches for tumor targeted delivery 
 
 
by 
 
 
Tuyen Duong Thanh Nguyen 
 
 
 
 
B.Sc., Cantho University, Vietnam, 2014 
 
 
A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
 
Department of Chemistry 
College of Arts and Sciences 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2019 
 
 
 Approved by: 
 
Major Professor 
Prof. Santosh Aryal 
  
 Copyright 
©Tuyen Duong Thanh Nguyen 2019. 
 
 
  
 Abstract 
Nanotechnology offers exciting options for the site-selective delivery of chemotherapeutics 
and diagnostic agents using nanoparticles. Varieties of organic and inorganic nanomaterials have 
been explored extensively as a delivery system either in the form of drug carriers or imaging agents. 
Successful stories include the clinical translation of anticancer nanomedicines such as PEGylated 
liposomal doxorubicin (DOXIL®), albumin-bound paclitaxel (Abraxane®), and polymeric micelle 
loaded paclitaxel (Genexol®), which are currently used in the clinic as one of the first lines for cancer 
chemotherapies. These conventional nanomedicines rely on passive-drug targeting taking advantage 
of leaky tumor vasculature, called the Enhanced Permeability and Retention (EPR) effect. However, 
delivering biologically active components selectively to the diseased cell, for example, cancer, is 
highly challenging due to the biological barriers in the body including blood pool cells/proteins, 
heterogeneous microenvironment, and intracellular degradation. Therefore, the goal of this 
dissertation is to develop nanoplatforms that can deliver the agents of interest in targeted fashion to 
cancer while bypassing or collaborating with the biological barriers. The design consideration of 
these nanoplatforms centralizes on using simple chemical reactions and cell biology to engineer 
nanoparticles. The presented nanoparticles were extensively studied and evaluated for their 
biological functions using in vitro and in vivo models. These nanoconstructs described herein address 
current limitations of conventional nanomedicine such as (1) the lack of understanding of the 
interaction of nanoparticle and biological system, and (2) the lack of an effective targeting strategy 
to deliver drugs to the cancer cell in the tumors. The significant findings of each system will be 
highlighted and discussed throughout this dissertation.  Results obtained highlight key findings such 
as nanoparticle intracellular fate, maximized tumor accumulation, and unique pharmacokinetics 
could open the avenues for systemic investigations for personalized medicine and lay the foundation 
for nanomedicine design to accelerate clinical translation
vi 
 
Table of Contents 
Table of Contents ........................................................................................................................... vi 
List of Figures .............................................................................................................................. viii 
List of Tables .................................................................................................................................. x 
Acknowledgments.......................................................................................................................... xi 
Dedication ..................................................................................................................................... xii 
Chapter 1 - Introduction .................................................................................................................. 1 
1.1 The concept of “Nanomedicine” ..................................................................................... 1 
1.1.1 Nanotherapeutics for treatment of disease .................................................................. 2 
1.1.2 Nanodiagnostics for early disease detection ............................................................... 4 
1.2 Biological barriers for nano-delivery system .................................................................. 5 
1.2.1 Protein blood opsonization and reticuloendothelial system sequestration ................. 5 
1.2.2 Tumor-microenvironment ........................................................................................... 6 
1.2.3 Intracellular environment ............................................................................................ 9 
1.3 Scope of dissertation ....................................................................................................... 9 
1.3.1 Central objective ....................................................................................................... 10 
1.3.2 Chemistry approach .................................................................................................. 11 
1.3.3 Biology approach ...................................................................................................... 11 
Chapter 2 - Engineering nanomedicine with Alendronic acid corona improves targeting to 
Osteosarcoma ......................................................................................................................... 13 
2.1 Introduction ................................................................................................................... 14 
2.2 Materials and Methods .................................................................................................. 18 
2.3 Results and discussion .................................................................................................. 23 
2.4 Conclusion .................................................................................................................... 35 
Chapter 3 - Nano-confinement driven enhanced magnetic relaxivity of SPIONs for targeted 
tumor bioimaging ................................................................................................................... 37 
3.1 Introduction ................................................................................................................... 38 
3.2 Materials and Methods .................................................................................................. 41 
3.3 Results and Discussions ................................................................................................ 47 
3.4 Conclusion .................................................................................................................... 59 
vii 
 
Chapter 4 - Biomimetic Natural Killer Membrane Camouflaged Polymeric Nanoparticle for 
Targeted Bioimaging ............................................................................................................. 60 
4.1 Introduction ................................................................................................................... 61 
4.2 Materials and Methods .................................................................................................. 63 
4.3 Results and Discussion ................................................................................................. 71 
4.4 Conclusion .................................................................................................................... 84 
Chapter 5 - Red Blood Cell Membrane Disguised Paramagnetic Polymeric Nanoparticle for 
Contrast Enhanced Magnetic Resonance Imaging ................................................................ 85 
5.1 Introduction ................................................................................................................... 86 
5.2 Materials and Methods .................................................................................................. 89 
5.3 Result and Discussion ................................................................................................... 98 
5.4 Conclusion .................................................................................................................. 115 
Chapter 6 - Summary and Future Outlook .................................................................................. 116 
References ................................................................................................................................... 118 
Appendix A - Supporting information of Chapter 3 ................................................................... 139 
Appendix B - Supporting information of Chapter 4 ................................................................... 147 
Appendix C - Supporting information of Chapter 5 ................................................................... 156 
Appendix D - List of Abbreviation ............................................................................................. 165 
Appendix E - List of publications ............................................................................................... 168 
Appendix F - Copyright permissions .......................................................................................... 170 
  
viii 
 
List of Figures 
Figure 1.1 The progress in the development of nanomedicine ....................................................... 2 
Figure 1.2 Schematic demonstrates the physiology of solid tumor ................................................ 7 
Figure 1.3 Scope of the dissertation for developing nanomaterials .............................................. 10 
Figure 2.1 Design of proposed bone targeted nanoconstruct. ....................................................... 17 
Figure 2.2 Chemical characterization of synthesized ALE-lipid.. ................................................ 24 
Figure 2.3 Characterization of TNPs. ........................................................................................... 26 
Figure 2.4 TNP’s interaction with Hydroxyapatite (HAp) ........................................................... 29 
Figure 2.5 Drug loading and release study.. ................................................................................. 30 
Figure 2.6 Cellular internalization study. ..................................................................................... 32 
Figure 2.7 Cellular cytotoxicity studies. ....................................................................................... 34 
Figure 3.1 Schematic represents the preparation process of HNC ............................................... 40 
Figure 3.2 Physicochemical characterization of targeted HNC. ................................................... 49 
Figure 3.3 Controlling SPION cluster density.. ............................................................................... 51 
Figure 3.4 Confinement driven relaxivity enhancement.. ................................................................ 53 
Figure 3.5 In vitro cellular studies. ............................................................................................... 56 
Figure 3.6 Ex vivo study................................................................................................................ 58 
Figure 4.1 Design of Biomimetic nanoconstructs......................................................................... 63 
Figure 4.2 Model diagram for two compartments. ....................................................................... 70 
Figure 4.3 BNc physicochemical properties. ................................................................................ 72 
Figure 4.4 Protein characterization of BNc. ................................................................................. 74 
Figure 4.5 Stability and gadolinium loading/release characteristics of BNc. ............................... 75 
Figure 4.6 Magnetic properties of BNc.. ...................................................................................... 76 
Figure 4.7 In vitro cellular studies. ............................................................................................... 77 
Figure 4.8. In vitro immunogenicity of BNc in THP‐1 cells ........................................................ 79 
Figure 4.9 In vivo tumor-targeting ability of BNc ........................................................................ 80 
Figure 4.10 In vivo pharmacokinetics and magnetic resonance imaging studies. ........................ 82 
Figure 5.1 Design and characterization of RBC-Gd-PLGA. ...................................................... 100 
Figure 5.2. Protein characterization of RBC-Gd-PLGA. ............................................................ 102 
Figure 5.3 Gadolinium loading and release study. ..................................................................... 104 
ix 
 
Figure 5.4 Magnetic properties of RBC-Gd-PLGA at 3T. ......................................................... 106 
Figure 5.5. In vitro macrophage uptake study. ........................................................................... 108 
Figure 5.6. In vitro biocompatibility studies. .............................................................................. 111 
Figure 5.7 In vivo pharmacokinetics and magnetic resonance imaging studies. ........................ 113 
Figure 5.8 In vivo time-dependent T1 weighted magnetic resonance image of mice ................. 114 
Figure A.1 Synthesis scheme of ALE conjugate lipid ................................................................ 139 
Figure A.2 Physicochemical properties of superparamagnetic iron oxide nanoparticles. .......... 140 
Figure A.3 Stability of different formulation of HNC in ionic condition (PBS) ........................ 142 
Figure A.4 MR decay curve of 4 different kinds of SPIOs nanocluster ..................................... 143 
Figure A.5 Confocal images of K7M2 cells incubated with RhB labeled HNC ........................ 144 
Figure A.6 Cellular uptake of HNC quantified by ICP-MS. ...................................................... 145 
Figure A.7 Ex vivo MR images of tumor bearing mouse ........................................................... 146 
Figure B.1 Confocal laser scanning micrograph of cellular uptake of BNc ............................... 147 
Figure B.2 Ex vivo MRI images of MCF-7 tumor bearing mouse.............................................. 148 
Figure B.3 Model fit to the percentage injected dose using two compartmental ....................... 155 
Figure C.1 Synthesis of DSPE-DOTA-Gd and its corresponding molecular analysis ............... 156 
Figure C.2 Optimize coating RBC coating condition ................................................................. 157 
Figure C.3 Stability of RBC-PLGA and RBC-Gd-PLGA .......................................................... 158 
Figure C.4 TEM analysis for core diameter and shell thickness of RBC-Gd-PLGA ................. 159 
Figure C.5.Stability of RBC-PLGA and RBC-Gd-PLGA under physiological condition ......... 160 
Figure C.6 Plasma RBC-Gd-PLGA concentrations in natural logarithmic scale. ...................... 163 
 
  
x 
 
List of Tables 
Table 2.1. IC50 of free DOX and DOX loaded TNPs on K7M2 cells. ........................................ 35 
Table 4.1 Physicochemical characteristics of BNc. ...................................................................... 73 
Table 4.2 Pharmacokinetic parameters of BNc injected NU/NU mice. ....................................... 83 
Table A.1 Physicochemical properties of HNCs with different SPIONs ................................... 141 
Table C.1 In vitro macrophage uptake study of PEGylated, PLGA and RBC-Gd-PLGA NPs . 161 
Table C.2 T1 relaxation time of RBC-Gd-PLGA........................................................................ 162 
Table C.3 Pharmacokinetic parameters of RBC-Gd-PLGA ....................................................... 164 
 
  
xi 
 
Acknowledgments 
Being a Ph.D. student at K-State has been exciting as well as a challenging experience for 
me. During these years, many people have directly, indirectly, and in different ways, been a part 
of my journey, and encouraged and supported me along the way.  
Foremost, I would like to express my special thanks to my advisor, Prof. Santosh Aryal; 
you have been a tremendous mentor for me. I would like to thank you for encouraging in my 
research and for teaching me how to become a research scientist. Your advice on my research and 
career development has been invaluable. You have set up a great example of who I want to become 
in the future. 
I would also like to thank my committee members, Prof. Stefan Bossmann, Prof. Mark 
Weiss, Prof. Jun Li, and Prof. Ryan Rafferty for serving as my committee. I am also grateful to 
Prof. Deryl Troyer who was one of my former committee members. I highly appreciate your 
guidance and support throughout my Ph.D. program. The valuable discussion with you has helped 
me to shape my research trajectory and diversify my way of thinking.   
I would especially like to thank my former and current colleagues, Dr. Arunkumar 
Pitchaimani, Dr. Meghana Ramani, Mukund Koirala, Soma Sekhar Sriadibhatla, Ramesh 
Marasini, Sagar Rayamajhi, Colin Ferrel, Jessica Marchitto, Javier Abello, Achini Eliyapura, 
Cesar Aparicio, my friends, faculties, and staffs at Department of Chemistry and Nanotechnology 
Innovation Center of Kansas State University. I am such a lucky girl that I have many special 
people surrounding me and supporting me in all aspects. Thank you, everyone, for being in my 
life, making it become so meaningful, and making every bit of my Ph.D. life so special. I am 
grateful to have all of you around.  
Most importantly, I would like to express my special thanks to my family. Words are not 
enough to express how grateful I am to you, Mom and Dad, for all of the love that you have for 
me. Thank you for supporting me, believing in me, and encouraging me in this journey. To my 
beloved sister, Thi Nguyen, you were the one who opened this door for me, gave me the 
opportunity so that I can become who I am now. I am so lucky to have you there, love me 
unconditionally, and take care of me on every step that I go. As promised, I will be your elder 
sister in the next life. Finally, I would like to thank all my family members, friends (there are a 
long list), and well-wishers for their support through this program.  
xii 
 
Dedication 
To my mentor 
Dr. Santosh Aryal 
To my dad and mom 
Thien Xuan Nguyen and Tuyet Thi Bach Duong 
To my beloved sister 
Dr. Thi Duong Thanh Nguyen 
Without whom this day would never come. 
 
 
  
1 
Chapter 1 - Introduction 
1.1 The concept of “Nanomedicine” 
In 1966, a movie named “Fantastic Voyage” presented a fantasy concept of miniaturizing 
submarine crews and sending them into a body to dissolve a life-threatening blood clot in the brain. 
At that time, the concept was just some kind of filmmakers’ imagination as millions of other 
Hollywood movies. They would never have thought that the “miniaturizing” idea for treatment of 
disease would someday become the foundation of an exciting research area with a rocket rate of 
development called “nanomedicine”. By definition, nanomedicine is a branch of nanotechnology, 
where the materials in sub 100 nm are investigated for possible prophylactic, diagnostic, and 
therapeutic applications.1 The ability to get smaller in size offers new opportunities to reveal 
exceptional properties of materials and the capability of manipulating individual atoms and 
molecules.  
Thirty years after the “Fantastic Voyage”, the first nanomedicine was approved by FDA 
under the name of DOXIL®, a polyethylene glycolated (PEGylated) liposomal doxorubicin (DOX, 
a clinical anticancer drug). The use of DOXIL® in cancer treatment has shown significant 
improvement in diminishing DOX-related cardiotoxicity, enhancement of drug tolerability, and 
extending overall pharmacokinetic profile in comparison to that of free DOX. Followed by the 
first successful story, other nanomedicines comprised of protein (Abraxane®), polymer 
(Genexol®), crystal (Emend®), and inorganic components (NanoTherm®) made their ways to the 
clinics.2 To date, various nanomedicines have been developed and commercially available in both 
clinical and non-clinical areas. Within the USA, more than 50 nanomedicines were approved along 
with hundreds of other nanoformulations entering various stages of clinical trials (Figure 1.1).2–4  
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Figure 1.1 The progress in the development of nanomedicine (collected from ref. 5 and 6)   
 
The attractive features of nanomedicine can be accountable for its versatility of modification 
with a variety of ligands, ability to incorporate both water-soluble/insoluble molecules, the 
capability of tuning the pharmacokinetic/pharmacodynamics of active components, and the 
opportunity of combining diagnostics with therapy in a single setting to achieve precision 
medicine. Varieties of organic and inorganic nanomaterials have been extensively explored as 
nanomedicine, and they can mainly be divided into two main areas including nanotherapeutics and 
nanodiagnostics. These two outstanding areas are further forwarded in recent years to explore their 
combination capabilities to form a multifunctional nanomedicine called theranostics. 
1.1.1 Nanotherapeutics for treatment of disease 
One of the biggest interest in exploring the area of nanomedicine is to design a nano-sized 
drug delivery system for the treatment of diseases. The idea of having a “magic bullet”, that can 
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(1) protect the active ingredient from degradation while traveling in the body and (2) be able to 
deliver its cargo precisely to the site of action while avoiding off-target effects, has always been 
an ultimate goal of researcher across the field. Most of the conventional drugs, when injected into 
the body, exhibit a short circulation time due to their small molecular structures. As a consequence, 
free drug molecules are often excreted out from the body before they can reach the intended site 
with the effective therapeutic concentration. The use of a nano-sized carrier for free drug provides 
an innovative mean of transportation to pass through the traffic jam in the biological system and 
overcome the shortcomings of conventional formulations. An example can be seen in the case of 
DOXIL, when free DOX is crystallized and enveloped in a lipid bilayer vesicle with polyethylene 
glycol decorated outside, the circulation half-life increases from 5 mins to 55 h.6  
Another aspect that makes nanotherapeutics becoming a “hot” topic, especially in cancer 
therapy, is driven by the discovery of the “enhanced permeability and retention” (EPR) effect in 
solid tumor. The EPR phenomenon arises due to the ability to develop a new vascular system in 
the tumor to enhance the sources of blood and nutrition supply for cancer progression.7 
Consequently, blood vessels in the solid tumor are often highly disorganized and abnormal with 
unaligned endothelial cells, lack of smooth muscle layer, and poor lymphatic drainage.7 These 
unique properties of tumor allow intravenously injected long-circulating nanoparticle to permeate 
and be retained within the tumor region. The first observation of EPR effect was reported by 
Matsumura and Maeda in which the injection of high molecular weight protein-polymer-dye 
complex revealed an extensive accumulation in cancer tissue and slower recovery via blood vessel 
and lymphatic system in compare to normal tissue when the molecular weight of complex increase 
from 15,000 to 70, 000 Da.8 As a result, the ratio of concentration of high molecular weight 
complex in tumor to blood (T/B) could go up to 5, whereas its counterpart’s T/B ratio never 
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reached to 1.8 Since then, the EPR effect stood out as a lodestar in designing nanosized drug 
delivery system. With the demonstrated success in various tumor models, EPR effect has now been 
widely accepted as a passive targeting strategy to deliver drugs or any kind of cargos to the solid 
tumor when non-targeted nanoparticles are used as carriers. 
1.1.2 Nanodiagnostics for early disease detection 
It is a common thought that improved patient outcomes rely on how early and precisely the 
diagnosis and treatment of a disease can be. To date, medical imaging has become an essential tool 
for clinical practitioners to assess disease pathology based on anatomical or functional evaluations. 
As the need of diagnostic imaging has grown significantly in treatment planning, a variety of 
imaging technologies such as positron emission tomography (PET), computed tomography (CT), 
optical imaging, magnetic resonance imaging (MRI), X-ray, and ultrasound are becoming routine 
procedures in the clinics.9 Aligning with the development of imaging modalities, a wide range of 
small molecules and molecular complexes used as tracer or contrast agents are also maturing and 
diversifying over time. These contrast agents or imaging tracers are employed to assist the 
conventional imaging modality for a clearer visualization of abnormality allowing the diagnosis 
of previously undetectable pathologies. The advantages of using imaging probes are further pushed 
forth by incorporating into nanosized materials with the hope of continuing the improvement in 
sensitivity, stability, and plasma residence times as compared to that of small molecules.  
The benefits of using a nanomaterial-based imaging probe have been well-documented in a 
wide range of imaging modalities.10–13 For example, when thousands of iron oxide molecules 
clustering and rearranging to form iron oxide nanocrystals, it becomes strongly paramagnetic to 
use as MR active agent. Moreover, the confinement of this small molecule or particulate contrast 
agent in the second stage nanoparticle system provides enhancement in contrast as well as an 
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increase in targeting specificity. For an instant, tiny iron oxide nanoparticles when confined into 
sub 100 nm polymeric matrix enhance an order of magnitude of its magnetic relaxivity, which will 
help on reducing the dose thereby reducing associated toxicity.14 Gao et. al. encapsulated 
superparamagnetic iron oxide nanoparticles into the polymeric micelles to enhance the imaging 
efficacy of tumor biomarker in vivo.15 Similarly, gadolinium (Gd)-based contrast agent in 
mesoporous silica nanoparticles is reported to be effective in enhancing contrast.16 In some other 
cases, the incorporation of gadolinium-based macromolecules into a liposomal system assist the 
brighter contrast compared to that of the small molecule counterpart via altering water tumbling 
mechanism.17,18,16  
1.2 Biological barriers for nano-delivery system 
1.2.1 Protein blood opsonization and reticuloendothelial system sequestration 
Despite their potential in the pre-clinical trial, the therapeutic impact of the nanomaterial-
based delivery system in the clinic remains modest due to the complexity of the biological 
environment. One of the first obstacles that nanoparticle encounters upon administration is the 
opsonization and the formation of protein corona.19 The interaction with these endogenous 
materials alters the designed properties of nanoparticle preventing them from performing their 
desired tasks in physiologically relevant condition. In 2013, Tenzer and coworkers identified the 20 
most abundant corona proteins that rapidly form onto the surface when silica and polystyrene 
nanoparticles are treated with human plasma.20 The constituents of corona highly depend on the 
physicochemical properties (size, surface chemistry, shape) of nanoparticles, but they all share 
common proteins including serum albumin, apolipoproteins, complement proteins, and antibodies. 
The formation of protein corona subsequently conceals the targeting ligands presence on the 
surface of the nanoparticle and ultimately change its pharmacokinetic behavior. An example can 
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be seen when transferrin (a transferrin receptor targeting ligand) functionalized silica nanoparticle 
was used to study the targeting efficiency toward lung cancer cell (A549).21 The result indicated 
that no matter if polyethylene glycol (a polymer that is believed to minimize the formation of 
protein corona) was used or not, the targeting specificity of all nanoparticle formulations toward 
corresponding receptors on A549 cells was lost upon the exposure to biological serum.21 In the 
case of nanodiagnostics, the binding of protein is more severe as it is also responsible for causing 
fluorescent quenching effect in optical imaging modality,22,23 reducing relaxivity of MRI contrast 
agent due to metal displacement competition with endogenous ions,24,25 and accelerating the decay 
rate of nuclei in PET.26  
Following the formation of protein corona, nanoparticles exhibit a new biological identity 
which is far different than its original synthetic characteristic. As a consequence, nanoparticle‘s 
unexpected biological events are initiated due to the recognition of resident macrophages of the 
mononuclear phagocyte system (MPS). The sequestration by MPS results in high accumulation of 
nanoparticles in organs, such as the spleen and the liver, preventing it to navigate to the targeted 
location successfully. More than 31.30% of targeted and 62.33% non-targeted gold nanoparticles 
(55nm) injected dose were found in reticuloendothelial system organ such as liver.27 With this 
excessive excretion phenomenon, just 0.7%  of injected nanoparticle dose could make its way to 
solid tumor as reveal in a meta-analysis of literature related to nanoparticle-based drug carriers 
conducted by Wilhelm et al.28  
1.2.2 Tumor-microenvironment 
Once the remaining small portion of nanoparticles get to the site of action, it continues to 
experience other obstacles in the disease microenvironment. Taking tumor as an example, tumor 
microenvironment is highly heterogeneous encompassing with fibroblast, stromal cells, and 
7 
immune cells along with distinct intratumoral conditions such as hypoxia, acidic pH, and 
interstitial pressure gradients.29 Such complex cellular network and physiological condition within 
tumor microenvironment making delivering the drug to the cancer cell becomes highly challenging 
(Figure 1.2). 
 
Figure 1.2 Schematic demonstrates the physiology of solid tumor encompassing with fibroblast, 
stromal cells, and the gradient of oxygen level along with necrotic and hypoxic regions. 
 
Tumor-associated endothelial, pericytes, and fibroblast cells: Apart from the cancerous 
cell, the tumor microenvironment contains other cells that create structural support and generate 
neovascularization for cancer growth. The thick layer of these cells surrounding the cancerous 
region hindering nanoparticle extravasation efficiency. Intractable pancreatic cancer is a good 
example of this scenario.30 The use of DOXIL® for the treatment of pancreatic cancer-bearing 
mouse model showed a minimal effect on tumor volume reduction.31 However, when DOXIL was 
used with TβR-I inhibitor that can decrease the coverage of pericyte in the neovasculature of 
pancreatic tumor, the accumulation, and antitumor efficiency was significantly increased.31,32 
Extracellular matrix 
(ECM)
Hypoxia Tumor Cells
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Smooth Muscle Cells
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Tumor-associated immune cells: Throughout tumor development, cancer cells behave 
like a “never healing wound” to recruit immune cells and turns them into their “partners”. Variety 
of immune cells including T-cell, B-cells, Natural Killer Cell, macrophages, dendritic cells, and 
neutrophils can be found in the tumor region. These cells play an important role in tumorigenesis 
and tumor progression. In the context of drug delivery, the phagocytic cells located in the tumor 
area serve as nanocarriers’ digesters, which responsible for capturing nanoparticles before they 
even have a chance to get close to cancer cells.  As a result, 90% of intratumoral nanoparticles 
were found to be residing in tumor-associated macrophages or other non-cancerous cells, leading 
to just 0.001%-0.003% nanoparticle injected dose found in cancer cells of human ovarian SKOV-
3 xenograft mouse model.27 
Acidic pH: In comparison with the pH in normal tissues, the pH of the tumor extracellular 
matrix (pHe) is slightly acidic with pH value around 6.0.
33 The acidity found in the tumor region 
is a result of excessive glucose metabolism under anaerobic condition of cancer cells so-called 
“Warburg effect”, leading to the increased production of lactic acid and protons intracellularly.34,35 
These acidic metabolites are then transferred in the extracellular milieu causing the acidic 
physiological condition. The gradient of acidic pHe appears as a barrier to drug delivery due to its 
ability to switching the charged state of the carriers and chemotherapeutic molecule, which further 
reduce the probability for active component reaching the cancer cell.  
Hypoxia is a pathological phenomenon used to depict the location where the shortage of 
oxygen occurred.36,37 Hypoxia has long been recognized to associate with various intractable 
diseases such as rheumatoid arthritis, tumor, ischemic heart disease, and stroke.37 In solid tumor, 
this phenomenon arises due to disorganization of the vascular network, sluggish, and irregular 
blood flow generated during the aggressive growing process of cancer.38 Such altered vasculature 
9 
consequently leads to a heterogeneous oxygen gradient within tumor microenvironment, where an 
extremely low partial pressure of oxygen (pO2) is present (Figure 1.2). Indeed, the median pO2 in 
breast tumor microenvironment accessed by electrode measurement revealed a value of 10 mmHg, 
which is 6 folds lower than that of normal breast tissue.39,40 In order to adapt to such severe 
conditions, cancer cell at hypoxic region must undergo a genetic modification to continue their 
survival and proliferation.41 Consequently, these hypoxic cells become even more aggressive and 
untreatable which have been linked to increased metastasis, and resistance to radiotherapy and 
chemotherapy.36,41,42  
1.2.3 Intracellular environment 
When nanoparticles are near cancer cells, a series of events take place before the 
nanoparticle‘s encapsulated cargo reach its intracellular target. The nanoparticles first attach to the 
cell surface via a non-specific or specific binding manner. Subsequently, bound nanoparticles 
trigger the cellular endocytic pathway to be transported across the cell membrane.43 Via this 
process, the nanoparticles get trapped in the acidic endosomal compartment (pH~6).44 These 
endosomal vesicles later mature to become late endosomes, lowering the pH further to ~5. The 
nanoparticle contained late endosome can continue to fuse to lysosome at which point the acidic 
pH of ~4.5 and presence of enzymes start the process of nanoparticle digestion and degradation.44 
As a result, the bioactive molecules are also destroyed with its carrier before they can get to the 
intracellular intended targets. 
1.3 Scope of dissertation 
Since the first nanosized delivery system was invented and approved by FDA, significant 
efforts have been given to obtain an optimized nanocarrier to bypass biological system and 
advance the therapeutic and diagnostic efficiency of drugs and contrast agents. Within the past 10 
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years, we observed an exponential increase in publications focusing on the topic of 
“nanomedicine”. However, although an extensive amount of research has been devoted to 
nanoparticle development, only a handful of nanoparticulate systems find their way to FDA 
approval. The retardation in the clinical translation of nanomedicine is a direct consequence of the 
nanoparticle’s inability to overcome many of the above mentioned biological barriers. 
 
Figure 1.3 Scope of the dissertation for developing nanomaterials using chemical and biological 
tools to study their biological functions for cancer diagnosis and therapy 
 
1.3.1 Central objective 
The central objective of this dissertation is to put forth the engineering strategy of 
nanomedicine using chemical and biological approaches (Figure 1.3). The proposed 
nanomedicines were extensively studied and evaluated for their biological functions in term of 
cancer diagnosis and therapy. Via the new design considerations, the nanoconstruct described 
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herein addresses the current limitations of the conventional nanoparticle. The significant findings 
of each system will be highlighted and discussed throughout this dissertation. 
1.3.2 Chemistry approach 
Under the chemical approach, targeted drug delivery systems which are made up of 
poly(lactic-co-glycolic acid) (PLGA) cores containing chemotherapeutic drug doxorubicin (DOX)  
and decorated peripherally by Alendronic acid-a bone targeting agent was developed (Chapter 2). 
The engineered nanoconstruct exhibit combinatorial actions including targeting and therapy for 
the treatment of cancer occurring in the bone. As a one step forward from the project, the 
nanomaterial was further advanced by incorporating contrast agent that can partner with Magnetic 
Resonance Imaging to enhance the effectiveness of early and non-invasive cancer diagnosis. In 
the approach, a confinement strategy was used to enhance the magnetic property of 
superparamagnetic iron oxide nanoparticle (SPIONs) (Chapter 3). By controlling the cluster 
density of SPIONs in the polymeric core of targeted nanoconstruct, we successfully tuned the 
magnetic properties of magnetic nanosystem up to 641 mM-1.s-1. The magnetic property of 
engineered nanoconstruct is five times higher than that of the clinically used contrast agent such 
as Feridex® (r2 = 120 mM
−1 s−1). With these results, we moved forward to test our nanomaterial 
using tumor-bearing mice model where we could observe the accumulation of SPIONs in the 
tumor by enhancing dark contrast at the tumor site. 
1.3.3 Biology approach 
On the other hand, under the biological approach, a biomimetic system that can 
communicate with our immune cells for precise delivery of chemotherapeutics and contrast agents 
to cancer was investigated. In this approach, the nanoparticle surface was modified with Natural 
Killer (NK) cell membrane and Magnetic Resonance Imaging (MRI) contrast agents (Chapter 4). 
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Since a NK cell naturally seeks and destroys cancer cells, the incorporation of its membrane onto 
the synthetic nanoconstruct could work in a similar manner to that of naïve NK cell. With the 
biomimetic nanosystem, that has advantages of both synthetic and biological derived materials, 
NK cell membrane coated nanoconstruct has been studied the tumor targeting in vivo for 
bioimaging and precise drug delivery. In addition, to further explore the structural relationship of 
cell membrane coating and MR contrast agent, a red blood cell membrane disguised gadolinium-
based polymeric nanoconstruct was fabricated (Chapter 5). This study resulted in an optimized 
red blood cell membrane disguised gadolinium-based polymeric nanoconstruct for tunable T1 
relaxivity to elucidate their corresponding MR mechanism on image enhancement output and 
biological performance under in vitro and in vivo condition. The isolated RBC membrane directly 
fused onto polymeric core pre-labeled with gadolinium lipid conjugate. The biomimetic strategy 
allowed to conceal contrast agent from the endogenous components, resulting in a long circulating 
and high longitudinal relaxivity of blood pool contrast agent for improved MRI visualization of 
the vascular lumen.  
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Chapter 2 - Engineering nanomedicine with Alendronic acid corona 
improves targeting to Osteosarcoma 
Chapter 2, in full, is a reprint of the material as it appears in Scientific Reports, 2016, Tuyen 
Duong Thanh Nguyen, Arunkumar Pitchaimani, and Santosh Aryal. doi: 10.1038/srep36707 
Abstract 
We engineered nanomedicine with the stealth corona made up of densely packed bone-
seeking ligand, alendronic acid. In a typical nanoconstruct, alendronic acid is conjugated with 
hydrophilic head moiety of phospholipid that has an ability to self-assemble with hydrophobic 
polymeric core through its hydrophobic long carbon-chain. Proposed nanomedicine has three 
distinct compartments namely; poly(l-lactic-co-glycolic acid) polymeric core acting as a drug 
reservoir and skeleton of the nanoconstruct, phospholipid monolayer covers the core acting as a 
diffusion barrier, and a densely packed alendronic acid corona acting as a stabilizer and targeting 
moiety. Thus engineered nanomedicine attain spherical entity with ~90 ± 6 nm having negative 
zeta potential, −37.7 ± 2 mV, and has an ability to load 7 ± 0.3 wt% of doxorubicin. In vitro bone 
targeting efficiency of nanomedicine was studied using hydroxyapatite crystals as a bone model, 
and found significant accumulation of nanoparticle in the crystals. Moreover, cellular 
internalization studies with mouse osteosarcoma confirm the selectivity of nanomedicine when 
compared to its internalization in non-targeted mouse melanoma. This nanomedicine shows 
prolong stability in serum and deliver the drug into the cell exhibiting an IC50 of 3.7 μM. Given 
the strong interacting property of alendronic acid with bone, the proposed nanomedicine hold 
promises in delivering drug to bone microenvironment. 
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2.1 Introduction 
 According to the American Cancer Society, an estimated 3,300 new cases of primary bone 
cancer are expected to occur during 2016.45 Although this number just accounts for 0.2% of new 
cancer diagnoses, bone is one of the most common sites to depot migrating cancerous cells from 
distant organs owing to its largest bodily scaffold covering from head to toe around 
compartmentalized organs. Every year, approximately 80% of breast, lung, and prostate cancer 
patients ultimately develop bone metastasis, which further entry the disease into an incurable 
phase.46,47 Since the connection between bone microenvironment and cancerous cells was 
proposed by Stephen Paget in 1889, this metastatic phenomenon has been extensively studied and 
widely accepted as “soil and seed” relation in which the unique property of bone 
microenvironment provides favorable environment for cancerous cells to develop, survive, and 
proliferate.48,49 Specifically, once cancerous cell homing to bone marrow, it starts to interfere bone 
remodeling process by a complex cascade of events including upregulating the expression of 
receptor activator of nuclear factor κB ligand (RANKL); thereby, activating bone resorption via 
receptor activator of nuclear factor κB (RANK) on osteoclast to assist its growth and expansion.50–
52 This in turn leads to bone being broken down without new bone being made i.e.; immoderate 
production of osteoclasts, or bone being made without breaking down old bones i.e.; excessive 
production of osteoblasts. With the abnormal acceleration or deceleration in osteoclasts and 
osteoblasts production, bone releases its mineral, becomes more fragile, porous, and consequently 
leads to bone fracture.  
 Despite intensive efforts in the development of therapeutic agent for cancer occurring at 
bone, tumor localized in bone still remains as an incurable fatal disease due to either the fast 
clearance or non-specific binding profile of therapeutic agents. In addition, due to the solid 
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composition and larger surface area of bone, targeting therapeutics to the desire location is the 
major problem in treating bone cancer. The difficulty of eliminating bone-residing cancer 
necessitates novel alternative treatment regimens to manipulate the tumor cells, drug resistance, 
and their microenvironment, with minimal off-target effects. 
 Among different types of bone targeting ligands, bisphosphonate has been long emerging as 
a bone-seeking agent owing to its greatly binding affinity with hydroxyapatite - a major mineral 
component in bone environment. In addition, with the acidic property and hydrophilic nature, 
bisphosphonate’s permeability through cellular membrane is insignificant, which in turn makes it 
more extensively accumulates in skeleton than other organs after the administration.53,54 Once 
considering bisphosphonate’s distribution within skeletal system, researchers have shown that 
bisphosphonate accumulates more in bone defect site where high bone turnover is associated.55,56 
High bone turnover occurs when the activity of osteoclasts and osteoblasts are uncontrolled or are 
aggressive. Taking an advantage of these properties at bone lesion sites, the bisphosphonate 
conjugation can be a promising approach to design targeted chemotherapy for bone cancer 
treatment. Moreover, the antiresorptive properties of bisphosphonate makes it suitable 
combination candidate with other drugs to treat cancer at bone.57 
 Recently, studies have been focused on utilizing bisphosphonate to construct bone-homing 
nanomedicine by either conjugating alendronic acid (a member in bisphosphonate class) with 
polymeric backbone or chemotherapeutic drugs via polyethylene glycol (PEG) linker.58–62 These 
targeted nanocarriers possess common stealth properties provided by well-hydrated PEG moiety 
decorated on the surface which could evade nanoparticle from reticuloendothelial system (RES). 
In 2006, Uludag et. al., reviewed on attempt to engineer bone seeking therapeutic agents based on 
formulating therapeutic agents with bisphosphonates.63 In this review authors have summarized 
16 
various classes of bisphosphonate and therapeutic agent conjugates such as: small molecule drugs, 
protein, and imaging agents capable of targeting bone. In recent study conducted by Swami et. al., 
bortezomid, a proteasome inhibitor, loaded polymeric nanoparticle was proposed, in which the 
stealth PEG corona was conjugated with alendronic acid to target bone.61 Despite promising 
achievements in enhancing antitumor activity on mice-bearing tumor models, a number of 
limitations and challenges related to those systems need to be considered. For examples, the 
acceleration on using PEG moiety in both pharmaceutical and non-pharmaceutical products have 
consequently leaded to anti-PEG antibody development in human body.64–68 Recent finding shows 
that 22-25% occurrence of anti-PEG in healthy blood donors is most probably due to the greater 
exposure to PEG containing consumer products.68 Therefore, a substitute material need to be 
developed in order to diminish the excessive usage of PEGylated products. Considering the 
important role of hydrophilic corona layer on the surface of nanoconstruct in stabilizing 
nanosystem, we hypothesized that the Alendronic acid moiety with hydrophilic phosphate groups 
could provide favorable environment for water to form hydration layer around the particle 
protecting it from opsonization when properly structured in nanoconstruct and further sustain the 
stability of nanosystem under physiological condition.  
 To this end, we proposed a targeted nanoparticle (TNP) which is made up of Alendronic acid 
modified lipid and PLGA polymeric core encapsulating chemotherapeutic drug - Doxorubicin 
(DOX) to simultaneously offer combinatorial actions including targeting and therapy of bone 
cancer treatment. Proposed nanostructured construct has three distinct layers (1) PLGA core acting 
as a skeleton of the nanoparticle and drug reservoir, (2) lipophilic phospholipid layer acting as a 
middle passivating layer and diffusion barrier for the encapsulated drug, and (3) hydrophilic 
alendronic acid, an outer corona layer, acting as stabilizer and driving of nanoparticle to its target 
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(Figure 2.1). This densely packed phospholipid conjugated alendronic acid creates a sufficiently 
thick hydrated shell and prevents nanoparticle from being disassembled. Therefore, the engineered 
nanomedicine not only has stealth properties providing by bone mineral targeting moiety but also 
deliver a large quantitative amount of therapeutic agent which could enhance the effectiveness of 
treatment. 
 
Figure 2.1 Design of proposed bone targeted nanoconstruct. The Alendronic modified 
phospholipids drive nanoparticle containing chemotherapeutic drug (Doxorubicin) to the high 
bone turn over site where tumor occur.  
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2.2 Materials and Methods 
Chemicals and reagents.  
Poly(D,L-lactide-co-glycolide) carboxylate end group (50:50, 0.55-0.75 dL/g) was 
purchased from DURECT Corporation (Birmingham, AL, USA). 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(succinyl) (sodium salt) (16:0 Succinyl PE) and L-α-
Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) (Ammonium Salt) (Egg-
Transphosphatidylated, Chicken) (Egg Liss Rhod PE) were purchased from Avanti Polar Lipid 
Inc. (Alabaster, AL, USA). Alendronic acid was purchased from TCI America. 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were 
purchased from Sigma-Aldrich (Milwaukee, WI, USA). Doxorubicin hydrochloride salt was 
purchased from LC Laboratories (Woburn, MA, USA). Osteosarcoma Cell line K7M2 and Mouse 
Melanoma (B16-F10) were purchased from ATCC and maintained according to the 
manufacturer’s recommendation. All other chemicals and solvents were purchased from Sigma-
Aldrich (Milwaukee, WI, USA) and used as received.  
Synthesis of lipid bisphosphonate conjugates.  
Alendronic acid conjugated lipid (ALE-lipid) was synthesized by simple coupling 
chemistry initiated by EDC and NHS. Briefly, 15 mg of Succinyl PE lipid was dispersed in 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (4 mL, pH=4.5), activated by 35.9mg EDC and 
37.5mg of NHS and stirred at room temperature for 15 min. To this 47.4 mg Alendronic acid 
(ALE) in 6 mL Phosphate Buffered Saline (PBS) containing 10% triethylamine (TEA) was added 
and stirred for additional 24h at room temperature. In order to purify product, conjugated lipid was 
placed inside the benzoylated cellulose dialysis bag (MWCO ~500 Da), and dialyzed against water 
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for 24 hours at room temperature. The samples were lyophilized to obtain a dry powder and stored 
at -20ºC for further use. FT-IR and 1H-NMR were used to confirm the formation of ALE-lipid. 
Nanofabrication of lipid bisphosphonate nanoparticles and multifunctional polymeric 
nanoparticles.  
Targeted hybrid nanoparticles were prepared by single step nanoprecipitation. In brief, 
400µL of PLGA (1mg) in acetonitrile was added drop wise to 2 mL of 200µg ALE-lipid (dispersed 
in 4% ethanol) under magnetic stirring condition at 60ºC. To this, 1 mL of Mili-Q water was added 
to cool down the mixture and stirred continuously for additional 1 hour to facilitate the formation 
of nanoparticles and evaporation of organic solvent at room temperature. The TNPs were further 
purified using Amicon Ultra-4 centrifugal filter (Millipore, MA) with a molecular weight cut-off 
of 10kDA and stored at 4ºC for further use.   
 For DOX-loaded TNP preparation, different amount of DOX (10, 25, 50, 100, and 150 µg) 
were mixed with 100 µL of PLGA (10 mg/mL) and dried under vacuum. Polymeric film with drug 
was then dissolved in 400µL acetonitrile prior to nanoparticle preparation. Controlled PLGA 
nanoparticles were also prepared by dropwise adding 100 µL of PLGA (1mg) in acetonitrile to 1 
mL of Milli-Q water and purified following aforementioned protocol.  
 Rhodamine dye labelled TNPs were also prepared by hydrating 20µg of L-α-
Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) (Ammonium Salt) (Egg Liss Rhod 
PE) film with 200µL ALE-lipid (1mg/mL) before performing nanoprecipitation process.  
 RhB-labeled PEGylated nanoparticles were prepared by adding 400µL PLGA (1mg) into 
2mL 4% ethanol containing 200µg DSPE-PEG-suc, 260µg DSPG, and 20µg of L-α-
Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) (Ammonium Salt) (Egg Liss Rhod 
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PE) under magnetic stirring condition at 60ºC, followed by addition of 1mL Milli-Q water and 
purified as described above. 
Characterization of nanoparticles.  
The hydrodynamic size and zeta potential measurements of the prepared TNPs and DOX-
loaded TNPs were analyzed by Dynamic light scattering (DLS) using a Zeta sizer Nano ZSP 
(Malvern, Worcestershire, UK). The Smoluchowski model was used to calculate the zeta potential 
value. All data represents the average of triplicate measurements of samples prepared in different 
preparations. The morphology of the prepared TNPs was further analyzed using Transmission 
Electron Microscope (TEM, Tecnia G2, Spirit Bio TWIN). TEM samples were prepared by drop 
casting and evaporation technique using fomvar coated cupper grid (400 mesh). TEM images were 
analyzed by GATAN digital imaging system (GATAN, Inc.). The amount of encapsulated DOX 
and the resulting encapsulation efficiency was quantified spectrophotometrically using UV-VIS 
microplate reader by measuring the absorbance at 490 nm. 
Stability study of nanoformulation.  
The stability of TNPs in physiological ionic condition was investigated at pH 7.4 using 
PBS. In brief, 500 µL of 1mg/mL nanoparticles suspension were added to 500 µL of 2X PBS and 
incubated at 37ºC with rotating motion for 7 days.  The stability of nanoparticles was determined 
by measuring the particle size and PDI every 24hr. The serum stability of the prepared PLGA NPs 
and TNPs were carried out as reported. 69–71 Specifically, 100µL of 1 mg/mL nanoparticles were 
incubated with 100µL of 10% Fetal Bovine Serum at 37°C and measure its change in absorbance 
at 560nm kinetically every 5s over a period of 1h, double-orbital shaking with slow speed was 
applied prior to each measurement using Microplate reader (BioTek, Synergy H1 hybrid reader). 
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Calcium binding affinity.  
Nanoparticles engineered herein are highly monodispersed and recovered as aqueous 
suspension. Under mild centrifugation (1000 to 3000 rpm for 10 mins), they are not pelleted down. 
We have taken this advantages for Ca2+ binding assay.  The binding affinity of TNPs to Calcium 
was determined indirectly by measuring the fluorescence intensity of RhB-labelled NPs presence 
in supernatant and compare to the initial fluorescence intensity of NPs fluorescent 
spectrophotometrically. To optimize binding assays, we first used different concentration of RhB-
labelled TNPs (100, 200, 400, 600, 800, and 1000 µg/mL) to incubate with 5 mg Hydroxyapatite 
(HAp) for 30 mins at 37°C. At the end of incubation time, samples were centrifuged at 1,500 rpm 
for 5 min to spin down HAp aggregates and the nanoparticles that bound to them. 100 µL of 
supernatant was used to indirectly quantify the relative amount of nanoparticles bind to HAp. In 
the case of kinetic binding experiment, 1 mL of RhB-labelled TNPs (100 µg/mL and 1 mg/mL) 
were incubated with 5 mg HAp in macro-crystal form for varying periods of time (30s, 2, 5, 15, 
30, 60, 120, and 240 mins) at 37°C and processed as aforementioned protocol. In addition, RhB-
labelled PEGylated NPs (100µg/mL and 1 mg/mL) were used as controlled particles followed the 
same experimental condition. 
Drug release study.  
The cumulative drug release from the DOX loaded TNPs was assessed under physiological 
condition at 37°C. In brief, DOX loaded TNPs (25µg/mL, 1mL) were placed in a dialysis bag 
membrane (Mw. Cutoff=10kDa) and dialyzed against 250mL of PBS (pH=7.4). At constant 
stirring (100 rpm), 200µL of sample was taken at predetermined time intervals. The amount of 
released DOX was quantified by measuring the DOX fluorescence with the excitation and 
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emission wavelength of 490nm and 580nm, respectively. As control experiment, 25µg/mL of Free 
DOX was placed in a dialysis bag and processed under the same condition. 
Intracellular uptake study.  
In order to verify cellular uptake efficiency of ALE-Lipid decorated NPs, RhB-labeled 
TNPs was used in mouse Osteosarcoma bone cancer cell line (K7M2). In brief, cells were seeded 
in Poly-D-lysine coated 8 chamber slide at a density of 50,000 cells per well and incubated for 
24h. Then, the cells were treated with 50µg/mL RhB-labeled TNPs suspension prepared in 
complete DMEM and incubated for 4h. After incubation, treated cells were washed twice with 1X 
PBS (pH 7.4), fixed with 4% paraformaldehyde for 30 min at room temperature, stained with DAPI 
for additional 10 min and imaged under a Confocal Laser Scanning Microscope (Carl Ziess, LSM-
700). 
Fluorescence-activated cell sorting (FACs) studies.  
To quantitatively evaluate the cellular internalization efficiency of ALE-Lipid decorated 
NPs, a comparative experiment was conducted on targeted Osteosarcoma cell line and non-
targeted Melanoma (B16-F10) cells. In brief, K7M2 cells (or B16 cells) were seeded in T25 tissue 
culture flasks at 4×106 cells per flask for 24 hr. After incubation, cells treated with 2 mg RhB-
labeled TNPs suspended in DMEM. Cells were then incubated at 37°C at varying periods of time 
(30 min, 1, and 3 h) at 37°C. After incubation, cells were washed twice with ice-cold PBS, detached 
with 0.08% w/v trypsin and analyzed on a flow cytometer. RhB-labeled PEGylated NPs at the 
same concentration were used as control particles. 
In vitro cytotoxicity assays.  
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The in vitro cytotoxicity of TNPs was conducted on Osteosarcoma K7M2 using MTT assay. 
In brief, 2 x 104 cells per well in DMEM medium were seeded in a 96-well plate and incubated for 
24h. After incubation, the media were replaced with different TNPs concentration (10, 25, 50, 100, 
150 and 200µg/mL) and DOX loaded TNPs along with free DOX (0.01, 0.05, 0.1, 0.5, 1, 2, 3 and 
5µM) and incubated for additional 24, 48, and 72 hr. Control cells were also maintained without 
any TNPs treatment (n=6). After incubation, MTT was added to each well and further incubated 
for 3h according to the manufacturer recommendation. The insoluble formazan crystals were 
solubilized using DMSO and their absorbance was recorded at 570 nm using a microplate reader 
(BioTek, Synergy H1 hybrid reader). 
2.3 Results and discussion 
Synthesis and characterization of ALE-Lipid conjugate.  
The synthesis of the lipid conjugate was carried using ethylcarbodiimide hydrochloride/N-
hydroxysuccinimide (EDC/NHS) conjugation chemistry as described in Figure 2.2A. The 
chemical structure of synthesized ALE-Lipid conjugate was confirmed by FT-IR and 1H-NMR. 
As shown in Figure 2.2B, the FT-IR spectrum of ALE-Lipid (spectrum in black) exhibits all of 
the characteristic peaks of both unconjugated lipid (spectrum in blue) and alendronic acid 
(spectrum in red) including strong signal of aliphatic C-H stretch at 2900 cm-1 corresponds to lipid 
backbone and broad O-H stretch at 3500-3100 cm-1 belongs to ALE moiety (Figure 2.2B). It is 
notable that after the conjugation, C=O acid stretch of lipid at 1750 cm-1 was shifted to 1650 cm-1 
due to the formation of C=O amide. Most importantly, broad peak ranges at 1300-750 cm-1 
corresponds to phosphate functional groups was broaden in ALE-lipid spectrum which could be 
attributed to the overlap of  
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Figure 2.2 Chemical characterization of synthesized ALE-lipid. (A) Coupling reaction scheme. 
(B) FT-IR spectrum showing functional peaks of starting materials (Alendronic acid, Lipid) and 
product (ALE-Lipid). (C) 1H-NMR spectra of Alendronic acid in D2O and ALE-lipid in CDCl3 
and its corresponding proton signals. 
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phosphate ester (1050 cm-1) and phosphonate vibration (985 cm-1,  1050 cm-1, and 1205 cm-1) of 
lipid and ALE, respectively. In addition, the primary N-H bend (1700 cm-1) in ALE spectrum was 
replaced by secondary N-H bend (1550 cm-1) in the spectrum of conjugated product; thereby 
confirming the formation of amide bond. Furthermore, in order to understand the structure of ALE-
lipid in detail we conducted 1H-NMR study. In the 1H-NMR spectrum (Figure 2.2C), Alendronic 
acid gave a simple spectrum characterized mainly by a triplet at 2.91 ppm corresponding to N-CH2 
protons and two complicated multiplets arise at 1.9 ppm and 1.88 ppm due to magnetically non-
equivalent nature of prochiral CH2 protons.
72 In the case of synthesized ALE-Lipid, proton signals 
that relate to lipid were observed at 1.26 ppm owing to the methylene groups of long hydrocarbon 
chain and proton signals of terminal methyl group appear as a triplet at 0.88 ppm. The presence of 
ALE moiety in conjugated product was confirmed by a small broad peak appears at 1.6 ppm and 
triplet locates at 2.73 ppm which were assigned for -CCH2CH2CH2NHCO- and CH2NHCO-, 
respectively. With the formation of ALE-Lipid conjugate these proton signals  were upfield shifted 
from their original chemical shift to 1.8 ppm and 2.91 ppm (in ALE spectrum), respectively, due 
to the emergence of amide bond and the attachment of lipid, which further verifies the presence of 
covalently conjugated ALE on fatty acid backbone.  
Physicochemical properties of nanoparticles.  
After successfully attaching ALE with lipid (ALE-lipid), conjugate ALE-lipid was used 
along with PLGA and DOX for nanofabrication of TNP and DOX-loaded TNP using 
nanoprecipitation (Figure 2.3A). The physicochemical properties and morphological 
characterization of TNP and DOX-loaded TNP were determined using dynamic light scattering 
(DLS), surface zeta potential, and transmission electron microscopy (TEM) as shown in Figure 
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2.3 B, C, and D respectively. The hydrodynamic size of the TNP showed a diameter of 69±5nm 
whereas DLS size  
 
Figure 2.3 Characterization of TNPs. (A) Schematic demonstrates nanofabrication technique 
and components of TNPs. (B) TEM showing morphology and uniformity of TNPs. (C) Dynamic 
light scattering showing hydrodynamic size of TNPs and DOX-loaded TNPs. (D) Surface charge 
Zeta potential. (E) Stability test conducted in ionic condition (PBS, pH 7.4). (F) Kinetic stability 
study in 10% Fetal Bovine Serum (FBS). Values represent mean ± s.d., n = 3. 
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of DOX-loaded TNP was found to be 90±6nm. Importantly, in both cases, the DLS data showed 
unimodal distribution with low poly dispersity index (PDI) which demonstrates that the TNP and 
DOX-loaded TNP are highly monodispersed in aqueous solution. The TEM image of TNP further 
confirmed the uniformity of nanoparticles with the size is around 50 nm. The significant different 
between hydrodynamic size and dry-stage diameter is likely due to well thick hydrating layer in 
which the densely packed hydrophilic phosphate moiety acting as a corona of nanoparticle. This 
hydrophilic corona layer works in a similar way to that of PEG moiety which could make 
nanoparticle bypass immune system and prolonged the circulation time. By taking this advantage, 
we not only avoid overusing of PEG moiety but also creating new material that can give similar 
stealth property.  
 In addition, the measurement of the TNP and DOX-loaded TNP surface zeta potential 
revealed a net charge of -37.7±2 mV owing to the presence of negatively charged phosphate moiety 
on the surface. The similarity in zeta potential value of bare and drug loaded nanoparticles further 
confirmed the unchanged of surface property of TNP after DOX encapsulation. Taking into 
account that DOX is the cationic drug, if it is nonspecifically absorbed onto the surface of TNP, 
the surface charge property of this NPs could change, however, after DOX encapsulation, the 
surface charge of TNPs remains constant. This observation gives strong evident for the localization 
of DOX into the core of NPs.  
 Besides physicochemical properties, stability of nanoparticles is another essential 
parameter that needs to be carefully evaluated in order to translate to biological application stage. 
Therefore, we conducted stability tests in various in vitro physiological conditions including ionic 
and pooled protein milieu at 37ºC using phosphate buffer saline (PBS) and Fetal Bovine Serum 
(FBS), respectively. After 7 days of incubation in PBS (pH 7.4), there is no noticeable 
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nanoparticles aggregation was observed demonstrating by unchanged in DLS and PDI indexes 
(Figure 2.3E). In addition, TNPs are found to be highly stable in its colloidal state when expose 
to serum environment as revealed by constant optical density at 560 nm (Figure 2.3F), whereas in 
the case of bare PLGA NPs, the absorption at 560 nm increase rapidly and reaches to  plateau 
within 15 mins indicating rapid aggregation of PLGA NPs. These kinetic absorption experiments 
conducted at 560 nm is the measurement of aggregation when NPs aggregated with protein and 
precipitated to block transparency of the light from the medium.71 These results implied that the 
TNPs exhibit robust stability which could enlarge therapeutic window by prolonging circulation 
time in bloodstream and enhancing chances of designed nanoparticles to target and accumulate at 
bone tumor site. This serum stability further supports our claim that the hydration layer around the 
NPs due to hydrophilic phosphate moiety is sufficient enough to act as a stealth layer of protection 
in a manner similar to that of PEGylated system.  
Calcium binding affinity.  
Since the surface of TNPs was decorated with bisphosphonate, we next investigated in 
vitro binding affinity of TNPs with hydroxyapatite (HAp) as a bone-model. Our expectation is that 
with increase in NP concentration treated with HAp, the more NPs bound to HAp. However, as 
the nanoparticle concentration increases, percentage nanoparticle bind to HAp decrease (Figure 
2.4A). This realized us to optimize the concentration of TNPs that need to be treated with HAp, 
and the results for optimized concentration is presented in Figure 2.4A. With the optimized 
concentration, we found that nearly 80% of NPs bind to HAp at concentration of 100 µg/mL, 
whereas only 20% of NPs were bound at the concentration of 800 µg/mL and 1000 µg/mL. 
Therefore, we selected minimum and maximum concentration (100 µg/mL and 1000 µg/mL, 
respectively) to elucidate kinetic binding property of TNPs toward HAp. Along with targeted NPs, 
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PEGylated NPs at the same concentrations was used as control sample.  To our expectation, more 
than 80% TNPs bound to the surface of HAp within 15 mins of incubation time (Figure 2.4B). 
This trend plateaued on further increase of incubation time. In contrast, in the case of PEGylated 
NPs, just 20% of NPs bound to  
 
Figure 2.4 TNP’s interaction with Hydroxyapatite (HAp). (A) Quantitative evaluation of HAp 
binding of NPs with varying concentration of TNPs. (B) Time dependent binding of TNPs with 
HAp. PEGylated NPs were used as control. (C) Representative fluorescence images of HAp crystal 
after incubation with RhB-labeled TNPs showing the interaction between HAp and targeted NPs. 
Values represent mean ± s.d., n = 3. 
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HAp after 2 hours of incubation, at this stage when bounded PEGylated NPs with HAp were 
centrifuged down and the supernatant was measured spectrophotometrically under fluorescence 
reader which shows sufficient amount of NPs. This non-specific binding of control NPs could be 
accounted for carboxylic functional groups presence on the surface of PEGylated NPs. The 
interaction between HAp and TNPs labelled with RhB was further confirmed by imaging of HAp 
crystal under fluorescent microscope where the presence of TNP highly enhanced fluorescent 
signal captured on the surface of incubated HAp crystals, while insignificant fluorescent signal 
were obtained on HAp samples incubated with PEGylated NPs (Figure 2.4 C & D, respectively). 
Drug loading and release study.  
TNP’s drug loading capacity and drug release profile were also evaluated. Figure 2.5A 
shows the DOX encapsulation efficiency of TNPs at varying DOX concentrations. There was more 
than 7wt% of DOX was successfully encapsulated in 1mg/mL PLGA. Among these five different 
formulations, 100µg/mL initial input of DOX gave the most effective loading efficiency without 
changing nanoparticle physicochemical property. Thus, this formulation was chosen to use in 
further experiments. 
 
Figure 2.5 Drug loading and release study. (A) Dox loading efficiency and (B) In vitro 
doxorubicin release study at pH 7.4. Values represent mean ± s.d., n = 3. 
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 With the optimized DOX loaded TNPs sample, the in vitro drug release was investigated at 
pH=7.4 in phosphate buffer saline (PBS). A cumulative drug release study was performed using 
10kDa molecular cut-off dialysis bags. A control experiment was also performed using an aqueous 
solution of free DOX placed in the dialysis tubing. As can be seen in Figure 2.5B, in the case of 
free DOX, 100% drug was burst released within the period of 6h, whereas DOX loaded TNP shows 
the extension of drug release up to 24h. This result indicates that DOX loaded TNPs exhibit typical 
sustained drug release profile of nanomedicine over a 24h time period at 37°C (Figure 2.5B).  
Cellular uptake study.  
After understanding the drug loading efficiency of the TNPs, we next studied the cellular 
internalization to evident the targeting capability of TNPs in in vitro environment against mouse 
osteosarcoma K7M2 cells. The cellular internalization of TNPs was first visualized under confocal 
laser scanning microscope by incubating RhB-labeled TNPs with K7M2 cells for 3h. Confocal 
micrographs revealed that a large quantity of NPs internalized into the cell and localized around 
the periphery into the cellular compartment (Figure 2.6A and B) with some localized into the 
perinuclear region as evident from merged z-stack CLSM images (Figure 2.6B).  
 A quantitative cellular uptake of RhB-labeled TNPs was then conducted using flow 
cytometry in compare to conventional PEGylated NPs. Our results showed the cellular uptake of 
both TNPs and PEGylated NPs displayed time-dependent uptake (Figure 2.6C). As the 
nanoparticle incubation time increased, the enhancement of cellular uptake was observed in both 
TNPs and PEGylated group. However, at an equal incubation time, the TNPs were taken up by 
K7M2 cells is higher than that of PEGylated NPs (Figure 2.6D), suggesting that conjugation with 
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bisphosphonate plays a significant role in targeting nanoparticles to bone cancer cell in compare 
to PEGylated NPs.  
 As most cancer cells display aggressive profile in unselectively uptake of substances 
presence in their growing environment, it is important to set up a comparative experiment in order  
 
Figure 2.6 Cellular internalization study. (A) Confocal microscopic micrograph of Rhodamine 
labeled TNPs. (B) Z-stack of single K7M2 cell incubated with Rhodamine-labeled targeted 
nanoparticles showing intracellular distribution of particles throughout the cytoplasm and 
perinuclear regions. (C) Time dependent fluorescence-activated cell sorting (FACs) studies 
showing TNPs time dependent internalization pattern into the K7M2 cell. PEGylated NPs without 
ALE-Lipid were used as controlled NPs. (D) Selectivity of TNPs among 2 different aggressive 
cancerous cell lines (K7M2: left; B16-F10: right) 
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to assess specificity of targeting ligands among different cancerous cell types. With this in mind, 
we have chosen another aggressive non-targeted melanoma (B16-F10) cell line to rationally 
evaluate the distinctive property of TNPs under cellular environment.  As a result, a dramatic 
increase in K7M2 cellular uptake was observed from 30 min to 3 hours of incubation as evidenced 
by an increase in fluorescence intensity. This time-dependent cellular uptake pattern was absence 
in the case B16-F10 melanoma cells where fluorescent intensity remains constant even after 3 
hours of incubation. The high cellular uptake of targeted nanoparticle toward K7M2 cells was 
attributed to cell membrane specific interaction with phosphate moiety of Alendronic acid, in a 
typical endocytosis-mediated receptor uptake. This observation was in agreement with previous 
study conducted by T.-K. Ryu et. al., where Alendronic acid conjugated nanodiamond showed 
extensive accumulation in osteoblastic cells (MC3T3-E1) but not non-targeted HepG2 and 
NIH3T3 cell types.73 Specifically,  protein tyrosine phosphatases was investigated as one of the 
possible bisphosphonate binding receptor presence on the surface of osteoblastic cells.74 Moreover, 
protein phosphatases were identified to be overexpressed in osteosarcoma in compared to that of 
normal osteoblast and osteoclast cells which would help targeting ligand to target cancerous cells 
efficiently.75,76 Also, the same phenomenon was observed by Toledo et. al., where researchers were 
studied in the bone tumor of thirty osteosarcoma patients and found that protein tyrosine 
phosphatases is over expressed in osteosarcoma.76 Osteosarcoma cells are of the osteoblastic 
lineage, which is characterized by cells secreting the osteoclast-inducing factor, receptor activator 
of nuclear factor-κB ligand. Receptor activator of nuclear factor-κB-Fc, osteoprotegerin, 
bisphosphonates, and Src inhibitor are shown as positive candidates and can control various 
aspects of osteoclast function.77 From the results, it could be interpreted that phosphate moiety on 
34 
the surface of nanoconstruct can selectively facilitate the accumulation of the nanoparticles in the 
targeted cancerous cells.  
Biocompatibility and cellular cytotoxicity study.  
The biocompatibility of TNPs and in vitro cytotoxicity of DOX loaded TNPs were studied 
in K7M2 Osteosarcoma bone cancer cells using MTT assay. As can be seen in Figure 2.7A, at 
low TNPs concentration, no significant toxicity related to TNPs was observed indicating the 
excellent biocompatible of ALE-lipid at low concentration. However, when this concentration 
increases up to 150ug/mL, cell viability decreases to 80%, this reflection could be explained by 
masking of cellular surface under 96-well plate environment, hence reduce the cellular 
accessibility to oxygen and creating unfavorable growing environment to cell which further induce 
unexpected cell death.  
 
Figure 2.7 Cellular cytotoxicity studies. (A) Concentration dependent cytotoxicity of TNPs. (B) 
A comparative cytotoxicity studies of free Dox and Dox loaded TNPs against K7M2 
Osteosarcoma. Values represent mean ± s.d., n = 6. 
 
 In a typical cellular cytotoxicity experiment of free DOX and DOX loaded TNPs, the results 
revealed that both agents exhibit a time- and dose-dependent cytotoxic effect (Figure 2.7B) in 
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DOX with the IC50 of 3.7 and 6.1µM, respectively (Table 2.1). This enhancement in cytotoxicity 
of DOX loaded TNPs in lower incubation time is likely due to nanoparticle’s internalization 
mechanism. First, the exterior phosphate groups of targeted NPs were attracted by protein tyrosine 
phosphatases receptor present on the surface of osteosarcoma cells leading to the acceleration in 
accumulation and distribution throughout cell membrane. These targeted nanoparticles further 
internalized into the cell via endocytosis with core holding drug; thereby, intensely increase 
intracellular drug concentration and resulted in enhanced cytotoxicity. Whereas, in the case of free 
DOX, water soluble drug slowly diffuse into the cell limiting intracellular drug concentration. 
However, when cells were under treatment for longer period of time (48hr and 72hr), both free 
DOX and DOX loaded TNPs exert similar cytotoxicity effect. This further supports the evidence 
of rapid uptake of nanoparticulate system thereby increasing intracellular drug concentration as 
compare to that of free drug molecules. 
Table 2.1. IC50 of free DOX and DOX loaded TNPs on K7M2 cells. 
 
2.4 Conclusion  
Targeted therapy holds great potential for minimizing drug related non-specific toxicity. 
Towards this end, we have demonstrated the target specific delivery of DOX using nanoparticulate 
system consisting of densely packed alendronic acid corona that strongly binds with bone mineral, 
hydroxyapatite, aiming to target bone microenvironment. Engineered nano-system shows active 
Incubation time 
IC50 value (µM) 
Free DOX DOX loaded NPs 
24 hr 6.144 3.793 
48 hr 2.621 3.064 
72 hr 1.44 1.717 
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accumulation into the osteosarcoma cell exhibiting dose dependent toxicity similar to that of DOX 
in in vitro condition. However, in lower incubation time nanomedicine shows higher toxic effect 
than that of free DOX, which reveals that the nanomedicine deliver higher dose of DOX into the 
cells. Most importantly, higher ionic and serum stability of nanoparticle revealed that decorating 
nanoparticle surface with alendronic acid provides sufficient hydration layer and strong negative 
surface charge to sterically stabilized NP, which could be an alternative to PEGylated system to 
design nanocarrier. Overall, alendronic acid decorated proposed nano-system could provide a 
promising and most effective platform technology in the treatment of osteosarcoma. 
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Chapter 3 - Nano-confinement driven enhanced magnetic relaxivity 
of SPIONs for targeted tumor bioimaging 
Chapter 3, in full, is a reprint of the material as it appears in Nanoscale, 2018, Tuyen Duong 
Thanh Nguyen, Arunkumar Pitchaimani, Colin Ferrel, Ravindra Thakkar, and Santosh Aryal.  
doi:  10.1039/C7NR07035G 
Abstract 
Superparamagnetic iron oxide nanoparticles (SPIONs) are highly biocompatible and have 
documented versatile synthetic technique based on coprecipitation, reduction-precipitation, and 
hydrothermal methods where Fe3+ and Fe2+ ions react in aqueous solutions. Both of these ions are 
present in our body and have clear metabolic pathways, therefore, have attracted extensive research 
and development in the field of diagnostic imaging and therapy. However, most of the SPIONs 
based clinical diagnostic contrast agents were discontinued due to severe pain, lower transverse 
magnetic relaxivity ranges from 80-180 mM-1s-1, short-lived, and lack of disease specificity. 
Therefore, in this research, we put forth to engineer bone cancer targeted hybrid nanoconstruct 
(HNC) with a higher transverse magnetic relaxivity of 625 mM-1s-1, which is significantly higher 
than that of clinical contrast agents. Engineered HNC is peripherally decorated with a bone-
seeking agent, alendronic acid conjugated phospholipid, exhibiting hydrodynamic size of 80 nm 
with negative surface potential, -35mV. The interior skeleton of the HNC is made up of 
biodegradable and biocompatible poly(l-lactic-co-glycolic acid) (PLGA) in which 5 nm SPIONs 
are confined. We have successfully tuned the distance between the confined SPIONs from 0.5 to 
4 nm as revealed by transmission electron microscopy (TEM) micrographs and the magnetic 
resonance image (MRI) phantoms. Such cluster confinement dramatically enhances the magnetic 
relaxivity possibly due to the increase in net local magnetization due to the proximal field 
inhomogeneity. In an in vitro examination, 80% of HNC was found to bind with hydroxyapatite 
(HAp), which when imaged under TEM shows a painting of SPIONs over a HAp crystal. HNC 
was found to accumulate in mouse osteosarcoma tumor (K7M2 tumor model), both MRI and 
histological examination of tumor show the potential of HNC as targeting agents for diagnosis of 
tumor at the bone.  
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3.1 Introduction 
Engineered magnetic nanoparticles, more specifically superparamagnetic iron oxide 
nanoparticles (SPIONs), have attracted extensive research and development in the field of 
diagnostic imaging and therapy.78–81 Iron being one of the major mineral components of a 
biological system, whose biocompatibility is extensively investigated and better understood, 
becomes a preferred choice for various biomedical applications.82–88 Among them, contrast-
enhanced magnetic resonance imaging (ceMRI) is one which widely explored, as these contrast 
agents can create extremely large microscopic field gradients, which shorten longitudinal and 
transverse relaxation times (T1 and T2) of proton thereby producing “bright” and “dark” image 
contrast, respectively. SPIONs used as T2 contrast agents primarily increase the rate of T2 
relaxation and create “dark” contrast effects, whereas paramagnetic metal ions such as Gd3+ used 
as T1 contrast agents accelerate T1 relaxation and produce the “bright” contrast in the image.  
Highly studied paramagnetic ions in MRI are manganese (Mn), chromium (Cr), and 
gadolinium (Gd). These metallic ions are relatively toxic in free metal ion forms, therefore need 
to be encapsulated into the chelating agents.17,89,90 In particular, Gd-based MR contrast agents, 
where Gd3+ is chelated into the macromolecular chelating agents such as Gd-BOPTA (gadobenate 
dimeglumine, Multihance®), GdDTPA (gadopentetate dimeglumine, Magnevist®), and Gd-EOB-
DTPA (gadoxetic acid disodium, sold as Primovist® in Europe, Eovist® in the USA), are in clinics 
with the greatest value. However, development of nephrogenic systemic fibrosis (NSF) has been 
recognized in patients with severe renal impairment.91–93 Reports have emerged regarding the 
accumulation of gadolinium in various tissues including bone, brain, and kidneys of patients who 
do not have renal impairment.94–96 Due to this reason, the United States Food and Drug 
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Administration (FDA) published a safety announcement in July 2015 that it is investigating the 
risk of brain deposits associated with the repeated use of GBCAs MRI.97 
On the other hand, SPIONs are highly biocompatible and have documented versatile 
synthetic technique based on coprecipitation, reduction-precipitation, and hydrothermal methods 
where Fe3+ and Fe2+ ions react in aqueous solutions.98–100 Both of these ions are present in our 
body and have clear metabolic pathways such as degradation in lysosome due to an acidic 
environment, or eliminated via hepatobiliary excretion due to their uptake by the 
reticuloendothelial system (RES). Owing to its safe and clear excretion pathway, there is a huge 
interest in the development of SPIONs based contrast agent. Unfortunately, commercially 
available iron oxide MRI contrast agents, such as Feridex® produced by Berlex-USA, EndoremTM 
produced by Guerbet-France, and Resovist® produced by Bayer Schering Pharma AG-Germany, 
were discontinued from the manufacturers. These clinical agents consist of 4-6 nm SPIONs, which 
are susceptible to rapid renal clearance (renal filtration threshold size is ~6 nm), and transverse 
magnetic relaxivity ranges from 80-180 mM-1s-1 at 3T. Broad applications of these discontinued 
MRI agents were strictly limited due to rapid uptake by the RES cells viz.; Kupffer cells lining the 
hepatic sinusoids, as well as similar cells in the spleen, lymphnodes, and bone marrow but not in 
neoplasms.87,88 Therefore, organ-specific cancer targeted SPIONs with high magnetic relaxivity is 
highly desirable in the clinic for the detection and monitoring therapeutic response against cancer. 
Among the organs susceptible to cancer, bone is a favorable site for tumor growth and a 
predominant destination for the metastatic cancer cells to reside such as metastatic breast cancer. 
Despite intensive efforts in the development of therapeutic and diagnostic agents against cancer 
occurring at the bone, tumor localized in bone remains as an incurable fatal disease due to the fast 
clearance or the non-specific binding profile of the agents. Among different types of bone targeting 
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ligands, bisphosphonate (e.g. alendronic acid (ALE)) has been long emerging as a bone-seeking 
agent owing to its strong binding affinity with HAp, a major mineral component in bone 
environment.101–104 However, there exists a knowledge gap regarding the unique design of the 
system that precisely targets to the bone and enhances the diagnostic effect. Herein, we uniquely 
engineered targeted HNC made up of PLGA and superficially decorated with covalently 
conjugated ALE whose inner polymeric core is loaded with 5 nm SPIONs in a controlled fashion 
by tuning the distance between the clustering SPIONs as demonstrated in Figure 3.1. Effect of 
such cluster confinement in the magnetic properties of HNC was studied in detail, and the 
possibilities of using proposed nanoconstruct as a MR contrast agent were also studied to picture 
the system as a bone tumor imaging contrast agent. 
 
Figure 3.1 Schematic represents the preparation process of HNC using nanoprecipitation 
technique. The clustering degree of HNC is tunable by changing the ratio (w/w) of SPIONs and 
polymeric matrix PLGA in organic phase. In the designed experiment, the amount of PLGA was 
kept constant at 1 mg while the amount of SPIONs was varied at 10, 25, 50, and 100 µg correspond 
to SPIONs:PLGA (w/w) ratio of 1:100, 1:40, 1:20, and 1:10, respectively. As a consequent, the 
interparticle distant of SPIONs get reduced and confined within polymeric matrix. Such cluster 
confinement dramatically enhances the magnetic relaxivity which could be attributed to the 
increase in net local magnetization due to the proximal field inhomogeneity when the external 
magnetic field (Bo) is applied. 
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3.2 Materials and Methods 
Chemicals and reagents 
Alendronic acid was purchased from TCI America. 1,2-Dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(succinyl) (sodium salt) (16:0 Succinyl PE), 1,2-distearoyl-sn-glycero-3-
phospho-(1′-rac-glycerol) (sodium salt), and L-α-phosphatidylethanolamine-N-(lissamine 
rhodamine B sulfonyl) (Ammonium Salt) (egg-transphosphatidylated, Chicken) (Egg Liss Rhod 
PE) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Iron oxide nanocrystals 
with an oleic acid coating (5 nm) were purchased from Ocean NanoTech (San Diego, CA, USA). 
50 : 50 poly(D,L-lactide-co-glycolide) carboxylate end group (0.55–0.75 dL g−1) was purchased 
from DURECT Corporation (Birmingham, AL, USA). Osteosarcoma cell line K7M2 was 
purchased from ATCC and maintained according to the manufacturer's recommendation. All other 
chemicals and solvents were purchased from Sigma-Aldrich (Milwaukee, WI, USA) and used as 
received. 
Animal and tumor model 
All animal experiments and protocols were performed in strict accordance with the NIH 
guidelines for the care and use of laboratory animals (NIH Publication No. 85-23 Rev. 1985) and 
approved by the Institutional Animal Care and Use Committee (IACUC) and Institutional 
Biosafety Committee (IBC), Kansas State University, Manhattan, Kansas. Six-week-old female 
NU/NU nude mice were purchased from Charles River Laboratories International, Inc. and used 
for the study after 7 days of adaptation. For mice bearing K7M2 tumor models, 1 × 106 K7M2 
cells in 1× PBS were subcutaneously injected into the hind rear flank region of the mice. Tumor 
size and body weight were monitored periodically. 
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Synthesis of ALE–lipid conjugate 
The reaction scheme for bone targeting ligand modified phospholipid is shown in 
supporting information Figure A.1 and generally follows previously reported procedure using 
EDC/NHS coupling reaction.105 To prepare head group modified phospholipid, 50 mg of Succinyl-
PE lipid was hydrated in 6 mL deionized water at 60⁰C until a clear viscous solution was obtained. 
After the mixture was cooled down, the lipid was activated by 67.2 mg EDC and 58 mg of NHS 
subsequently under a vigorous stirring condition at room temperature for 30 min. To this reaction 
mixture, 120 mg of ALE dissolved in 2 mL water containing 15% TEA was added and stirred for 
additional 24h at room temperature. At the end of reaction time, the reaction mixture was 
transferred into a cellulose dialysis bag (MWCO ~500 Da), and dialyzed against water for 24 h at 
room temperature; the water was freshly changed every 6h. The samples were lyophilized to obtain 
a dry powder and stored at -20°C for further use. The obtained product was 35 mg (90% yield). 
The formation of lipid bisphosphonate (ALE-Lipid) was confirmed by FT-IR and 1HNMR. 
Preparation of nanoparticles 
Bone-targeted hybrid nanoconstruct (HNC) was prepared using one-step 
nanoprecipitation. Briefly, SPIONs were precoated with PLGA polymer by mixing 1 mg PLGA 
with different amounts of hydrophobic SPIONs (10, 25, 50, 100, and 150 μg) in chloroform and 
dried under vacuum. The iron oxide nanoparticles entrapped in the polymeric film was dissolved 
in 400 μL acetonitrile. The mixture was then added drop-wise to 3 mL of 4% ethanol containing 
200 μg ALE–lipid conjugate and 260 μg DSPG under a magnetic stirring condition at 60 °C. At 
the end of the nanoprecipitation process, 1 mL of Mili-Q water was added to cool down the reaction 
mixture. The mixture was stirred continuously for an additional 1 h to facilitate the formation of 
nanoparticles and evaporation of the organic solvent at room temperature. The obtained 
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nanoparticles were further purified using an Amicon Ultra-4 centrifugal filter (Millipore, MA) 
with a molecular weight cut-off of 10 kDa and stored at 4 °C for further use. Nanoparticles labeled 
with RhB-lipid were prepared following a similar protocol with the introduction of 20 μg RhB-
lipid in the lipid mixture prior to nanoparticle preparation. The controlled PEGylated nanoparticles 
were also prepared following a similar protocol using DSPE-PEG-COOH as an alternative to the 
ALE–lipid conjugate. 
Characterization of HNC 
The morphology of the prepared nanoparticle loaded SPION cluster was analyzed using a 
transmission electron microscope (TEM, Tecnai G2, Spirit Bio TWIN). TEM samples were 
prepared by drop casting and evaporation using formvar coated copper grid (400 mesh). TEM 
images were analyzed by a GATAN digital imaging system (GATAN, Inc.). The hydrodynamic 
size and zeta potential measurements of the prepared nanoconstructs were analyzed by dynamic 
light scattering (DLS) using a Zeta sizer Nano ZSP (Malvern, Worcestershire, UK). Brownian 
motion and the Smoluchowski equation were used to calculate the average hydrodynamic size and 
zeta potential value, respectively. The colloidal stability of HNCs was investigated in both ionic 
and serum conditions to mimic biological environment. In brief, 1 mg HNC was dispersed in PBS 
(pH 7.4) or 10% FBS. The change in size was recorded at a predetermined time using DLS. All 
data represent the average of triplicate measurements of samples prepared in different preparations. 
The amount of iron loaded into the HNC was determined using inductively coupled plasma mass 
spectrometry (ICP-MS, PerkinElmer, NEXion 350X). For ICP-MS, the HNC samples were 
digested with 2.0 ml of concentrated HNO3 for 5 h. After chemical digestion, 100 μl of the sample 
was diluted with 10 ml of 2% HNO3 and analyzed using ICP-MS. 
In vitro bone targeting assay 
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The binding affinity of HNCs to HAp was determined directly by measuring the amount 
of iron oxide nanoparticles present in HAp pellets and comparing it with the initial concentration 
of iron oxide nanoparticles by ICP-MS. Briefly, 100 μL of HNC (100 μg mL−1) was incubated 
with 1 mL HAp (1 mg mL−1) in 1 ml Eppendorf tubes for varying periods (0.5, 2, 5, 10, 15, 30, 
60, and 120 min) at 37 °C. At the end of the incubation, the samples were centrifuged at 1500 rpm 
for 5 min to obtain HAp crystals and the HNC bound to them. Pellets were substantially washed 3 
times with Milli-Q water, digested with 70% HNO3, and quantified using ICP-MS. 
In vitro magnetic properties 
The MRI relaxivity of HNC was performed using a 14.1 T MRI system (Bruker Avance 
III, WB, 600 MHz NMR-MRI). The transverse relaxation time (T2) of different formulations of 
the HNCs (10, 25, 50 and 100 μg mL−1 initial input concentration) in Milli-Q water was determined 
using turbo spin echo sequence. T2 relaxation was calculated using six measurements acquired 
with a constant repetition time (TR) of 1500 ms by varying echo time (TE) from 8 ms to 240 ms. 
The transverse relaxivity (r2) was determined from the T2 relaxation time and the concentration of 
iron (in mM). The corresponding T2 weighted MRI phantoms were recorded using a turbo spin 
echo sequence with TR = 1500 ms, TE = 15 ms and slice thickness = 1 mm. The confinement 
effect of the SPION nanocluster in the polymeric core of nanoparticles was confirmed by 
evaluating the r2 relaxation time of different SPION cluster compactness at the same iron 
concentration. 
In vitro cellular uptake study 
To detect the presence of intracellular SPIONs, we performed cellular histology using the 
Prussian blue staining procedure. K7M2 mouse osteosarcoma cells were seeded onto poly-D-
lysine coated glass coverslips at the density of 2 × 105 cells per coverslip and incubated for 24 h 
45 
for adherence. Then cells were treated with 100 μg mL−1 non-targeted or targeted NPs for 3 h at 
37 °C. At the end of the incubation time, cells were washed twice in PBS, fixed with 4% 
paraformaldehyde for 30 min followed by Prussian blue staining (5% potassium ferrocyanide II in 
5% hydrochloric acid (ratio 1 : 1)) for 1 h at 37 °C. Then, the cells were washed with PBS and 
subsequently counterstained with a 0.1% (w/v) nuclear fast red solution in distilled water for 1 
min. After washing with distilled water, the images of the cell were obtained through an inverted 
microscope. 
To further quantify the amount of HNC taken up by the cells, ICP-MS was adapted. In 
brief, cells were seeded in a 12-well plate with a density of 6.5 × 105 cell per well and incubated 
for 24 h. When cell confluency reached 80%, the cell medium was replaced with 1 mL of 10 μg 
mL−1 of HNCs or PEGylated NPs suspended in culture media and incubated for 3, 6 and 12 h. At 
the end of the predetermined time, the cells were washed 3 times with PBS, trypsinized, and 
collected by centrifugation at 5000 rpm for 10 min. Cellular uptake of HNCs and PEGylated NPs 
was further processed by sonicating with 2 mL HNO3 at 70 °C for 60 min. The digested cell was 
diluted and subjected to ICP-MS for iron concentration analysis. Cells without HNC treatment was 
taken as the control. 
Confocal study 
Confocal laser scanning microscopy (CLSM) with Z-stack was used to confirm the 
intracellular distribution of HNCs. Non-treated cells and non-targeted SPION loaded PEGylated 
NPs were used as the control. In brief, cells were seeded in poly-D-lysine-coated 8 chamber slides 
at a density of 20 000 cells per well and incubated for 24 h. Then, the cells were treated with 50 
μg mL−1 RhB-labeled NP suspension and incubated over varying periods (1, 2, and 3 h). After 
incubation, the treated cells were washed twice with 1× PBS (pH 7.4), fixed with 4% 
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paraformaldehyde for 30 min at room temperature, stained with DAPI for an additional 10 min 
and imaged using CLSM (Carl Ziess, LSM-700). The cellular uptake was accessed by measuring 
RhB fluorescence intensity using Image-J software (National Institute of Health). 
Cellular cytotoxicity studies 
The in vitro biocompatibility of HNCs was investigated on osteosarcoma K7M2 using 
MTT assay. In brief, 2 × 104 cells per well in DMEM were seeded in a 96-well plate and incubated 
for 24 h. To evaluate the biocompatibility of NPs, the media were replaced with different NP 
concentrations (10, 25, 50, 100, 150 and 200 μg mL−1) and incubated for an additional 24, 48 and 
72 h. Control cells were also maintained without any NP treatment (n = 6). After the completion 
of incubation, MTT was added to each well and further incubated for 3 h according to the 
manufacturer recommendation. The insoluble formazan crystals were solubilized using DMSO 
and the absorbance was recorded at 570 nm using a microplate reader (BioTek, Synergy H1 hybrid 
reader). 
Ex vivo magnetic resonance imaging study 
A pilot MRI study was conducted in female Nu/Nu mice bearing subcutaneous mouse 
osteosarcoma (K7M2) tumors. When the tumor size reached around 40–80 mm3, the animals were 
treated with HNCs or non-targeted SPION-loaded PEGylated NPs containing 0.25 mg of Fe per 
kg of body weight in 100 μL volume via the tail vein. Two hours post-injection, the animals were 
euthanized to simplify the MRI pilot experiment and immediately imaged using a Bruker WB 600 
MHz NMR-MRI (14.1 tesla). The MR images were obtained using a QTR 30 mm coil at 25 °C 
with a FLASH (fast slow angle shot) protocol. The T2 weighted images were taken with fat 
suppression parameters viz. TE/TR = 21/1500 ms, slice thickness = 1 mm, flip angle = 90°, image 
size 256 × 256, FOV = 30 × 30, and the total acquisition time = 16 min. The signal intensity of the 
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tumor area was further analyzed using Image-J software (National Institute of Health) to access 
signal distribution within the tumor region quantitatively. 
Histological analysis 
After imaging, the animals were euthanized and the tumors were dissected and fixed in 
formalin for histology analysis. The tumor samples were embedded in paraffin wax and sections 
were made of around 6 μm thickness. Further, the tissue sections were stained with H&E and 
Prussian blue to locate iron distribution in the tumor. 
3.3 Results and Discussions 
Design, synthesis, and characterization of targeted HNC 
 ALE is a member of bisphosphonate that has a high binding affinity toward bone cancer.101 
Structurally, ALE is a zwitterion compound functionalized with phosphate, primary amine, and 
tertiary hydroxyl that have rich electron density and capable of undergoing a coupling reaction 
with carboxylic acid. However, due to acidic functionality (pKa2 = 2.6, pKa3 = 6.73, pKa4 = 11.51, 
and pKa5 = 12.44), the reaction capability of primary amine of ALE was severely hindered.
106 
Therefore, it is critical to use a certain kind of base (e.g., Triethylamine) to neutralize and further 
expose the lone pair electron presence on primary amine of ALE to drive the coupling reaction. 
Previously, we have established a protocol to attach ALE to the hydrophilic head of phospholipid 
using triethylamine as a base to deprotonate primary amine of ALE and increase the solubility of 
this compound in water.105 A two-step coupling reaction was performed as outlined in Figure A.1. 
The obtained phospholipid conjugation was characterized by its proton environment to confirm 
the conjugation, as can be seen from the change in neighboring proton at δ 2.75 (m) and δ 3.29 
(m), which corresponds to -CCH2CH2CH2NHCO- and -CCH2CH2CH2NHCO-, respectively.  
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With the confirmation of the formation of ALE-Lipid conjugate, next, we synthesized HNC 
in which 5 nm SPIONs (Figure A.2) were embedded and confined into the core of the 
nanoconstruct.  Nanoprecipitation of SPION and polymer mixture in lipid suspension resulted in 
spherical SPIONs clusters entrapped in a polymeric matrix and decorated peripherally with a bone 
targeting ligand (ALE-Lipid), as demonstrated in schematic representation (Figure 3.1). HNCs 
exhibited unimodal size distribution with  Z-average hydrodynamic diameter of 80±6 nm 
regardless to SPIONs number and density of confinement (Table A.1), while the average core size 
of the SPIONs clusters in HNC was 50 nm (Figure 3.2 C) as shown in transmission electron 
micrographs (TEM). This significant difference between hydrodynamic and TEM sizes indicates 
that ALE-Lipid provides significantly thick hydrating layer over the surface of the nanoparticle. 
Such dense hydrating layer could enhance the nanoparticle stability by minimizing steric attraction 
between nanoparticles, which also minimizes the protein corona formation in the blood stream and 
evade nanoconstruct from being recognized as a foreign material by the immune system.105,107 
Indeed, over a long period of incubation in ionic and serum condition, the size of HNC remained 
constant (Figure 3.2D and Figure A.3). The stability of nanoconstruct, being coated by bone 
targeted ALE-Lipid, would be advantageous not only for prolonging circulation time in biological 
condition and enhancing bone tumor targeting but also facilitating interaction with surrounding 
water for MRI contrast enhancement.  
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Figure 3.2 Physicochemical characterization of targeted HNC. (A) Hydrodynamic size 
distribution of nanoparticles with and without SPION loading. (B) Zeta potential showing 
consistent negative surface charge property of HNCs before and after loading of SPION 
nanocluster. (C) Representative transmission electron micrograph demonstrates SPION clustering 
in the core of the targeted nanoconstruct. (D) Stability of HNCs with different SPION loading in 
medium mimicking biological conditions (10% FBS in PBS). (E) Representative binding profile 
of HNCs with biomimetic bone hydroxyapatite (HAp) crystal. (F) TEM showing the interaction 
between HAp and HNC with abundance of SPION aggregates on the surface of HAp. Values are 
represented mean ± s.d., n = 3. 
 
In bone microenvironment, the prevalence of osteosarcoma cells subsequently lead to the 
abnormal activity of osteoblast and osteoclast and consequently cause the release of bone mineral, 
predominantly in the form of calcium ion for tumor persistence.108 Previous studies have shown 
that the released calcium ion at bone cancer sites can be selectively targeted by using Ale in the 
form of free molecule or nanoformulation.109,110 Hence, by formulating nanoconstruct with the 
surface decorated with ALE to target the areas with high bone turnover could be advantageous for 
bone-targeted bioimaging. In this present study, HAp, a biomimetic bone mineral, was used for 
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preliminary evaluation of the in vitro binding affinity of targeted HNC toward the bone cancer. 
The binding affinity was measured by quantifying the amount of iron presence on HAp crystal 
using inductively coupled plasma-mass spectroscopy (ICP-MS). The result demonstrated a rapid 
binding kinetic in which more than 80% NPs bound to the surface of HAp within 10 mins of 
incubation (Figure 3.2E). Imaging of HAp crystal under TEM further confirmed the targeting 
ability of HNCs, which showed the presence of SPIONs (dark spot) on the surface of HAp (Figure 
3.2E), note: as no staining agents were used, the polymer was not visualized under TEM. 
Controlling SPION cluster density and tuning magnetic relaxivity 
Clustering of SPIONs is an interesting phenomenon that governs the r2 relaxivity of SPIONs.
111–
114 In general, T2 relaxation of water proton depends on the water diffusion rate, interaction time 
between water protons and local magnetic moment of nanocluster.111,114–116 Therefore, to simplify 
and fully gain the understanding of the confinement effect, in this study, we controlled 
nanofabrication process in such a way that the obtained HNC exhibit consistency in size 
distribution regardless to SPIONs confinement (Figure 3.1). The overall hydrodynamic and TEM 
size distribution of HNC with different SPION loading were well-ordered by consistently 
following the same ratio between polymer and lipid suspension during the preparation process. 
Meanwhile, the SPIONs loading density was tuned by changing SPIONs feeding amount in 
polymer pre-coating step. As shown in Figure 3.3A, the degree of clustering increased when the 
feeding amount of SPIONs increased from 10 µg to 100µg per 1 mg PLGA. As a result, the inter 
SPIONs distance inside the polymer core got shorter and confined. Specifically, the average 
interparticle distance (distance between the confined SPIONs) inside the polymer core obtained 
from TEM images by measuring 100 HNC in each formulation indicated the average gap between 
two individual SPIONs was successfully tuned from 5, 3, 2, to 0.4 nm in accordance to initial  
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Figure 3.3 Controlling SPION cluster density. (A) TEM images showing tunable SPION packing 
density. (B) Average distance between two SPIONs in various packing nanoclusters (data obtained from 
100 HNCs of each formulation using TEM images). (C) Iron loading efficiency measured by ICP-MS 
(n = 6). 
 
feeding amount of 10, 25, 50, and 100 µg SPIONs, respectively (Figure 3.3B). The Fe loading 
efficiency in these formulations was assessed by ICP-MS, which gets plateaued at 100 µg/mL 
input with the maximum loading of 7% (w/w) SPIONs per 1 mg polymer (Figure 3.3C). When 
the feed amount of Fe increases up to 150ug per 1mg PLGA, the nanoconstruct started to aggregate 
due to the destabilization initiated by the excess amount of hydrophobic SPIONs in the suspension 
(Figure A.3). Therefore, we used the feeding amount of 10, 25, 50, and 100 µg SPIONs per 1 mg 
PLGA for further investigation. 
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To further investigate the effect of SPIONs confinement in MR-relaxivity, a serial dilution 
of each HNC samples corresponds to 0.4, 2, 3, and 5 nm interparticle distant was carried out to 
obtain constant Fe concentration. Resulting diluted samples were subjected to T2 map 
measurement using a Bruker 600MHz (14.1T) Avance III with microimaging capability. The 
magnetic properties of HNCs were first investigated by measuring the signal intensity of water 
proton in the presence of different formulation with an echo time (TE) varying from 0 to 240 ms 
at constant repetition time of 1500 ms. Surprisingly, even though the Fe content in 4 different 
HNCs was kept constant at 0.4 mM, the signal intensity of water proton dramatically decreased 
(becomes dark) when interparticle distance decreased (Figure 3.4A). In comparing to 5 nm 
interparticle (SPIONs) confined clusters, the 0.4 nm exhibited 5.5 fold shorter T2 relaxation time 
and ~40 times faster than pure water. To further investigate the dependence of MR relaxation rate 
on clustering density, we measured T2 relaxation time of two more Fe concentration in HNC (0.1 
and 0.2 mM) for each formulation (Figure A.4). T2 relaxation time obtained from 0.1 and 0.2 mM 
concentration Fe was used to convert T2 relaxation rate in s
-1 (1/T2) and plotted against Fe content 
in mM concentration. The transverse relaxation rates exhibited a linear relationship with respect 
to iron concentration in bulk solution in all cases (Figure 3.4B) with the coefficient factor (R2) 
greater than 0.98. In our measurements, the confined structure that had interparticle distant of 0.4 
nm was measured to exhibit an r2 of 641.2 s
−1mM−1 [Fe], while the less dense confined 
nanoconstruct had  r2 of 335.3, 162.6, and 124.2 s
−1mM−1 [Fe] in relation to interparticle distant 
of 2, 3, and 5 nm, respectively (Figure 3.4B). The results showed that a denser packing of SPIONs 
in HNCs could serve as an excellent T2 contrast agent. This phenomenon was also depicted by T2 
-weighted images of different HNC samples with the equivalent amount of iron concentration as 
shown in Figure 3.4C, water was used as a control. Our results demonstrated that the sample that 
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has 0.4 nm interparticle distant always give darker contrast in comparison to that of other samples 
at the same iron concentration. Hence, MR relaxivity of designed nanoconfinement displayed the 
SPIONs density-dependent behavior, characterized by dramatically increasing the relaxivity with 
higher packing density. 
 
Figure 3.4 Confinement driven relaxivity enhancement. (A) Plot of 1/T2vs. the concentration of iron 
in aqueous solution measured in a 14.1 T MRI system at 25 °C. (B) r2 relaxation rate (s−1 mM−1) with 
different SPION packing density. (C) T2-Weighted MR images of HNC aqueous suspensions with 
different concentrations and packing densities. The T2-weighted MRI phantoms were taken at TR = 
1500 ms, TE = 15 ms, and slice thickness = 1 mm. 
 
The relaxivity of Iron oxide nanocluster with a hydrophilic coating was governed by these 
following factors: net magnetic moment, interaction time between water protons and magnetic 
fields, and water diffusion rate. Of the different design consideration to rebuild the relaxivity of 
SPIONs, packing individual SPIONs into the cluster is one of the effective ways observed so 
far.111–117 Clusters of different sizes are created by encapsulating SPIONs into the self-assembled 
amphiphilic polymers. This is the principle that an increase in the size of SPION increases its 
transverse relaxivity. The core of densely packed SPIONs generates high relaxivity due to the 
resulting high magnetic moment of the particles, and if the envelope is hydrophilic, it enhances 
the interaction with water proton thereby boosting the relaxivity up. An approach has been put 
forth by Paquet et. al., where authors encapsulated the cluster of SPIONs into the core of hydrogel, 
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which results in 2 to 3 times enhancement in the relaxivity.114 It has also been reported that 
clinically used contrast agents, such as Resovist® or Endorsed®, when encapsulated into the 
liposome exhibit a high degree of particle aggregation and therefore high r2 relaxivity, ranges from 
150 to 200 mM-1s-1.118,119 Similarly, Lin et. al. demonstrated the encapsulation of iron oxide 
nanoparticles into the chitosan matrix showing an 8-fold increase in magnetic relaxivity and 
assumed this is due to the effect of the cluster of iron oxide nanoparticle.112 In an another study, 
an oil-in-water emulsion technique was used to encapsulate SPIONs into the Poly(isobutylene-alt-
maleic anhydride)  polymer to enhance the relaxivity and observed maximum r2 of ~430 mM
-1s-
1.120 A number of theoretical studies have illustrated that such enhancement in relaxivity is due to 
the fact that the decrease in the diffusion coefficient of water at the vicinity of the clustering 
particles increases the interaction time of water protons and the magnetic field generated by the 
particles. In efforts above, although the attention has been given in the enhancement in T2 
relaxivity of SPIONs, less attention has been given to the distance induced confinement of 
individual SPIONs and the influence of confinement in the T2 relaxivity.  
In the present study, densely packed SPIONs core generates a cooperative magnetic effect 
among each particle led to the increase in magnetic moment resulting in high relaxivity.121 The 
ALE-Lipid with phosphate moiety on the outer layer traps water molecules via hydrogen bonding, 
creating bulk water protons environment surrounding magnetic fields near the SPIONs core which 
further increase the possibility of the interaction between water and magnetic particles. Similarly, 
the PLGA polymeric matrix also contributes in arresting water, which in turn slows down the water 
diffusion rate and as a consequence extending the interaction time of water proton and contrast 
agent, which is also observed in a similar system where chitosan was used as a polymeric matrix.112 
As a result, these three components together generate a synergistic effect of shortening the T2 
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relaxation times, resulting in the relaxivity enhancement of the nanoconstruct. Therefore, by 
controllably confining SPIONs, the r2 relaxivity of HNCs could be easily tuned and used as a 
technological platform for designing T2 MRI contrast agent. 
In vitro uptake of HNCs in osteosarcoma cells 
Before evaluating the cellular targeting capability of HNC, we first assessed the cellular 
biocompatibility of HNC in vitro by incubating HNC with K7M2 for 24, 48, and 72hr with a wide 
range of concentration from 10 to 200 µg/mL. As shown in Figure 3.5A, there was no dose-
dependent cytotoxicity of HNC over a long period of incubation, suggesting biocompatibility of 
HNC in the cellular environment. To confirm the cellular interaction of HNC with K7M2, a 
cellular Prussian blue staining technique was adopted. By using this technique, the ferric iron 
present in the cell undergoes histochemical reaction with potassium ferrocyanide to form ferric 
ferricyanide exhibiting blue. For this experiment, cells were incubated with 100 µg/mL PEGylated 
SPIONs (control nanoparticle) or HNC (targeted nanoparticle) in culture media at 37°C for 3hr. 
Figure 3.5B showed a higher accumulation of iron in K7M2 cell treated with HNC as indicated 
by the blue staining of a large number of cells, whereas a few cells treated with control PEGylated 
SPIONs nanocluster showed accumulation. Although the Prussian blue staining technique can give 
an idea about the presence of iron in the cell, intracellular distribution of HNC is not clearly 
understood. Therefore, to study the cellular colocalization of HNC, we peripherally labeled HNC 
with red fluorescent dye (Rhodamine B) and investigated the intracellular distribution of HNC 
using confocal laser scanning microscope (CLSM). The CLSM technique is capable of providing 
continuous slices along the z-axis for acquiring an image of exterior and interior compartment of 
the cell body.122 The representative middle slice of cell image was shown in Figure 3.5C, a blue 
channel for DAPI stained nuclei, and RhB labeled targeted HNCs in the red channel, which  
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Figure 3.5 In vitro cellular studies. (A) Biocompatibility of HNCs. The result is represented as 
mean ± SD (n = 8). (B) Prussian blue cellular staining showing the presence of intracellular 
SPIONs. (C) Confocal images of K7M2 cells incubated with RhB labeled NPs over the period of 
incubation at 37 °C. The cell nuclei were stained by DAPI (blue). (D) A quantitative cellular NP 
uptake by measuring RhB fluorescence intensity in panel C using Image-J software. 
 
indicated the relative distribution of HNC throughout cell body. A control experiment with non-
targeted SPION loaded PEGylated NP was also carried out to evaluate the HNC. As shown in 
Figure 3.5D, it is clear that the cellular accumulation of HNC is the order of magnitude higher 
than that of non-targeted NP over the period of incubation. The quantitative evaluation of cellular 
internalization was also conducted by measure the RhB fluorescent intensity using Image-J 
software, which supported our hypothesis of targeting (Figure 3.5D). In addition, the z-stack 
image of single cell presented in supporting information Figure A.5, further assured that these 
NPs are inside the cell body. The sequential slices taken horizontally from a stack of images 
indicated that targeted HNCs predominantly distributed in the cell, implying the targeting property 
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of targeted HNCs towards K7M2. This observation was further quantitatively supported by 
measuring cellular iron concentration using ICP-MS (Figure A.6). The results revealed that 
targeted HNC was associated with cell more efficient than that of control PEGylated HNC giving 
us strong evidence of targeting property of HNC.  
Ex vivo imaging study and tumor histological analysis 
To further examine the tumor targeting ability of HNC for potential MRI application, we 
injected 100 µL of HNC (0.25 mg/kg of iron) into nu/nu mice bearing K7M2 tumor systematically 
via the tail vein. After 2-hour post-injection, the mouse was euthanized and immediately taken for 
T2-weighted MR imaging acquisition. Since HNC showed significant enhancement in transverse 
relaxation, the dose of iron used in our experiment is lower than previously reported dose as well 
as the clinical dosage of Feridex® (0.56mg/kg).123 Representative T2-weighted MR images taken 
at TE/TR = 21/1500 ms along z-axis was shown in Figure 3.6A. As can be seen in Figure 3.6A, 
the significant reduction in MR signal (negative contrast) was observed not only around the 
periphery of the tumor but also from the different depth of tumor slice, and this signal dramatically 
reduced at the central of tumor region. The results indicated the effective accumulation and 
penetration of HNC into the deep tumor. On the other hand, there is less contrast enhancement was 
observed in the case of non-targeted SPION loaded PEGylated NPs (Figure A.7A). The darker 
contrast enhancement of HNC was further confirmed using ImageJ software to quantitatively 
access the signal intensity distribution throughout the tumor (Figure A.7B). Such significant 
enhanced contrast at depth MR signal localization behavior is probably caused by the selective 
accumulation of HNC driven by ALE that targets to the bone tumor lesion. The ALE can 
distinctively chelate with released Ca2+ ions at the tumor site thereby increasing the possibility of 
HNC accumulation in K7M2 cells as demonstrated in in vitro studies. To further verify the 
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presence of HNC accumulation in tumor, after imaging, the tumor tissue was subjected to 
histological analysis to study the distribution of SPIONs in the tumor. It is well known that 
Prussian blue dye has higher affinity with iron and can be used to detect the presence of iron in 
hard tissues. As expected the large number of blue-stained iron oxide NPs were observed in the 
histological slice of the tumor, augmenting the distribution data of NPs (Figure 3.6B). This further 
supports the accumulation potential of HNC in tumor tissues for tumor diagnosis. 
 
Figure 3.6 Ex vivo study. (A) MR images of a tumor bearing mouse at different z-planes with 
plane thickness of 1 mm, TE/TR = 21/1500 ms, flip angle = 90°. (B) Histology of tumor section 
of HNC treated animals stained with Prussian blue indicates the presence of SPIONs at the tumor 
site. 
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3.4 Conclusion 
In summary, a targeted hybrid nanoconstruct was successfully engineered using a bone 
targeting ligand, ALE, and hydrophobic PLGA polymeric core. The core of the nanoconstruct was 
loaded with SPIONs in a controlled fashion by tuning the distance between the clustering SPIONs. 
The designed HNC was found to be of 80 ± 5 nm size and showed enhanced r2 relaxivity from 124 
to 641 mM−1 s−1 at 14.1 T, which is one order of magnitude higher than that of iron oxide-based 
clinically used magnetic contrast agents, such as Feridex® (r2 = 120 mM
−1 s−1, 3 T) and 
Supravist® (r2 = 57 mM
−1 s−1, 3 T). Moreover, the results from a binding study using HAp as a 
bone model revealed that HNC had strong binding affinity to the bone. In an in vitro cellular study 
against K7M2, HNC showed biocompatibility over a range of concentrations and exhibited higher 
cellular uptake than conventional PEGylated nanoparticles. Due to its higher targeting affinity and 
magnetic relaxivity, the MRI of the bone tumor-bearing mice showed an enhanced contrast capable 
of distinguishing the surrounding soft tissue. Therefore, the targeting and nanoconfinement 
strategy presented herein could be a promising design to enhance the contrast ability of SPION 
based contrast agents in the diagnosis and treatment of cancer. 
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Chapter 4 - Biomimetic Natural Killer Membrane Camouflaged 
Polymeric Nanoparticle for Targeted Bioimaging 
Chapter 4, in full, is a reprint of the material as it appears in Advanced Functional Materials, 
2019, Arunkumar Pitchaimani, Tuyen Duong Thanh Nguyen, Ramesh Marasini, Achini Eliyapura, 
Tahmineh Azizi, Majid Jaberi‐Douraki, and Santosh Aryal.  The dissertation author is equal co-
first authors of this paper. doi: 10.1002/adfm.201806817 
Abstract 
In the present study, a biomimetic nanoconstruct (BNc) with a multimodal imaging system 
is engineered using tumor homing Natural Killer cell membrane (NKM), near-infrared (NIR) 
fluorescent dye, and gadolinium (Gd) conjugate-based magnetic resonance imaging (MRI) 
contrast agent onto the surface of a polymeric nanoparticle. The engineered BNc is 110 ±20 nm in 
size and showed successful retention of NKM proteins. The magnetic properties of the BNc are 
found to be tunable from 2.1±0.17 to 5.3±0.5 mM-1s-1 under 14.1T, by adjusting the concentration 
of Gd-lipid conjugate onto the surface of the BNc. Confocal imaging and cell sorting analysis 
reveal a distinguishable cellular interaction of the BNc with MCF-7 cells in comparison to that of 
bare polymeric NP suggested the tumor homing properties of NKM camouflage system. The in 
vitro cellular interaction results are further confirmed by in vivo NIR fluorescent tumor imaging 
and ex vivo MR imaging, respectively. Pharmacokinetics and bio-distribution analysis of the BNc 
show longer circulation half-life (~9.5h) and higher tumor accumulation (10% of injected dose) in 
MCF-7 induced tumor-bearing immunodeficient NU/NU nude mice. Owing to the proven 
immunosurveillance potential of NK-cell in the field of immunotherapy, the BNc engineered 
herein would hold promises in the design consideration of nanomedicine engineering. 
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4.1  Introduction  
The recent advent of biomimetic nanocarrier system shows tremendous progress in the 
field of nanomedicine.69,70,124 Biomimetic nanoconstructs (BNcs) inspired by biologically occurred 
materials show promising biomedical applications, not only as a biocompatible methodology in 
nanotechnology, but also it mimics the function of natural biological materials.125,126 This 
technology has already proven the advantages of transforming natural materials into functional 
materials ranging from drug delivery to bio-sensors, for example, application of nanomaterials in 
cancer theranostics.127,128 The advantages of incorporating biological materials with synthetic 
materials include biocompatibility, resistivity, cellular interaction, enhanced circulation half-life, 
and cellular retention.70,127,129 Among various biological materials, mammalian cell membranes 
such as blood pool materials like red blood cell membrane,130 leukocyte membrane,127 and platelet 
cell membrane131 possess both targeting moieties, as well as immunomodulating markers, showing 
the potential application in cancer therapy. Among various blood pool agents, Natural Killer (NK) 
cell is a predominant member of the innate immune system.132–134 The major function of NK cells 
includes host defense against microbial infections and tumor cells by immunosurveillance of cell 
surface abnormalities in major histocompatibility class I markers and cell stress markers.132,135,136 
Recently, we have shown the inclusion of NKM in the liposome for water-soluble drug delivery.137 
The result shows a promising therapeutic effect in human tumor xenografts in a mouse model. 
  NK cells comprise about 5-20% of total peripheral blood mononuclear cell count and are 
also found in tissues like liver, placenta, and peritoneal cavity. NK cells can lyse cancer cells by 
the mechanism of interplay between its activating inhibitory signals without prior sensitization.132 
Currently, NK cells and their products are in Phase I clinical trials for immunotherapy. 138,139 
Among various engineered NK cell lines, clinical grade NK-92 shows promising results in 
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immunotherapy, as it lacks inhibitory markers of NK cells along with ease of in vitro expansion. 
140–142 NK-92 cells are stable IL-2 dependent NK cells characterized by the presence of activated 
receptors such as NKG-2D, NKp30, NKp44, etc.  
Other than therapeutics, various bioimaging contrast agents are also 
encapsulated/conjugated with the synthetic nanoparticles (NP) aiming to prolong circulation half-
life and enhance tumor accumulation.14 Among different bioimaging modalities, MRI has 
advantages with excellent spatial resolution and soft-tissue contrast for diagnosis and monitoring 
the therapeutic response.143 The most predominantly used MR contrast agent belongs to the Gd-
based contrast agents (GBCA) (25-30%). The GBCA include Gd-BOPTA (gadobenate 
dimeglumine, Multihance®), GdDTPA (gadopentetate dimeglumine, Magnevist®), Gd-EOB-
DTPA (gadoxetic acid disodium, Eovist®), MS325® (gadofosveset trisodium, Ablavar®), etc. 
Despite advances in cancer bioimaging, early detection and targeted bioimaging using MRI are 
highly challenging in most tumor types. 144–146 This is due to the lack of targeting moiety, short 
resident time and free distribution to the extracellular spaces upon injection. 
In the present study, we designed tumor targeting biomimetic nanoconstruct made up of 
the NKM camouflaged onto the surface of carboxylate terminated polylactic-co-glycolic acid 
(PLGA) NP. To this BNc, phospholipid conjugated GBCA and NIR dye was incorporated and 
studied their feasibilities under MRI and further supported by NIR fluorescent imaging (Figure 
4.1). The NKM was isolated from the NK-92 cells and hybridized with imaging components and 
PLGA NP using membrane extrusion technique. This technique gives us the opportunity to tune 
magnetic relaxivity by varying the Gadolinium- (Gd) lipid concentration onto the BNc. 
Considering the acquired properties of NK cell, we hypothesized that the engineered BNc would 
have an ability to function as NK cell, which could help in maximizing the delivery of payloads, 
63 
herein contrast agents, into the tumor by co-working with blood pool agents, hence enhancing the 
diagnostic efficiency in targeted cancer bioimaging.  
 
Figure 4.1 Design of Biomimetic nanoconstructs comprised of three distinct components 
including contrast agents, tumor navigators protein derived from cell membrane and polymeric 
core.  
 
4.2  Materials and Methods 
Materials 
Poly (D,L-lactide-co-glycolide) carboxylate end group (50:50 dL/g) was purchased from 
DURECT Corporation (USA). L-α-Phosphatidylethanolamine-N-(lissamine rhodamine B 
sulfonyl) (Ammonium Salt) and (Egg-Transphosphatidylated, Chicken) (Egg Liss Rhod-PE) were 
purchased from Avanti Polar Lipid Inc. (USA). Gd (III) acetate was purchased from Alfa Aesar 
(USA). Primary antibodies for NKG2-D, NKp30 and Pan-cadherin were procured from Santa Cruz 
Biotechnology. NCAM (CD56) and secondary HRP-linked anti-mouse IgG antibody were 
purchased from Cell Signaling. Fluorophore-conjugated antibodies like FITC Mouse anti-Human 
CD56 and κ Isotype Control were purchased from BD Bioscience. All other reagents and 
chemicals used were of analytical grade. 
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Cell lines and tumor models 
Human NK cells, NK-92, were procured from ATCC, Manassas, USA. NK-92 cells were 
grown and regularly passaged in Alpha Minimum Essential Medium (α-MEM) without 
ribonucleosides and deoxyribonucleosides and supplemented with 1.5 g/L sodium bicarbonate, 
2mM L-glutamine, 0.1mM 2-mercaptoethanol, 0.02mM folic acid, 0.2mM inositol, 200U/mL 
recombinant IL-2, 12.5% (v/v) horse serum and 12.5% (v/v) fetal bovine serum. The human breast 
cancer cells, MCF-7, were procured from ATCC (USA). The cells were grown and maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum 
(FBS), penicillin/streptomycin (100µg/mL) and maintained at 37°C in 5% CO2 environment. 
For tumor studies, six-week-old female immunodeficient NU/NU nude mice were procured 
from Charles River Laboratories International, Inc. (USA). All animal experiments and protocols 
were approved by the Institutional Animal Care and Use Committee (IACUC) and Institutional 
Biosafety Committee (IBC), Kansas State University, Manhattan. For solid tumor models, 1 × 106 
MCF-7 cells in saline were implanted sub-cutaneously into the hind rear flank region of the mice 
and the tumor growth were monitored periodically. 
Isolation of NK cell membrane 
Isolation of NKM were performed using sucrose gradient ultracentrifugation method as 
reported.137 In brief, nearly ~2 × 108 NK cells, NK-92, grown in multiple T-75 culture flask were 
harvested and washed twice with 1x PBS. Further, the washed cell pellet was suspended in 
homogenization buffer (10mM Tris-HCl, 1mM MgCl2, 1mM KCl, 2mM PMSF, 25mM Sucrose, 
200μg/mL Trypsin-chymotrypsin Inhibitor, 10μg/mL DNase and 10μg/mL RNase) and 
homogenized in ice for 5 min (20s pulse and 30s in between pulses). The homogenized suspension 
was pooled over the discontinuous sucrose gradient (55%, 40% and 30% (w/v) sucrose in 0.85% 
65 
saline) in polycarbonate tubes and ultracentrifuged in a Beckman SW 27 rotor at 28,000g for 30min 
at 4°C. The NKM fraction at 30% to 40% interface was collected in a clean tube and analyzed for 
its protein characterization using the dot-blot technique. For purification, collected membrane 
fractions were diluted with twice the volume of normal saline and ultra-centrifuged in a Beckman 
SW 27 rotor at 28,000g for 1h at 4°C. The purified membranes were lyophilized, weighed, 
quantified for its protein content using Bradford Assay and stored at 4°C for further use. 
Preparation of Biomimetic Nanoconstruct 
BNc were prepared using the simple nanoprecipitation method.70,71,81 In brief, 1mg of 
PLGA dispersed in acetonitrile was added drop-wise to different concentrations of Gd-lipid (50-
400µg) dispersed in 2ml of 4% ethanol under magnetic stirring at 60°C. After 15 min, 1mL of 
Milli-Q water was added to cool down the suspension and further stirred at room temperature. 
After 1h of stirring, the clear nanoparticle suspension (PLGA core) was extruded in the presence 
of isolated NKM (100µg dispersed in PBS) using 100nm pore-size Millipore membrane filter, 
concentrated in Amicon centrifugal filter (10kDa), and stored at 4°C for further use. For 
DiR/Rhodamine labeling, 10 µg of the dye dispersed in chloroform was dissolved in the PLGA 
dispersion and followed the same protocol of the preparation of BNc. 
Characterization of BNc 
The hydrodynamic size and zeta potential of the prepared BNc were characterized using 
Dynamic light scattering analysis (Malvern, Nano ZSP). The size and the shape of the prepared 
BNc were confirmed using transmission electron microscope (FEI Technai G2 Spirit BioTWIN). 
Further, the concentration of Gd3+ in BNc were determined using an inductively coupled plasma 
mass spectrometry (ICP-MS, NEXion 350X, Perkin Elmer). The concentration of proteins in all 
samples was determined using Bradford Assay following manufacture’s recommendation.  
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Protein Characterization of BNc 
For SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis), all 
samples were prepared with the overall protein concentration of 50µg/wells loaded in a 4-20% 
Mini-PROTEAN® TGX Protein Gels and stained with Coomassie brilliant blue. For western blot, 
protein samples were transferred to the PVDF membrane and treated with primary antibodies for 
CD-56 (Cell Signaling), NKG2-D (Santa Cruz), NKp30 (Santa Cruz) and Pan-cadherin (Santa 
Cruz) along with HRP-conjugated anti-mouse IgG secondary antibody (Cell Signaling). The 
blotted films were further developed using SignalFire™ ECL Reagent (Cell signaling) and imaged 
chemiluminescent signals Bio-imager (Kodak). 
Stability of BNc 
The physiological stability of the prepared BNc at 4°C in PBS (pH=7) was investigated 
using dynamic light scattering size analysis. In brief, 50µg/mL of BNc samples in PBS were 
incubated at 4°C for two weeks and investigated their change in size by measuring the samples in 
DLS every day. The serum stability of the prepared BNc was carried out as reported earlier.147 In 
brief, 100µL of 500µg/mL of BNc were mixed with 100µL of 90% FBS at 37°C and record their 
change in absorbance with incubation time kinetically by recording at every 3sec over a period of 
3h using Microplate reader (BioTek, Synergy H1 Hybrid reader). 
Gd3+ release study 
The cumulative Gd3+ release characteristics of BNc under the physiological condition at 
37°C was determined as reported periodically. In brief, 50µg/mL of BNc was placed in a 500 Da 
dialysis membrane bag and dialyzed against 250mL of PBS (pH=7.4) and acetate buffer (pH=5.2). 
At constant agitation (70rpm), 200µL of the buffer samples were collected at predetermined time 
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intervals (0-72h) and replace with an equivalent volume of fresh PBS buffer. The amount of Gd 
release from the BNc is determined using ICP-MS as reported before.  
In vitro magnetic properties of BNc 
The MRI relaxivity of Gd-loaded BNc was determined as reported previously.17,148 The 
longitudinal relaxation (LR) time of BNc in the presence and the absence of NKM in an equivalent 
Gd3+ concentration (10 µg/mL) was determined using a RARE (Rapid Acquisition with Relaxation 
Enhancement) pulse sequence with variable repetition time on a 14.1T NMR system (Bruker 
Avance III, 600 MHz NMR-MRI). Concentration-dependent recovery curve of BNc was also 
investigated using a different concentration of BNc (0.05-0.4mM). The LR was determined from 
the T1 relaxation time and the concentration of Gd
3+. The corresponding T1-weighted magnetic 
resonance phantom images were also recorded using a turbo spin echo sequence (TR=1500 ms, 
TE= 6.50 ms, and slice thickness= 1mm).  
Cellular uptake and biocompatibility studies 
The cellular uptake efficiency of BNc in the presence and the absence of the NKM coating 
were investigated using FACS analysis (BD FACSCalibur™). In brief, 3 X 106 MCF-7 cells were 
grown in T25-flask and treated with 50µg/mL of Rhodamine-labelled BNc dispersed in DMEM 
media. After 6h of incubation, cells were trypsinized, washed and analyzed in FACS for the 
quantitative determination of NP uptake by MCF-7 cells. For the confocal study, Rh-labelled BNc 
were treated in an 8-chambered micro-chamber slide seeded with the cell density of 50,000 
cells/well and incubated for 3h. After incubation, cells were washed, fixed, and immunostained 
with FITC-anti-CD 56. Nuclei of the cells were stained with DAPI, and the slides were observed 
directly in a Confocal Laser Scanning Microscope (Carl Zeiss, LSM-700).  Further, the 
biocompatible nature of the BNc was investigated in MCF-7 cells using the [3-(4,5-
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Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] (MTT) Assay.149 In brief, MCF-7 cells 
were seeded in a 96-well plate at the density of 10,000cells/well and incubated for 24h. After 
confluence, cells were treated with different concentration of BNc (10-150µg/mL) and incubated 
for additional 24h. After incubation, the medium was removed, 10µL of MTT (5mg/mL) dye were 
added and incubated further for 3h in the dark at 37°C. After 3h incubation, the formazan crystals 
were dissolved using DMSO, and the plates were read for absorbance at 590nm using Microplate 
reader (BioTek, Synergy H1 Hybrid reader). 
In vitro cytokine release assay 
The immunogenicity of the prepared BNc along with the bare PLGA NP was tested for its 
immunoregulatory potential using standard cytokine release assay.127,137 In brief, 8 × 105 THP-1 
cells were seeded in a 12-well plate and treated with bare PLGA NP (100μg/mL), NKM 
(100μg/mL), Gd-lipid (100μg/mL) and BNc (100μg/mL) at 37°C for 24h. After 24h incubation, 
cell culture supernatants were collected, centrifuged, removed cell debris and stored at -20°C as 
small aliquots. For cytokine assay, samples were thawed and analyzed for pro-inflammatory 
cytokines, IL-1β (LOD:1.7 pg/ml), IL-6 (LOD:1.5 pg/mL), and TNF-α (LOD:1 pg/mL) using 
Magnetic Human Cytokine Multiplex Assays Kit (R&D Systems, Inc. Minneapolis, MN) in 
Luminex MagPix® instrument (Millipore Inc.,) as per the manufacturer recommendations. For 
positive control, cells were dosed with 3μg/mL of lipopolysaccharide for 24h. 
Pharmacokinetics and Bio-distribution of BNc 
The circulation half-life and pharmacokinetic profile of the BNc were investigated using 
Six-week-old female NU/NU nude mice (n=3). In brief, BNc (5mg/kg) were administered 
intravenously via tail vein injection, and the blood samples were collected at predetermined time 
intervals (0.5-48h) through tail vein puncture. The amount of BNc in the blood samples was 
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quantified using ICP-MS as described earlier. For the bio-distribution study, 5mg/kg of BNc were 
injected (i.v.) into the MCF-7 tumor-bearing mice, and after 24h of study, animals were sacrificed 
to collect major organs and tumor tissues. The tissue samples were weighed, digested using 2 mL 
of aqua regia (3:1 ratio of HCl:HNO3), diluted in 2% HNO3 and analyzed for the Gd concentration 
in ICP-MS as described earlier. Pharmacokinetic parameters were analyzed by a two-
compartmental model using the MATLAB software (MathWorks, 2017b).150–152 
Mathematical model 
 
Pharmacokinetic models are employed to illustrate the process of nanodrug distribution in 
the whole body. When we follow a particular nanodrug administered with a specific route, we may 
study the whole body as a kinetically single unit, conventionally termed as compartment, which is 
homogeneous. For this purpose, we assume that the administered drug distributes uniformly in the 
body and that the drug equilibrates between different tissue/organ in a time-dependent fashion. 
However, we cannot conclude that the concentration of drug is the same in tissue or plasma. The 
bicompartmental model divides body into two different units or compartments. This division helps 
us study each tissue and its interaction with its relative components. In bicompartmental model, 
we assume that the administered drug enters the first compartment and then transported into the 
second compartment, tissue or organ.153The remaining drug will come back to the compartment 1 
and then we have elimination of drug from first compartment.   
In this study, we assumed that disposition of drug from blood to tissue follows a 
bicompartmental model (scheme 1). For the bicompartmental model, we assume that we have a 
first order transfer rate between two compartments, 𝑘23 and 𝑘32, and we consider a first order 
elimination rate from the second compartment, 𝑘𝑒𝑙, without any elimination or metabolism in the 
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tissue. The schematic diagram for this case is outlined in the following diagram (Please see 
supporting information for details).  
 
Figure 4.2 Model diagram for two compartments. 
 
In vivo bio-imaging 
For in vivo bio-imaging studies, near-infrared fluorescent dye 1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindotricarbocyanine Iodide (DiR) labeled BNc (10mg/kg) were injected intravenously 
into the MCF-7 tumor-bearing mice along with bare control PLGA NP and analyzed its 
bioaccumulation and tumor targeting efficiency using Pearl® Trilogy Small animal imaging system 
(LI-COR®). The fluorescent images at the near-infra-red window were taken at pre-determined 
time intervals (0, 3, 6, 12 and 24h) and the images were analyzed in Image Studio® software. At 
the end point, mice were euthanized, and excised organs were imaged and analyzed for the 
quantitative determination of BNc accumulation. 
Ex vivo MRI imaging 
A pilot ex vivo MRI study was performed using NU/NU mice bearing MCF-7 tumors on a 
14.1T NMR system (Bruker Avance III, 600 MHz NMR-MRI, 14.1T). In brief, NU/NU mice were 
intravenously injected with BNc (equivalent Gd concentration of 0.008 mmol/kg), and the animals 
were sacrificed after 2h post-injection. Within 15min of the sacrifice time, animals were imaged 
in MRI. The T1-weighted MR images were recorded using a QTR 30 mm coil with a FLASH 
(Fast, slow angle shot) protocol at 37ºC. The axial MR imaging parameters were TR = 1500ms, 
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TE = 6.5ms, flip angle = 90, image size 256x256, FOV=30x30 and slice thickness = 0.5mm. 
Further, the ex vivo MRI images were analyzed using DICOM software (Santesoft Ltd). All animal 
experiments and protocols were approved by the Institutional Animal Care and Use Committee 
and Institutional Biosafety Committee, Kansas State University, Manhattan. 
Statistical Analysis All experimental data represent the mean ± standard deviation. 
Depending on the experiment parameters One-way and Two-way ANOVA were used for the 
statistical analysis. ***P<0.001, **P<0.01, *P<0.05 were considered statistically significant. 
4.3 Results and Discussion 
BNcs were fabricated using membrane extrusion method in the manner similar to that of 
liposomal fabrication.69–71 The process involves the preparation of PLGA NP, extraction and 
isolation of NKM, and the cloaking of PLGA NP with isolated NKM, GBCA, and NIR dye. The 
biocompatible polymeric NP, PLGA, was prepared using the simple nano-precipitation following 
our earlier reports.70,71  Further, the NKM was isolated and extracted from the NK-92 cells through 
sucrose gradient centrifugation.137 The extracted NKM was lyophilized and re-dispersed in 
PBS.The amount of NKM yield was quantified by measuring the protein concentration. From ~2 
x 108 NK-92 cells, the NKM yield was found to be ~300µg protein equivalent. Finally, the BNc 
were fabricated by extruding PLGA NP and Gd-lipid with isolated NKM [with the weight ratio of 
(5:1:1)] through 200nm pore sized polycarbonate membrane. For NIR dye labeling, constant 1.0 
wt% of dye with respect to the 1 mg of PLGA was used in all cases. Gd3+ conjugated phospholipid 
(Gd-lipid) was synthesized via simple convenient coupling chemistry as described in earlier 
reports.17,148,154 Figure 4.3A illustrated the schematic representation of the process of BNc 
fabrication. The hydrodynamic size of the bare PLGA NP was found to be 109±2.8nm, whereas 
the BNc were found to be in the range of 110±20nm, respectively (Figure 4.3B). The 
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Figure 4.3 BNc physicochemical properties. (A) Schematic illustration of the preparation of 
biomimetic nanoconstructs made up of natural killer cell membrane isolated using sucrose gradient 
differential centrifugation. BNc were prepared using simple extrusion technique, where PLGA 
nanoparticles and Gd‐lipids were extruded with isolated NKM. (B) DLS size of the BNc before 
and after NKM coating. (C) Transmission electron microscopic image of the prepared BNc, inset 
shows the magnified image of the BNc with distinct biomolecular corona (NKM and Gd‐lipid). 
 
transmission electron microscopic images of the BNc show clear coating materials onto the surface 
of the PLGA NP (Figure 4.3C). Further, to investigate its fabrication efficiency, three different 
formulations of BNc were fabricated as represented in Table 4.1 as follows: BNc-A = (1000µg 
PLGA) : (200µg Gd-lipid) : (20µg NKM) ; BNc-B = (1000µg PLGA) : (200µg Gd-lipid) : (100µg 
NKM); BNc C = (1000µg PLGA) : (200µg Gd-lipid) : (200µg NKM). The hydrodynamic sizes of 
the BNc A, B, and C were found to be 111±2.1nm, 128±1.6nm, and 134±4.4nm, respectively. 
 
 
1. Cell lysis
2. Ultracentrifuge 
30%
40%
50%
Sucrose gradient
NK cells membranesActivated NK-92 cells PLGA NPs Biomimetic Nanoconstruct
Cell membrane proteins 
(CD 56, NKG-2D, etc., )
Cellular phospholipids
Gd-lipid
PLGA-NPs
A
B C
Extrusion
DSPE-DOTA-Gd
(Gd-lipid)
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Table 4.1 Physicochemical characteristics of BNc. 
* Ratios indicate in BNc corresponds to PLGA:GD-lipid: NKM protein ratio (by weight) 
NA sample not measured. 
 
The results from hydrodynamic size indicated that the size of the BNc slightly increases with the 
increase in the concentration of NKM, which is presumably due to the presence of a larger amount 
of NKM that becomes hydrated in an aqueous environment. Further, the zeta potentials of the BNc 
A, B, and C were found to be -20±0.76mV, -36.9±4.07 and -41.1±0.59, respectively. The zeta 
potentials of the isolated NKM and bare PLGA NP were found to be -26±0.21mV and -
20.1±0.82mV, respectively. This proves the evidence that the coating of NKM changes its zeta 
potential value more negative among different formulations, which is attributed to the negative 
zeta potential of the cell membrane that was organized onto the negatively charged PLGA NP. 
Based on physicochemical characteristics, more stable BNc-C (5:1:1) were chosen for further 
characterization studies. Hereafter, BNc represents BNc-C.  
Next, we identified signature proteins in the BNc using SDS-PAGE and western blot analysis. 
Figure 4.4A and B represent the SDS-PAGE and western blot of the isolated NKM along with the 
engineered BNc. SDS-PAGE analysis revealed that the proteins from the NKM were successfully 
 Hydrodynamic Size 
(d.nm) PDI 
Zeta Potential 
(mV) 
BNc A (5:1:0.1)* 111 ± 2.1 0.16 ± 0.02 -20.7 ± 0.76 
BNc B (5:1:0.5) * 128 ± 1.6 0.19 ± 0.01 -36.9 ± 4.07 
BNc C (5:1:1) * 134 ± 4.4 0.28 ± 0.04 -41.1 ± 0.59 
Bare PLGA Nps (5:1) * 109 ± 2.8 0.14 ±.0.01 -20.1 ± 0.82 
NKM NA NA -26 ±  0.21 
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retained in the BNc. Among the proteins, the characteristic signature proteins such as CD56, NKG-
2D, and NKp30 were identified from the western blot analysis along with the control pan-cadherin 
(Figure 4.4B). NKG-2D and NKp30 are activating receptors found on the NK-cells for effective 
cytolytic functions on the tumor cell, which overexpress their ligands.155 NK cells recognize tumor 
cells and stressed cells through these ligands. Thus, the presence of these signature proteins would 
facilitate the tumor targeting, thereby delivering maximum contrast agents to help distinguish tissue 
contrast. 
 
Figure 4.4 Protein characterization of BNc. (A) SDS‐PAGE analysis of protein bands in NK‐
92 cell extract, isolated NKM, and the BNc. (B) Western blot analysis of BNc for its characteristic 
protein, CD 56, NKG‐2D, and NKp30. 
The stability of BNc in in vivo serum/plasma conditions was investigated by storing the 
BNc in PBS at 4°C and measuring the variation in hydrodynamic size for 14 days. Figure 4.5A 
shows the stability of BNc after 14 days in PBS. No significant change in its size was observed 
over 14 days of study. Further, the serum stability of the BNc was investigated by incubating the 
BNc with 90% FBS, Figure 4.5B. Compared to bare PLGA NP, BNc show higher stability in 
serum conditions as evident from the no change in its optical density over the period at 560nm. 
This optical measurement records the change in absorbance due to particle aggregation.71,137 
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Figure 4.5 Stability and gadolinium loading/release characteristics of BNc. A) Stability of 
BNc in PBS (pH = 7.4) at 4 °C. B) Serum stability of BNc and bare PLGA‐NP in 90% FBS at 37 
°C. C) Gd3+ loading efficiency of BNc with different initial input concentrations of Gd‐lipid (50–
400 µg). D) Gd3+ release characteristics of BNc in PBS (pH = 7.4) and in acetate buffer (pH = 
5.2) at 37°C. 
 
The Gd3+ loading in BNc was further investigated in detail by increasing the concentration 
of Gd-lipid input during BNc fabrication. With the fixed concentration of PLGA and NKM (5:1), 
the concentration of Gd-lipid was varied between 50 and 400µg/mg of PLGA (Figure 4.5C). The 
maximum Gd loading efficiency of BNc was found to be ~19%, and the Gd loading content was 
found to be 4.5±0.1µg/mg of PLGA. However, we observed that the higher loading of Gd3+ results 
in instability of BNc in physiological pH. For further studies, BNc with the Gd3+ content of 
3±0.4µg with the loading efficiency of 11% was used for all other experiments (BNc). Further, the 
Gd3+ release characteristics of BNc were investigated at pH=7.4 in PBS as well as at pH=5 in 
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acetate buffer in order to map the Gd3+ stability in BNc which is directly related to toxicity. We 
further assumed that by stabilizing Gd3+ in BNc, Gd3+ associated toxicity would be reduced as its 
ionic form is toxic. A cumulative Gd3+ release from the BNc was performed by dialyzing the 
samples using 500Da dialysis bag, which gives easy passage to release free Gd3+ (Mw 157.25 Da) 
to the dialysis reservoir. The cumulative release percentage of Gd3+ from BNc at pH=5 and 7.4 
and 5.2 was found to be around 2% and 10% after 48h (Figure 4.5D). This further confirms the 
stability of Gd3+ in the fabricated BNc. 
 
Figure 4.6 Magnetic properties of BNc. A) T1 recovery curve of BNc in the presence and the 
absence of NKM, showing r1 = 5.0 mm−1 s−1. B,C) T1 contrast phantoms of different 
concentration of BNc (0.05–0.4   10−3 m) with corresponding recovery curve acquired at 14.1 T. 
 
Figure 4.6 shows the magnetic resonance properties of BNc dispersed in water. The r1 
relaxivity of the BNc in the presence and the absence of NKM was found to be 4.8±0.6 mM-1s-1 
and 5.0±0.5 mM-1s-1, respectively. We did not observe significant differences in the r1 relaxivity, 
which further assures us that the distribution of Gd-lipid in the BNc is not affected by the NKM 
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coating. This is in agreement with the earlier report where authors discussed alternation in r1 
relaxivity due to the distance induced confinement of Gd3+.145,156  In the present case, if NMK has 
inserted in between Gd-lipids instead of surface coating, this would increase the distance between 
Gd-lipids, and we should experience a significant change in relaxivity.  Figure 4.6B shows the 
MR phantom images of different concentration of BNc acquired at 14.1T. The phantom images 
showed brighter contrast as the concentration increased to 0.4mM, this was further confirmed by 
corresponding T1 curve (Figure 4.6C).  
 
Figure 4.7 In vitro cellular studies. (A) Confocal laser scanning micrograph of cellular uptake of 
BNc in MCF‐7 cells after 3 h of incubation, immunostained with FITC‐anti‐CD 56. (B) FACS 
analysis of quantitative cellular uptake of BNc in comparison with bare PLGA‐NP after 6 h 
incubation. (C) Biocompatibility of different concentration of BNc (10–150 µg) in MCF‐7 cells 
after 24 h incubation. 
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The cellular uptake and intracellular distribution of the Rhodamine labeled BNc were 
investigated in MCF-7 cells using confocal laser scanning microscope and flow cytometry (Figure 
4.7). MCF-7 cells treated with BNc show rapid uptake of the BNc within 3h of incubation. The 
uptaken BNc were found intact in the cells as evident from the bioaccumulation of immunostained  
FITC-anti-CD56 and Rhodamine signals inside the cells (Figure B.1). The nuclei of the cells were 
further stained with DAPI, and this shows BNc were distributed in perinuclear regions. Z-stack 
images of MCF-7 show clear evidence of intracellular distribution of BNc (Figure 4.7A). Further, 
the selective targeting of the BNc in MCF-7 cells was compared with the bare PLGA NP labeled 
with Rhodamine dye. Flow cytometry analysis was conducted to assess the cellular uptake 
efficiency. The results indicate that cellular uptake of BNc was more predominant than the bare 
PLGA NP illustrating the targeting potential of BNc towards cancer cells (Figure 4.7B). The 
biocompatibility of the BNc and bare PLGA NP was investigated in MCF-7 cells through MTT 
assay. 24h incubation results show that even at higher concentration (150µg/mL) BNc were not 
cytotoxic (Figure 4.7C). This clearly demonstrated the biocompatible nature of BNc, which can 
be used for bioimaging applications in vivo. 
Further, the immunogenicity of the NKM derived BNc was investigated in human 
peripheral blood monocytes, THP-1, using pro-inflammatory cytokine release assay (Figure 4.8). 
Pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) are important biomarkers to identify the 
immunoregulatory potential of nanoformulations. As documented in Figure 4.8, engineered BNcs 
are non-immunogenic as they exhibit minor response against IL-1β, IL-6, and TNF-α in 
comparison with the control cells and positive control (Figure 4.8). No significant levels of 
immunogenicity were observed for isolated NKM, bare PLGA NP, Gd-lipid in comparisons with 
the control cytokine levels (Figure 4.8). Only the positive control, LPS (3µg/mL), shows the 
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elevated levels of IL-1β, IL-6, and TNF-α in the tested cells. This clearly confirms the immuno 
compatibility of BNc for further in vivo imaging studies. 
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Figure 4.8. In vitro immunogenicity of BNc in THP‐1 cells assessed by evaluating the 
proinflammatory cytokines (IL‐1β, IL‐6, and TNF‐α) release after 24 h incubation. 
 
With the assurance of BNc colloidal stability, in vitro cancer targeting, and 
biocompatibility, we moved forward to understand their in vivo targeting ability in 
immunodeficient NU/NU nude mice bearing an MCF-7 tumor. As shown in Figure 4.9A, DiR 
labeled BNc (10mg/kg) were injected via the tail vein, and the distribution of the particle was 
studied under live animal imaging over a period of 24h. Distinguishable kinetics of BNc 
accumulation in the tumor from 3, 6, 12, and 24 h, as shown by the increase in fluorescent intensity 
in the tumor, further suggests the tumor targeting ability of BNc. Accumulation of BNc over the 
24h period also suggests us the blood availability of BNc, thereby providing us a key to its long 
circulating properties. After 24h of the imaging session, mice were euthanized, and the major 
organs were collected. These collected organs were washed with PBS and subjected to ex vivo 
fluorescent imaging (Figure 4.9B). Ex vivo imaging proves the overall tissue distribution of BNc 
with major accumulation in tumor and RES organs like liver and spleen. Compared to the control 
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group (bare PLGA NP), BNc show significant accumulation in the tumor which is twice as much 
as that of bare PLGA NP (Figure 4.9C). 
 
Figure 4.9 In vivo tumor-targeting ability of BNc. (A) Time dependent live animal imaging of 
MCF-7 tumor bearing NU/NU mice after intravenous injection of DiR-labelled BNc (10mg/kg). 
Images were recorded prior to injection and after 3h, 6h, 12h and 24h, respectively. (B) Bio-
accumulation of BNc in tumor bearing mice after 24h post-injection. (C) Comparative tumor 
accumulation of BNc and Bare PLGA nanoparticles in MCF-7 tumor bearing NU/NU mice after 
24h post-injection. 
 
Next, in vivo pharmacokinetics of BNc was investigated after a single intravenous injection 
of 5 mg/kg of NP in MCF-7 tumor-bearing immunodeficient NU/NU nude mice. We used Gd3+ as 
a handle using ICP-MS to assess the pharmacokinetics and additional biodistribution studies. For 
this purpose, BNc were concentrated using Amicon Ultra centrifuge unit (3000 Da molecular 
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weight cutoff) and characterized for its hydrodynamic size and weight yield after lyophilization. 
Both size and weight of BNc were found to be consistent in a number of experiments conducted 
blindly by a research technician. Figure 4.10A shows the blood clearance of BNc after 72 h. The 
blood retention of BNc was found be high (60%) in the first 10h and it gradually reduced with 
time. The amount of BNc in the blood was determined using ICP-MS analysis. The biodistribution 
efficiency of BNc was investigated after a single intravenous administration of BNc (5 mg/kg). 
After 24h, animals were euthanized, and the major organs were investigated for the presence of 
BNc by estimating organ content of Gd using ICP-MS. The percentage of BNc in the liver and the 
spleen was found to be high, as they are the principal reticuloendothelial system that clears NP 
from the body. The percentage of BNc in the tumor tissue was found to be 10±3% of the injected 
dose (Figure 4.10B). This further confirms the tumor affinity of NKM fabricated BNc for targeted 
bioimaging applications and supports our results for NIR imaging session. The pharmacokinetic 
parameters of the BNc were obtained by fitting the concentration of BNc in blood and tissues with 
respect to time intervals and dosage using a two-compartmental model (MATLAB 2017b). Table 
4.2 shows the pharmacokinetic parameters of BNc in MCF-7 tumor-bearing NU/NU mice. The 
circulation half-life (t1/2), area under the curve (AUC), volume of distribution (Vd), Clearance 
(CL), and mean resident time (MRT) of the BNc were found to be 9.51±6h, 1069±507 %ID h/mL, 
3.85±1.16 mL, 0.28±0.14 mL/h, and 13.61±1.38 h, respectively. 
Finally, the advantage of NKM coated BNc in MR imaging of tumors were demonstrated 
using 14.1T NMR system (Bruker Avance III, 600 MHz NMR-MRI). For ex vivo MR imaging, 
following our approved IACUC protocol, tumor animals were intravenously injected with BNc 
(equivalent Gd concentration of 0.008 mmol/kg) and euthanized after 2h. After euthanization, 
following our approved protocol for MRI, animals were rapidly imaged for T1-weighted MR image 
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Figure 4.10. In vivo pharmacokinetics and magnetic resonance imaging studies. (A) 
Circulation half-life of BNc in MCF-7 tumor bearing NU/NU mice over 72h time. (B) Bio-
distribution profile of BNc after single intravenous tail-vein injection in MCF-7 tumor-bearing 
NU/NU mice. (C) Ex vivo T1 weighted magnetic resonance image slices of NU/NU mice bearing 
MCF-7 tumor after 2h post-injection. Slice thickness: 0.5mm. Color circles indicate the standard 
controls; red: water, yellow: 18µM Magnevist®, blue: 37µM Magnevist®. 
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contrast, recorded using a QTR 30 mm coil with a FLASH protocol at 37ºC. Figure 4.10C shows 
the T1-weighted MR images slice of NU/NU mice treated with BNc (Please see negative control 
MRI in Figure B.2). Compared with different image contrast of Gd standards, illustrated in 
different color circles (red: water, yellow:18µM Magnevist®, blue: 37µM Magnevist®), BNc 
shows distinctive brighter image contrast in tumor tissues. Along the various MRI slices (slice 
thickness of 500µm), it is clearly evident that the BNc were deeply penetrated into the tumor 
tissues and shown enhanced MR image contrasts to evaluate tumor as compared to that of 
surrounding soft tissue contrast. Comparing the data from MRI ex vivo imaging and data from in 
vivo NIR bioimaging, the engineered BNc show promises in targeting MCF-7 tumor. 
Table 4.2 Pharmacokinetic parameters of BNc injected NU/NU mice by two-compartmental 
analysis. 
PK parameters Biomimetic Nanoconstruct (BNc) 
t1/2 (h) 9.51±5.74 
AUC (%ID.h/mL) 1068.8±507.27 
Vd (mL) 3.85±1.16 
CL (mL/h) 0.28±0.14 
MRT (h) 13.61±1.38 
 
t
1/2
: half-life, AUC: Area under the curve, Vd: Volume of distribution, CL: Clearance, MRT: Mean residence time  
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4.4 Conclusion  
Herein, we described a biomimetic approach to fabricate a multifunctional NP system that 
has acquired properties from NK cells and studied its potential for tumor targeting and imaging. 
This hybrid platform technology, where synthetic and biological components were merged to 
exhibit unique properties, and consisting of both hydrophilic and hydrophobic assembly, shows 
versatile properties and feasibilities in surface functionalization and have a vacancy in the 
hydrophobic core for cargo encapsulation. Moreover, the existence of BNc in the cancer cells and 
the tumor as compared to that of bare particle suggested the dependence of targeting due to the 
acquired properties from the NK-92 cells. Considering the fact that successful cancer therapy 
requires drugs being precisely delivered to the tumors, the engineered BNc would have promises 
in drug delivery and monitor the therapeutic response in a single session.  
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Chapter 5 - Red Blood Cell Membrane Disguised Paramagnetic 
Polymeric Nanoparticle for Contrast Enhanced Magnetic 
Resonance Imaging 
Abstract 
Recent progress in bioimaging nanotechnology has greatly impacted on the diagnosis, 
treatment, and prevention of disease, especially by enabling early detection and diagnosis. Among 
different type of bioimaging modalities, magnetic resonance imaging (MRI) with a gadolinium-
based contrast agent (GBCA) is one of the most commonly used in the clinic. These small 
molecular agents distribute rapidly between plasma and interstitial spaces following intravascular 
injection. They are ultimately eliminated through the renal route with half-lives of 1-2 h.  Due to 
the short half-life of these agents, the clinical impact of this imaging technique is limited. To 
improve the usage of GBCA in diagnosis, herein, an effort has been put forth by incorporating 
GBCA into a nanoscale delivery system mimicking the property of red blood cell (RBC) that could 
facilitate contrast enhancement and prolong retention time in the biological system. The proposed 
nanoconstruct is made up of biocompatible/biodegradable poly(lactic-co-glycolic acid) (PLGA) 
polymeric core surface imprinted with RBC membrane and followed by the insertion of lipid 
conjugated GBCA. The proposed nanoparticle exhibits a hydrodynamic diameter of 120 ± 5 nm 
with a zeta potential of -25±2 mV and can load 8±0.3 wt% of gadolinium with robust stability in 
physiological and in blood serum condition. The retention of surface properties of RBC into the 
polymeric nanoparticle (PNP) was further confirmed by surface protein analysis. Upon the 
infusion of GBCA, the magnetic properties of PNPs exhibit r1 relaxivity of 16±0.2 mM
-1s-1 at 3 
Tesla (T) which is five times greater than that of conventional clinically used MR contrast agent 
(i.e., Magnevist®, r1=3±0.15 mM-1s-1, 3T). As a result of higher relaxivity, it enhances the 
contrast in live animal and cell and the cell-free environments without causing toxicity. Given a 
higher magnetic and biomimetic property and stability, the biomimetic PNP proposed herein is a 
promising agent for therapy and diagnosis. 
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5.1  Introduction 
Magnetic Resonance Imaging is one of the most routinely used imaging modalities in the 
clinic representing for total 4 million scans within the USA in 2017.157,158 The extensive clinical 
use of MRI mainly attributed to its non-invasively abnormal detection of tissues and superior 
spatial and temporal contrast resolution when compared to that of X-ray and CT. The contrast in 
MR images are mathematically defined and converted based on the relaxation process of water 
proton within different tissue environment under strong external magnetic field. For example, 
when water protons undergo spin-spin T2 relaxation process, no energy transfer occurs giving a 
negative contrast signal (dark images). On the other hand, when water protons undergo spin-lattice 
T1 relaxation process, the absorbed energy transfers to surrounding tissue leading to the production 
of positive contrast signal (bright images). To further push forth the clarity of region-of-interest in 
advanced clinical image application, MRI is usually used in the presence of contrast agents. There 
are two main types of contrast agents that are classified based on their capability of altering the 
longitudinal (T1) and transverse (T2) relaxation time of the surrounding water protons. The T2 
based contrast agent, representing by super-paramagnetic iron oxide nanoparticles, generates a 
large local inhomogeneous magnetic field to shorten T2
 relaxation time, further enhancing the dark 
image.14,159 On the other hand, T1 based contrast agents, taken paramagnetic ions such as Gd
3+ or 
Mn2+ as examples, facilitate bright contrast enhancement via proton-electron dipole interaction.157 
Due to the ability to produce a brighter image, T1 contrast agents (particularly gadolinium-based 
contrast agents) become a preferable choice to use in the clinic for better image resolution and 
easy detection. 
 To date, approximately 40 out of 100 MR scans is acquired with the injection of GBCAs 
with a total up to 40 million administrations worldwide.160 The current commercially available 
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GBCAs include Gd-DOTA (Dotarem®), Gd-HP-DO3A (ProHance®), Gd-BT-DO3A 
(Gadovist®), Gd-DTPA (Magnevist®), Gd-DTPA-BMA (Omniscan®), Gd-DTPA-BMEA 
(OptiMARK®), Gd-BOPTA (Multihance®), and Gd-EOB-DTPA (Eovist®). These gadolinium 
ions (Gd3+) are chelated in linear or macrocyclic molecules comprising a total nine coordinating 
sites. Eight out of nine coordinate ligands bind tightly to Gd3+ to increase thermodynamic, kinetic 
stability and avoid toxicity related to free Gd3+. Meanwhile, the remaining coordination site offers 
an open space for a single water molecule to impermanent bind and generate dipolar interactions 
with electron spins of gadolinium ion leading to an increase in magnetic relaxation of proton 
nuclei. This ultimately gives a contrast enhancement under MRI.161,162 However, due to small 
chemical structure, those listed GBCAs tend to distribute throughout the body and quickly 
extravasate into interstitial compartment. Consequently, the ability to obtained precise image 
interpretation is hampered due to the increase of signal-to-noise ratio and short image window 
(inability of prolonging plasma residence time).162–165 In the case of blood pool agent, the above 
mentioned limitations become more severe when contrast agent have to circulate for a longer time 
in the vascular lumen to obtain clinical relevant MR-images. As such, different strategies to 
incorporate GBCA into a nanoscale delivery system including liposome,166 micelles ,167–169 
polymeric nanoparticle,79,81 and dendrimer170–172 have been extensively developed. However, the 
translational pathway of these engineered gadolinium-based nanoconstruct remains uncertain due 
to the difficulties of overcoming complex biological barriers of these exogenous synthetic 
materials.19,173  
Recently, the development of biomimetic nanoparticle consists of cell membrane coating 
over synthetic core has drawn significant attention owing to its ability to translate natural materials 
into functional materials and conquering biological system. Over the last decade, a variety of cell 
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types and core materials were studied covering a broad spectrum of nanotechnology ranging from 
drug delivery,70,137 vaccination,174 detoxification,71,175,176 immunotherapy,177,178 and now starting 
to expand toward bioimaging arena.179–182 By preserving complex biological functionalities of the 
cell membrane, the synthetic core can acquire the corresponding cellular designated biological 
function while keeping or enhancing their ordinary properties. Particularly in the field of 
bioimaging, different organic and inorganic imaging agents have been studied extensively for the 
possibility to conceal by cell membrane with the hope of further improving tumor diagnosis and 
tracking therapeutic response. Example of the application of cell membrane technology in MRI 
application can be seen in by hybrid nanoconstruct made up of red blood cell, cancer cell, and 
platelet cell membrane functionalized iron oxide and gadolinium-based nanoparticles.179,182–184 
The use of these proposed nanostructures has proven their outstanding disease targeting properties 
for the improvement of diagnosis and therapy.  
Although the functional role of the biomimetic delivery agent is well-documented, the in-
depth understanding on the variations in its performance at the structural levels, such as when the 
contrast agent is arranging in the biomimetic system, have not received sufficient attention. In the 
context of MRI, the questions regarding physical effects such as the imaging probe orientation, 
water exposure, protein interference, confinement, and quenching effects are still waiting for the 
investigation. Encouraged by these unanswered questions, we sought into constructing a 
biomimetic imaging nanoconstruct that allowed us to take a deep understanding of a structural 
relationship of cell membrane coating and MR contrast agent. We further extended knowledge 
gained to elucidate their corresponding MR mechanism on image enhancement and biological 
performance under in vitro and in vivo conditions. This study resulted in an optimized red blood 
cell membrane disguised gadolinium-based PNP for tunable T1 relaxivity. The isolated RBC 
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membrane directly fused onto polymeric core pre-labeled with gadolinium lipid conjugate. The 
biomimetic strategy allowed to conceal contrast agent from the endogenous components resulting 
in a long circulating and high longitudinal relaxivity for improved MRI visualization of the 
vascular lumen. 
5.2  Materials and Methods 
Material and chemical 
50:50 Poly(D,L-lactide-co-glycolide) carboxylate end group (0.55-0.75 dL/g) was 
purchased from DURECT Corporation (Birmingham, AL, USA). 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl) 
(sodium salt) (16:0 Succinyl PE), and L-α-Phosphatidylethanolamine-N-(lissamine rhodamine B 
sulfonyl) (Ammonium Salt) (Egg-transphosphatidylated, Chicken) (Egg Liss Rhod PE) were 
purchased from Avanti Polar Lipid Inc. (Alabaster, AL, USA). N-Hydroxysuccinimidyl ester 
activated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) was purchased 
from Macrocyclics (Dallas, TX). Gadolinium (III) acetate hydrate (Gd(OAc)3) were purchased 
from Sigma-Aldrich (Milwaukee, WI, USA). All other chemicals and solvents were purchased 
from Sigma-Aldrich (Milwaukee, WI, USA) and used as received. 
Cell line and animal model 
Human peripheral blood monocyte THP-1 cells were maintained in RPMI medium with 
10% (v/v) fetal bovine serum (FBS) and penicillin/streptomycin (100μg/mL) and maintained at 
37 °C in 5% CO2 environment. Macrophage (J774) was purchased from ATCC and maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) FBS and 
penicillin/streptomycin (100μg/ml) and maintained at 37 °C in 5% CO2 environment.  
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Six-week-old female NU/NU nude mice were procured from Charles River Laboratories 
International, Inc. and used for the study after ten days acclimatization. All animal experiments 
and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) and 
Institutional Biosafety Committee (IBC), Kansas State University, Manhattan 
Synthesis of DSPE-DOTA-Gd 
The synthesis of Gadolinium ion chelated DSPE-DOTA was performed using a two-step 
preparation method as previously described with some modifications. In brief, 75 mg of DSPE 
was first dissolved in 10 mL chloroform containing 2% (v/v) triethylamine (TEA). The mixture 
was stirred for 30 mins at room temperature to activate the amine end group of DSPE. After that, 
86 mg DOTA-NHS ester was added and stirred vigorously until all reagents were completely 
dissolved. The reaction was allowed to take place for another 3 h at 40ºC. At the end of incubation, 
the obtained clear reaction mixture was concentrated and dried under vacuum to recover white 
powder. To purify the conjugating DSPE-DOTA lipid, 6 mL of deionized water was used to 
disperse reaction crude, the suspension underwent 5 cycles of freezing and thawing in liquid 
nitrogen and 60ºC water bath, respectively, and then centrifuged at 4500 g for 10 mins. The 
resulted DSPE-DOTA suspension was filtered through a 0.2 µm membrane to remove insoluble 
by-product and lyophilized to get dry powder.  
The gadolinium ion was thermodynamically chelated to DSPE-DOTA conjugated lipid 
under an acidic condition at 50oC. Specifically, 50 mg DSPE-DOTA (0.05 mmole) was hydrated 
in 10 mL of acetate buffer (pH = 5.5) and further treated with 0.1 mmole of Gd(OAc)3 50ºC for 12 
h.  After incubation, the Gd-DOTA-DSPE was purified by centrifugation at 4500g for 10 min. The 
obtained white product was washed 3 times with acetate buffer (pH 5.5) and 2 times with water to 
remove all non-chelated Gd3+ ion. The samples were lyophilized to obtain a dry powder. The 
91 
percentage yield of the gadolinium concentration in the reaction mixture was analyzed by using 
Inductively Coupled Plasma Mass spectrometry (ICP-MS, Perkin Elmer, NEXion 350X). The 
resulting yield was 98%. 
Red blood cell membrane extraction 
Red blood cell membrane (RBC-M) was extracted from whole blood using hypotonic 
treatment.71 In brief, whole blood was centrifuged to remove any buffy coat and plasma and mixed 
with 10 volume of Mili-Q water to disrupt RBC. The aliquot was sonicated briefly using bath 
sonication for 5 mins to hemolysis RBCs. The blood suspension was then centrifuged at 5,000 rpm 
for 5min to separate RBC-M from the hemoglobin by carefully removing the suspension. The 
RBC-M pellet was washed several times to remove hemoglobin completely. The purified RBC-M 
was stored at -20ºC for further use. The amount of protein in extracted RBC-M was quantified by 
bicinchoninic acid (BCA) assay. 
Preparation and characterization of red blood cell membrane coated paramagnetic polymeric 
nanoparticles (RBC-Gd-PLGA) 
RBC-Gd-PLGA nanoparticles (NPs) were prepared by nanoprecipitation technique 
following by imprinting of RBC membrane on the surface. In brief, the paramagnetic polymeric 
cores were prepared by adding dropwise 100µL of PLGA in acetonitrile stock (10mg/mL) into 
1mL Milli-Q water containing various amount of Gd-L (50, 100, 150, 200, and 400 μg/mL) under 
magnetic stirring condition. The mixture was stirred continuously overnight to evaporate off the 
organic solvent. The final RBC-Gd-PLGA were fabricated by coating RBC-M onto 1 mg of 
preformed paramagnetic polymeric cores at various membrane protein amount (1, 5, 10, 100, 250, 
500, and 1 mg) using bath sonication (Branson CPXH 2800, 40kHz) for 10 mins with 50% power. 
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The sample was further purified using Amicon Ultra-4 centrifugal filter (Millipore, MA) with a 
molecular weight cut-off of 10 kDA and stored at 4 °C for further use. 
Rhodamine dye labeled RBC-Gd-PLGA was prepared by mixing 30µg of L-α-
Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) (Ammonium Salt) (Egg Liss Rhod 
PE) with Gd-L suspension prior to the fabrication of paramagnetic polymeric core.  
Characterization of RBC-Gd-PLGA 
The hydrodynamic size and zeta potential of the RBC-Gd-PLGA were characterized using 
Dynamic light scattering analysis (Malvern, Nano ZSP). The morphology of RBC-Gd-PLGA was 
further confirmed using transmission electron microscope (FEI Technai G2 Spirit BioTWIN). 
TEM samples were prepared by incubating 50 μL of RBC-Gd-PLGA (200μg/mL) with 50 μL of 
2% Uranyl acetate for 2 mins at room temperature. The sample was then placed on a fomvar coated 
copper grid (400 mesh) and let stand for an additional 5 mins. The excess amount of sample was 
removed prior to TEM acquisition. TEM images were acquired at 120kV and analyzed by GATAN 
digital imaging system (GATAN, Inc.).  
The serum stability of the prepared PLGA NPs, Gd-PLGA, RBC-PLGA, and RBC-Gd-
PLGA were carried out as reported. Specifically, 150µL of 1mg/mL nanoparticles were incubated 
with 50µL of Fetal Bovine Serum at 37°C. The change in absorbance at 560nm was measured 
kinetically every 6s over a period of 1h, a double-orbital shaking with slow speed was applied 
prior to each measurement using Microplate reader (BioTek, Synergy H1 hybrid reader). 
The stability at physiological condition was investigated by dispersing nanoparticles in 
phosphate buffer saline (PBS, pH 7.4) at the particle concentration of 1mg/mL. The nanoparticles 
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were incubated at 37°C for 7 days. The changes in hydrodynamic size were tracked daily using 
Dynamic light scattering analysis 
Fluorescence resonance energy transfer 
To track the insertion of RBC-M onto the surface of Gd-PLGA, fluorescence resonance 
energy transfer study was conducted. For the experiment, a FRET pair of chromophores, a 
fluorescent donor (L-α-phosphatidylethanolamineN-(4-nitrobenzo-2-oxa-1,3-diazole) 
(Ammonium Salt) (Egg-transphosphatidylated, Chicken), PE-NBD and a fluorescent acceptor (L-
α-Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) (Ammonium Salt) (Egg-
transphosphatidylated, Chicken) PE-RhB, was incorporated separately into RBC-M vesicle and 
Gd-PLGA (or PLGA) with a 3:7 mole ratio, respectively. In particular, the NBD labeled RBC-M 
vesicles were prepared by sonicating 250 μg RBC-M with 30 μg PE-NBD for 10 mins. Similarly, 
99.4 μg PE-RhB was used to label 1 mg PLGA or Gd-PLGA by dispersing in 1 mL water/Gd-lipid 
suspension prior to polymeric core fabrication.  
Typical fusion study was performed by mixing 100 μL of NBD-RBC with 100 μL RhB-
PLGA/RhB-Gd-PLGA. The mixture was incubated for a varying period (5, 30, and 60 mins) at 
37ºC with gentle shaking or bath sonicated for 10 mins. Thereafter, 100 μL of the suspension was 
used to record the fluorescence emission spectrum at λex = 470 nm and λem = 500-700 nm. 
The in vitro structural integrity of the RBC-Gd-PLGA was also assayed by labeling core 
and shell of RBC-Gd-PLGA with different color dyes following the aforementioned protocol. The 
colocalization of NBD and RhB fluorescent was studied using K7M2 cells, and fluorescent images 
were acquired with a Confocal Laser Scanning Microscope. 
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Red blood cell membrane protein characterization 
The retention of characteristic proteins of the red blood cell membrane and its translocation 
into paramagnetic polymeric core was confirmed by SDS-PAGE analysis, dot blots and western 
blot. For SDS-PAGE analysis, whole cell lysate, RBC-M, RBC-Gd-PLGA samples were prepared 
at a protein concentration of 300 μg/mL. RBC-Gd-PLGA were collected by centrifugation at 
13,000 rpm for 30 mins and redispersed in gel loading dye. All samples were heated at 90 °C for 
5 min, and 20 μL of samples were loaded into wells of 4–20% Mini-PROTEAN® TGX Protein 
Gels and stained using Coomassie Brilliant Blue. For Western blot analysis, proteins were 
transferred to PVDF membrane by the wet-blot method. The transfer was carried out for 1 hr at 
2500 mA, 500 W, and 100 V. After that, the membranes were blocked in 5% milk in TBST for 30 
mins at room temperature under rocking condition. The membrane was subsequently treated with 
primary antibodies for Glycophorin A (Santa Cruz), β-actin (Santa Cruz), and CD47 (Santa Cruz) 
along with HRP-conjugated anti-mouse IgG secondary antibody (Cell Signaling). The blotted 
films were further developed using SignalFire™ ECL Reagent (Cell signaling) and imaged 
for chemiluminescence signal under Bio-imager (Kodak).  
Gadolinium loading and release study 
The cumulative gadolinium release from the RBC-Gd-PLGA was assessed at 37°C under 
physiological and endogenous ionic condition. In brief, RBC-Gd-PLGA (1mg/mL, 2mL) were 
placed in a dialysis bag membrane (Mw. Cutoff=500Da) and dialyzed against 250mL of PBS 
(pH=7.4) under shaking condition (100rpm). At predetermined time intervals, 500µL of the sample 
was collected and replaced by 500 μL fresh media. The amount of released Gd was quantified by 
ICP-MS. As a control experiment, 25µg/mL of gadolinium (III) acetate was placed in a dialysis 
bag and processed under the same condition. 
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Relaxation properties 
Effect of coating on magnetic property: The changes of longitudinal relaxation time in the 
presence and absence of RBC membrane coating was investigated under clinical MRI (3 Tesla). 
Five different concentrations of GdL input (400, 200, 100, 50, and 25 µg/mL) were used to prepare 
RBC-M coated, and non-coated NPs follow the abovementioned protocol. A serial dilution of 
samples was prepared prior to MRI acquisition. The longitudinal relaxation time of RBC-Gd-
PLGA in an aqueous solution at different Gd3+ concentration was obtained at 25⁰C using a fast 
spin echo sequence with variable repetition time. Scans were performed with the following 
imaging parameters: repetition time (TR)= 6000, 3000, 1500, 800, 600, 400, 200 ms, echo time 
(TE) = 10 ms, slice thickness=2 mm, flip angle (FA) =90⁰, image size 256×256, FOV=25.6×25.6. 
The representative T1 weighted magnetic resonance phantom images of RBC-Gd-PLGA were 
taken at TR=400 ms, TE=10 ms, and slice thickness = 2mm. The longitudinal coefficient relaxivity 
value r1 was determined from the slope of the plot of 1/T1 versus the sample concentration. 
Magnevist with similar Gd3+ was used as a control. 
Effect of gadolinium lipid density of magnetic property: The gadolinium lipid density on 
the surface of the polymeric core was tuned by changing the feed amount of GdL while keeping 
all other parameters (volume of water, amount of polymer, and RBC-M protein) constant. The 
samples were concentrated to get final GdL concentration of 100 µg/mL. The longitudinal 
relaxation time of RBC-Gd-PLGA in an aqueous solution at different Gd3+ concentration was 
obtained as described above. The longitudinal coefficient relaxivity value r1 was determined from 
the slope of the plot of 1/T1 versus the sample concentration. Magnevist with similar Gd
3+ was 
used as a control. 
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In vitro immunogenicity assay 
The immunoregulatory potential of the prepared nanoparticles was tested standard cytokine 
analysis assay. In brief, 4 × 105 human monocytic cell line (THP-1) were seeded in a 24-well plate 
and treated with bare PLGA NPs (10μg/mL), RBC-M (10μg/mL), Gd-lipid (10μg/mL), and RBC-
Gd-PLGA (10μg/mL) at 37°C for 24h. After 24h incubation, cell culture supernatants were 
collected, centrifuged to remove cell debris and stored at -20°C for further analysis. For cytokine 
assay, samples were thawed and analyzed for pro-inflammatory cytokines, IL-1β (LOD:1.7 
pg/ml), IL-6 (LOD:1.5 pg/mL) and TNF-α (LOD:1 pg/mL) using Magnetic Human Cytokine 
Multiplex Assays Kit (R&D Systems, Inc. Minneapolis, MN) in Luminex MagPix® instrument 
(Millipore Inc.,) as manufacturer recommendations. For positive control, cells were treated with 
5μg/mL of lipopolysaccharide for 24h. 
In vitro macrophage uptake study 
J774 murine macrophage cells were plated at a density of 20,000 cells per well on an 8-
well chamber slide (BD Biosciences). After 24hr, cells were treated with RhB labeled PLGA, 
RBC-Gd-PLGA, and PEGylated NPs with a final NP concentration of 50 μg/mL and incubated 
over varying periods (0.5, 1.5, 3, and 6 hrs). After incubation, the treated cells were washed twice 
with 1× PBS (pH 7.4), fixed with 4% paraformaldehyde for 15 min at room temperature, stained 
with DAPI for an additional 10 min, mounted with Fluoromount aqueous medium (Sigma-
Aldrich), and imaged using CLSM (Carl Ziess, LSM-700). The cellular uptake was assessed by 
measuring RhB fluorescence intensity using Image-J software (National Institute of Health). The 
data were analyzed using one-way ANOVA with Turkey’s multiple comparison post-test. 
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Circulation half-life and bio-distribution study 
To assess the accumulation of contrast agents in the different tissues, the amounts of Gd3+ 
in organs at predetermined time points after injection of RBC-Gd-PLGA or Magnevist were 
analyzed by ICP-MS. In brief, each mouse was administrated of Gd3+ at a dose of 
0.05 mmol Gd3+/kg body weight of mouse in 100 μL PBS (Clinical Gd dose is 0.1 mmol/kg).185 
At an appropriate time after the intravenous injection, blood was collected and the mice were 
euthanized, different tissues were collected, weighed, and completely digested in 1.0 mL solution 
of 70% nitric acid through heating at 90⁰C for 8 hrs. After digestion, the solution was filtered and 
diluted. The Gd3+ concentrations in the samples were determined by calculating with a standard 
curve obtained with using Gd(III) calibration standard. 
In vivo Magnetic Resonance Imaging 
In vivo MRI study was performed using NU/NU mice on a 3T MRI clinical scanner. In 
brief, the mice were intravenously injected with RBC-Gd-PLGA (equivalent Gd concentration of 
0.017 mmol/kg) or Magnevist (equivalent Gd concentration of 0.03 mmol/kg). The MRI images 
were acquired immediately at injection and post-injection at 15 mins and 30 mins.  The T1‐
weighted MR images were recorded using fast spin echo sequence. The recorded images with 
different slices were subtracted with pre-contrast images and processed using maximum intensity 
projection. All images were analyzed using Medical Image Processing, Analysis, and 
Visualization (MIPAV) software.  All animal experiments and protocols were approved by the 
Institutional Animal Care and Use Committee and Institutional Biosafety Committee, Kansas State 
University, Manhattan. 
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5.3 Result and Discussion 
RBC membrane is one of the first biological materials that was utilized to provide effective 
concealment for nanoparticles.69,70 A variety of nanoparticle type has been tested for the possible 
incorporation of this biologically derived material to extend their use to cover a broad spectrum 
biomedical application ranging from drug delivery, detoxification to bio-sensors.71,137,179,180,186 
Among different type of core materials being tested, PLGA is well known for its capability of 
being coated by RBC membrane. Even though the molecular mechanism underlying the cloaking 
of the cell membrane and the synthetic nanoparticle is unclear, the hybridization between RBC-
membrane and PLGA core was suggested to be in favor of negatively charged core with right-
side-out membrane conformation.187,188 Adapting the well-established protocol of RBC membrane 
coating over PLGA nanoparticle, we engineered a biomimetic paramagnetic polymeric 
nanoparticle with the inclusion of Gadolinium ion (a paramagnetic ion) to obtain a long circulating 
MRI contrast agent.  
To achieve a stable paramagnetic complex that can be inserted on the surface of biomimetic 
nanoconstruct, we conjugated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-
a cyclic gadolinium macro-chelator to the hydrophilic head of phospholipid using carbodiimides 
follow by N-hydroxysuccinamide (EDC/NHS)  crosslinking reaction (Figure C.1). The obtained 
modified lipid (DOTA-DSPE) was incubated with Gadolinium Acetate at pH 5 to entrap Gd3+ into 
DOTA chelator yielding gadolinium lipid or GdL. Owing to the amphiphilicity, nanoprecipitation 
of PLGA polymer in GdL suspension spontaneously form a lipid-polymer paramagnetic 
nanoparticle core. To further enhance the biological functionality and stability, we conceal the 
surface of lipid-polymer hybrid nanoparticle with RBC-M using sonication technique. The amount 
of RBC-M used to coat paramagnetic nanoparticle was optimized by varying the amount of RBC-
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M protein input. The optimal concentration of 750 µg protein/ 1mg particle core was chosen due 
to the excellent stability in physiological pH 7.4 over a long incubation time (Figure C.2 and C.3). 
Upon coating RBC-M, a core-shell structure was obtained as evidence in TEM image (Figure 
5.1B) with a core diameter of 48 ± 10 nm and the shell thickness of 9 ± 2 nm (Figure C.4). Both 
Gd-PLGA and RBC-Gd-PLGA exhibited similar hydrodynamic diameter around 120 ± 5 nm 
(Figure 5.1C). The significant different between TEM and hydrodynamic size is presumably due 
to the presence of hydrated glycan moieties of protein on the surface of the RBC membrane.188 In 
naïve RBC, the glycan is responsible for maintaining negatively charged property and avoid the 
attachment with other cells while circulating.189 While translocation onto the engineered 
nanoconstruct, besides the biological designated properties, the polysaccharide moieties on the cell 
membrane is capable of forming hydrogen bonding with a water molecule, hence forming a thick 
hydrating layer which contributes to the stability of nanosystems. The successful insertion of the 
RBC membrane on the surface of the paramagnetic polymeric core was further confirmed by 
surface zeta potential. The highly negative charge of Gd-PLGA core (-40mV) was shifted toward 
more positive number (-26 mV), equivalent to that of RBC, displaying a median charge value 
between Gd-PLGA core and RBC-M surface upon fusion of RBC-M (Figure 5.1D). With the 
presence of RBC-M, RBC-Gd-PLGA became highly stable under serum condition in a similar 
manner to that of RBC-PLGA, whereas uncoated PLGA and Gd-PLGA were immediately 
aggregated as indicated by the increase in absorbance at 560 nm (Figure 5.1E).  
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Figure 5.1 Design and characterization of RBC-Gd-PLGA. (A) Schematic illustration of the 
preparation of biomimetic paramagnetic nanoconstruct made up of the red blood cell membrane, 
Gd-Lipid, and PLGA using lipid insertion process. (B) Transmission electron microscopy (TEM) 
image of RBC-Gd-PLGA NPs negatively stained with uranyl acetate. (C) Hydrodynamic size of 
bare Gd-PLGA cores, RBC membrane-coated Gd-PLGA measured by dynamic light scattering 
(DLS). (D) The surface zeta potential of bare Gd-PLGA, RBC membrane vesicles, and RBC-Gd-
PLGA showing the shift of surface charge upon the insertion of RBC membrane onto the Gd-
PLGA NPs. (E) Serum stability test measured dynamic aggregation of nanoparticles using 90% 
serum environment, here we look at the rapid increase in optical density of 560 nm due to NPs 
aggregation in serum protein. 
 
When nanoparticle travel in the bloodstream, the surface of nanoparticle serve as the first 
point of cell recognition which directly determines the effectiveness of nanoparticle’s performance 
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in biological condition. In many cases, under physiological condition, the binding of endogenous 
materials such as proteins can form the protein corona on the surface of nanoparticle which further 
alters the physiological properties and the in vivo fate of nanoparticle. To prevent this scenario, we 
utilized the RBC membrane as a concealment layer to (1) limit the absorption of protein on the 
surface of nanoparticles and (2) protecting Gd complex from other endogenous ions. The insertion 
of RBC-M onto paramagnetic nanoparticle was monitored by fluorescence resonance energy 
transfer (FRET) in which the distance of fluorophores can be monitored based on the energy 
transfer phenomenon between electron donor and acceptor. The NBD-PE (electron donor) lipid 
was used to labeled RBC membrane by sonication while RhB-Egg PC (electron acceptor) labeled 
paramagnetic polymeric core was prepared during nanoprecipitation. As the distance between 
NBD labeled RBC-M and RhB-labelled became shorter, the NBD fluorophore can be more 
efficient in donating an electron to the RhB fluorophore. As a result, the fluorescent intensity of 
NBD peak at 525 nm would be diminished while the fluorescent signal of RhB at 600 nm would be 
enhanced, which we observed in our experiment as depicted in Figure 5.2B and 5.2C. The FRET 
phenomenon took place in a time-dependent manner in which FRET efficiency increased up to 45% 
(RBC-M and PLGA) and 54% (RBC-M and Gd-PLGA) over 60 minutes of incubation (Figure C.5). 
The translocation process of cell membrane onto paramagnetic nanoparticle core can be facilitated 
by brief sonication (~ 30 sec) follow by incubation leading to the improvement of FRET efficiency 
up to 60% (RBC-M and PLGA) and 71% (RBC-M and Gd-PLGA). In all cases, the %FRET 
efficiency of RBC-M with Gd-PLGA is higher than that of RBC-M with PLGA, indicating that the 
RBC-M is more effective in infusing onto the surface of paramagnetic nanoparticle core than that of 
bare PLGA. This observation indicated that synthetic Gd complex (Gd-lipid) might provide the 
additional driving force for the rearrangement of RBC-M on the polymeric core. 
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Figure 5.2. Protein characterization of RBC-Gd-PLGA. (A) Schematic representation of the 
re-arrangement of the cell membrane and synthetic lipid and typical characteristic proteins 
presence on RBC membrane. (B) and (C) FRET study showing the insertion of RBC-M onto the 
Gd-PLGA in the manner similar to that of bare PLGA. (D) The SDS-PAGE analysis of protein 
bands in a whole cell lysate, isolated RBC-M, PLGA, and RBC-Gd-PLGA. (E) and (F) Dot blot 
and western blot analysis, respectively, of RBC-Gd-PLGA depicting the presence of characteristic 
proteins, β-actin, CD47, and Glycophorin A.  
 
To further confirm the successful translocation of RBC-M onto proposed nanoconstruct, 
we conducted SDS-PAGE and western blot analysis. The total proteins profile of RBC-M and 
RBC-Gd-PLGA were well-resolved on SDS-PAGE gel with the typical bands of spectrin, band 3, 
band 4, GAPDH, Glycophorin A, and Actin (Figure 5.2D). More specifically, CD 47 - a major 
“don’t-eat-me” protein responsible for the survival of RBC in vivo was observed in dot blot and 
western blot for both RBC-M and RBC-Gd-PLGA (Figure 5.2E and F). In addition, the presence 
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of Glycophorin A (GPA), one of the most abundant transmembrane protein of RBC was also 
confirmed (Figure 5.2E and F). Glycophorins are densely glycosylated and contain a sialic acid 
molecule that was proven to give the cell structural integrity and mechanical properties.189 The 
removal of glycoprotein causes the collapse of RBC-PLGA NPs as indicated in a previous 
publication.188 Hence the presence of both CD 47 and GPA in our nanoconstruct help us to ensure 
the stability and immune evasion of RBC-Gd-PLGA when used in in vivo environment. 
  After getting the confirmation of the structural arrangement of nanoconstruct, the retention 
efficiency of GdL on the surface of biomimetic nanoparticle was investigated by inductively 
coupled plasma mass spectroscopy (ICP-MS). The amount of Gd3+ in RBC-Gd-PLGA was varied 
by changing the feed amount of GdL (50, 100, 200, and 400) while keeping the polymer weigh 
constant in the polymeric core preparation step. As a result, five different cores were obtained and 
underwent RBC-M coating (the same amount of protein membrane was used in all cases) using 
the same protocol as describe above. As shown in Figure 5.3A, the retention efficiency of GdL 
increased from 75% to 90% as the initial input of GdL increased from 50 to 400 μg per 1 mg of 
PLGA polymer. Note that when the concentration of initial GdL input fell below 25μg, the bare 
paramagnetic polymeric core became unstable and aggregated. This phenomenon together with 
the increase of GdL retention efficiency indicates that the PLGA core surface is partially stabilized 
and capable of holding a different density of GdL.  Furthermore, the Gd3+ release under various 
physiological condition was examined. As we anticipated that the RBC-Gd-PLGA nanoconstruct 
could be served as a blood pool contrast agent, the phenomenon such as transmetalation with 
endogenous scavenger cations (Zinc, Iron, and Copper ion) while traveling in the bloodstream 
should be minimized in order to achieve a better safety profile. Therefore, the RBC-Gd-PLGA was 
challenged with different ion media in simulated body fluid. The Gd3+ release characteristics of 
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RBC-Gd-PLGA was mapped in term of cumulative Gd3+ release from a 500 Da dialysis bag. This 
selected molecular weight cutoff gives a free passage of all ion presence in the media. As a result, 
in simulated body fluid (pH 7.4), RBC-Gd-PLGA appeared to be highly stable with just 1% 
cumulative release over 72 hours of incubation (Figure 5.3B). On the other hand, the amount of 
Gd3+ released from Magnevist (a clinical contrast agent) under the same condition increase 
significantly as the incubation time increase leading to the cumulative release of 10% at 72hr of 
incubation (Figure 5.3B). All of this information together confirms the stability of Gd3+ in the 
nanoconstruct. 
 
Figure 5.3 Gadolinium loading and release study. (A) Gd3+ loading efficiency of RBC-Gd-
PLGA with different initial input concentrations of Gd-lipid. (B) Gd3+ release characteristics of 
RBC-Gd-PLGA in simulated body fluid at 37°C. 
 
To investigate the MRI contrast of the RBC-Gd-PLGA, we first looked into the effect of 
cell membrane coating on the magnetic relaxivity of the nanoconstruct. Two sets of samples in the 
presence and absence of RBC coating with different GdL input concentrations were fabricated. 
The phantom image revealed that the contrast is slightly enhanced when paramagnetic core coated 
with RBC-M (RBC-Gd-PLGA) as compared to that of non-coated counterpart (Figure 5.4A). 
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Specifically, the contrast was enhanced by 10 % upon cell membrane coating. This type of slight 
contrast enhancement can be explained on the basis of two possible reasons (1) the proteins 
presence in the cell membrane outer layer introduce mass and steric hindrance surrounding 
paramagnetic Gd3+ ion, leading to the restriction in rotation and retardation in molecular tumbling 
time and (2) the carbohydrate moieties on the outer layer trap water molecules via hydrogen 
bonding, creating a water proton in close proximity with paramagnetic Gd3+ ion, accelerating water 
exchange phenomenon. Both mechanisms are well known to enhance the longitudinal relaxivity 
of gadolinium-based contrast agents and have been successfully adapted into the design of 
commercially used albumin-targeted contrast agent (MS-325).190 Within the cellular construct, a 
similar effect also can be seen when GdL is inserted into the lipid bilayer of naïve RBC as reported 
by Aryal et al.154 The immobilization Gd3+ ions on cell membranes boosts the r1 relaxivity up to 
19.0 mM−1 s−1 (3T MRI scanner).  
To further optimize the contrast enhancement, the packing density of GdL per nanoparticle 
was varied by changing the amount of GdL input (50, 100, 200, and 400 µg GdL per 1 mg PLGA) 
during the paramagnetic polymeric core preparing step. Samples obtained from each formulation 
were concentrated or diluted to achieve the same final Gd3+ concentration ranging from 1.75, 3.5, 
7, and 14 µg/mL. The magnetic properties of these different formulations of RBC-Gd-PLGA were 
investigated at a constant echo time of 10 ms while repetition time (TR) varying from 200 to 6000 
ms. The T1 relaxation times (Table C.2) were obtained and used to calculate r1 relaxivity by 
plotting 1/T1 (s
-1) vs Gd3+ (mM) concentration (Figure 5.4B).  As shown in Figure 5.4C, the r1 
relaxivity increased with the increasing of GdL per nanoparticle until it reached maximum r1 value 
and then significantly dropped down when the amount of GdL per nanoparticle further increased.  
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Figure 5.4 Magnetic properties of RBC-Gd-PLGA at 3T. (A) The phantom image represents 
the effect of RBC coating to the magnetic contrast enhancement of paramagnetic polymeric core. 
(B) T1 longitudinal relaxation rate vs. Gd
3+ concentration measured in a 3 T MRI system at 25 °C. 
(C) r1 relaxation rate (s
−1.mM−1) with different GdL packing density as a function of Gd3+ 
concentration. (D) T1-Weighted MR images of RBC-Gd-PLGA aqueous suspensions with 
different concentrations and packing densities. The T1-weighted MRI phantoms were taken using 
Fast Spin Echo Sequence at 3 T with TR = 400 ms, TE = 10 ms, FA = 90, FOV 256 × 256, and 
slice thickness = 2 mm. 
 
Specifically, r1 relaxivity increased from 7.9 mM
-1.s-1 to 16.7 mM-1.s-1 when the amount of GdL 
per 1 mg PLGA increased from 50 µg to 200 µg. When the amount of GdL per 1 mg PLGA 
increased further to 400µg, the r1 relaxivity dropped down to 15.7 mM
-1.s-1. This phenomenon was 
also depicted by T1-weighted images of different RBC-Gd-PLGA samples with equivalent Gd
3+ 
concentrations as shown in Figure 5.4D; water and Magnevist were used as a control.  The 
D
400 200 100 50 25 Magnevist
Initial GdL input (μg/mg PLGA)
14
7
3.5
1.75
[G
d
3
+
]
(μ
g
/m
L
)
0
25400 200 100 50
Initial GdL input (μg/mg PLGA)
Gd-PLGA
RBC-Gd-PLGA
[Gd3+] (μg/mL)
56 28 14 7 3.5
A B
C
y = 15.762x + 0.2324
R² = 0.987
y = 16.782x + 0.1813
R² = 0.9943
y = 12.252x + 0.0554
R² = 0.9884
y = 7.9997x + 0.0665
R² = 0.9974
0
0.5
1
1.5
2
0 0.025 0.05 0.075 0.1
1
/T
1
(s
-1
)
Concentration (mM) 
400 µg/mg 200 µg/mg
100 µg/mg 50 µg/mg
0
3
6
9
12
15
18
0 50 100 150 200 250 300 350 400
r1
 r
el
ax
iv
it
y
 (
m
M
-1
.s
-1
)
GdL input (µg/mg polymer)
107 
increasing of r1 at lower GdL density range (from 50 to 200 µg/mL) can be attributed to the 
distance-dependent enhancer between two GBCAs. When the distance between two GdLs gets 
closer, the flexibility of individual GdL reduces, hindering the local rotation of GBCA, as a 
consequent, the r1 relaxivity increase. However, with the increasing of GdL input (beyond 200 μg 
GdL per 1 mg polymer), the GdL packing density on the surface of PNP are possibly jammed, 
limiting the access of H2O molecules to the inner coordination sphere of Gd
3+. At this point, the 
contribution of local rotation is no longer a predominant factor instead of the number of inner 
coordination sphere H2O molecules take over the mechanism of proton spin relaxivity. As a result, 
a significant reduction (or quenching effect) was observed when the amount of GdL per 1 mg 
polymer increase up to 400 μg. A similar relaxivity pattern was reported in a previous publication 
conducted by Marangoni et al, in which the Gd3+ ions were embedded in the silica layer of gold 
nanoshell particles.156 Even though the GBCA in previous study is located in different  
compartments of the  nanoconstruct compared to that of our study, the magnetic properties 
exhibited similar pattern in which the r1 relaxivity increased from 8 to 14.6 mM
-1.s-1, and then 
decrease to 5.3 mM-1.s-1 when the Gd(III) ion per nanoparticle varies from 0.7 × 105 to 2.5 × 105 
and further increase to 8.2 × 105.156  
Unlike other imaging modality, the contrast agent used in MRI does not directly emit a 
signal for detection but rather influencing the microenvironment surrounding it to shorten the 
relaxation time of proton spin. The magnitude of this effect strongly depends on chemical 
properties and structural complexity when the contrast agent is incorporated into a nanoparticulate 
system.157,159,191 In the case of GBCA, the presence of paramagnetic ion will mainly increase the 
longitudinal relaxation rate (1/T1) of water. According to Solomon-Bloembergen-Morgan (SBM) 
and outer sphere quantum mechanical theory, this enhancement of relaxivity is governed by 
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rotational correlation time, the distance between metal-water hydrogen, number of coordinated 
water molecules, the exchange rate of a water molecule from inner sphere to outer sphere, and 
water residence time. Therefore, by infusing GdL onto the surface of cell membrane coated PNP, 
we could simultaneously slow down rotational correlation time, shorten the distance between the 
paramagnetic ion and water hydrogen, prolong water residence time, and enrich the number of 
water molecules nearby metal ion. The combination of these effects together with an optimal 
packing density of Gd3+ generated by our nanoconstruct leads to the significant increase in 
observed r1 relaxivity.  
 
Figure 5.5. In vitro macrophage uptake study. (A) Representative confocal images showing 
comparative macrophages uptake of PEGylated, PLGA, and RBC-Gd-PLGA NPs after 0.5, 1.5, 3, 
and 6hr incubations. (B) Fluorescent quantification of cellular uptake by measuring corrected total 
cell fluorescent intensity of the cell population for each treatment and group. The data were 
statistically analyzed using one-way ANOVA with Turkey’s multiple comparison post-test. (n = 
~50 cells, mean ± sd). ns = not significant, *p < 0.05, ** p < 0.01, *** p < 0.001) 
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After getting the confirmation of magnetic relaxivity, we moved forward to study the 
interaction of RBC-Gd-PLGA with an immune cell. The capability of preserving CD47 from RBC, 
as evident in western blot, signifies the RBC-Gd-PLGA’s ability for immune evasion by inhibiting 
phagocytosis via signal regulatory protein alpha (SIRPα) expressed by macrophages.187,192,193 To 
confirm the ability to escape from macrophage phagocytosis of RBC-Gd-PLGA, we labeled the 
nanoparticle with RhB fluorescent dye and incubate with macrophage cell (J774.A1) over a period. 
We included RhB labeled PEGylated PLGA NPs, bare PLGA, and cell without treatment as 
positive and negative controls. After each incubation time, an excess amount of nanoparticles were 
washed out; cells were fixed and imaged under a confocal microscope. As can be seen in Figure 
5.5A, PLGA NPs were immediately taken up by cells indicated by the high fluorescent signal at 
30 min of incubation, whereas the PEGylated NPs and RBC-Gd-PLGA NPs showed minimal 
cellular uptake. The corrected total cell fluorescence revealed that at 30 min of incubation, the 
fluorescence intensity of cell treated with PLGA was two and four times higher than that of 
PEGylated NPs and RBC-Gd-PLGA NPs, respectively (Figure 5.5B). The high cell fluorescent 
signal at the early incubation time point of PLGA NPs is due to the lack of stability in serum condition 
(Figure 5.1E), whereby they immediately aggregate and trigger macrophage uptake. We also observed 
the decrease in fluorescent signal of cell treated PLGA NPs at a later time point which probably 
attributed to the degradation of PLGA NPs intracellularly (Figure 5.5B). Similarly, as the incubation 
time increase, PEGylated NPs started to lose its immune evasion ability leading to the significant 
increase in cellular uptake. At 6 hour time point, cell treated with PEGylated NPs exhibited the 
highest fluorescent signal intensity indicating the acceleration in macrophage phagocytosis. 
PEGylation has been routinely used to provide the stealth effect for nanoparticle in biological 
condition by reducing protein adsorption on nanocarrier surfaces. However, after a long time being 
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exposed to the biological condition, polyethylene glycol shield fails to prevent the adherent of 
proteins, making nanoparticle become visible to phagocytic cells and leading to the increase in 
cellular uptake over time as found in our result. A similar phenomenon was also observed in vitro, in 
vivo and even clinical trials.194–196 On the other hand, the macrophage treated with RBC-Gd-PLGA 
showed the lowest fluorescent intensity with minimal change throughout the incubation time course, 
suggesting the superior stability and successful immune evasion of our nanomaterial.   
When endogenous-derived materials such as cell membranes are used in in vivo, questions 
about the effect of these materials on the immune system are always of major concern. Among 
different immunogenicity stimulated by NPs, the release of pro-inflammatory cytokines play an 
important role owing to their ability to mediating the innate immune system to promote 
inflammation.197 As RBC-Gd-PLGA was designed to serve as a blood pool contrast agent that can 
circulate for a long time in the body, the probability of RBC-Gd-PLGA to be in contact with blood 
pool cell is also increasing. Therefore, we carefully evaluated the immunomodulatory potential of 
our RBC-Gd-PLGA NPs by incubating with human peripheral blood monocyte cells, THP-1. The 
cytokines released in the cell culture supernatant were analyzed by magnetic human cytokine 
multiplex assays kit to quantify the amount of IL-1b, IL-6, and TNF-a cytokines (Figure 5.6). 
These cytokines are often used to predict the immunomodulatory effects of nanomaterials and the 
possibility of inflammation-mediated toxicity.197 After 24 hour of incubation, the detected amount 
of IL-1b, IL-6, and TNF-a cytokines released by THP-1 cell treated with RBC-Gd-PLGA were in 
the same level with control cell (without treatment) and control materials (RBC-M, PLGA, and 
GdL). On the other hand, there was a significantly high amount of cytokines released when the 
cell was treated with 5μg/mL lipopolysaccharides (LPS, positive control). The data indicate that 
the RBC-Gd-PLGA NPs does not interfere with the regular function of monocytes. 
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Figure 5.6. In vitro biocompatibility studies. Immunogenicity assessment of RBC-Gd-PLGA in 
THP-1 cells after 24 h incubation. The immunostimulant effect of RBC-Gd-PLGA was monitored 
by quantitative determination of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in THP-1 
cells. Lipopolysaccharides (5μg/mL) were used as a positive control.  
 
After validating the in vitro biocompatibility, the potential of NPs for in vivo imaging was 
assessed. We first started with pharmacokinetic and biodistribution using NU/NU mice to gain an 
understanding how RBC-Gd-PLGA moved and distributed throughout the body. Magnevist, a 
widely used gadolinium-based contrast agent, was used as a control. Taking the advantages of the 
natural absence of Gadolinium, we used Gd3+ in RBC-Gd-PLGA as a handle for analysis. As 
shown in Figure 5.7A, Magnevist was rapidly clear out from the blood with just 2% injected dose 
remained in the plasma after 2 hr post-injection. In contrast, with the biomimicry design, RBC-
Gd-PLGA displayed a much longer circulation time. A two-compartmental model was applied to 
assess the pharmacokinetic parameters (Table C.3. RBC-Gd-PLGA exhibited a circulation half-
life of 11.6 hr, which is much longer than that of commercially available contrast agents (Table 
C.3). The natural logarithmic scale with linear components for RBC-Gd-PLGA plasma 
concentration depicted by 2 main phases, a short distribution phase with t
1/2α
=3.12 h and a long 
elimination t
1/2β
=11.6 h (Figure 5.7A inset and Table C.3). The volume distribution of RBC-Gd-
PLGA at steady state (Vdss) was found to be 2.78 mL which is similar to the volume of blood in a 
mouse (2-3 mL). The similarity between Vdss
 and plasma volume suggest that the RBC-Gd-PLGA 
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mainly stays in the circulation system and poorly distributed in the tissue compartment. After 12 
hr of circulation, RBC-Gd-PLGA gradually cleared out from the body with the clearance rate 
(Cltotal) of 0.21 mL per hour. With the extension in circulation time, the RBC-Gd-PLGA was still 
a presence in tissues after 24hr of injection (Figure 5.7B).  RBC-Gd-PLGA mainly resided in liver 
and spleen along with minimal accumulation in lungs, bone and kidneys. Considering that liver 
and spleen are highly vascularized organs and the blood perfusion was not performed due to the 
restriction of IACUC protocol, the high amount of RBC-Gd-PLGA in liver and spleen is attributed 
for nanoparticle concentration presence in both tissue and blood vessels within the organ. In 
contrast to RBC-Gd-PLGA, Magnevist was completely cleared out from the body after 24 hours 
with less than 0.1% injected dose was found in most organs. The significant small amount of 
Magnevist in all tissue is also in agreement with our circulation half-life data in which the amount 
of Magnevist in blood was just 0.7% injected dose at 24 hrs time point. Importantly, the 
distribution data revealed that the kidney was the main organ for Magnevist to accumulate and 
eliminate whereas accumulation of RBC-Gd-PLGA in the kidney was significantly smaller than 
that of other organs. The high accumulation of Magnevist in kidney increases the risk of 
nephrogenic systemic fibrosis as it has been well documented when Gadolinium-based contrast 
agents are used in the clinic. Therefore, by constructing the gadolinium in a macrocyclic chelator 
and tuning the route of elimination from kidney to another excretion organ such as liver and spleen, 
we could avoid the side effect caused by the release of free Gd 3+ in renal impaired patient thereby 
enhancing in vivo safety profile of RBC-Gd-PLGA.   
113 
 
Figure 5.7 In vivo pharmacokinetics and magnetic resonance imaging studies. (A) Circulation 
half-life of RBC-Gd-PLGA and Magnevist in NU/NU mice over 72 h time (n=5). (B) 
Biodistribution profile of RBC-Gd-PLGA and Magnevist after single intravenous tail-vein 
injection in mice (n=4).  
 
Finally, we conducted in vivo vascular imaging with RBC-Gd-PLGA using mice. RBC-Gd-PLGA 
0.01 mmol Gd3+/kg was injected intravenously via tail vein. Images were acquired precontrast and 
immediately at injection, 15 mins, and 30 mins post injection under a 3T clinical scanner. 
Similarly, another set of the mouse was dedicated for Magnevist contrast agent as control using 
the same experimental parameters. A side by side comparison of 3D reconstruction of images 
acquired at injection using maximum intensity projection with pre and post contrast subtraction is 
presented in Figure 5.8A. In the case of clinical contrast agent, Magnevist was quickly extravasate 
into surrounding tissue with most of the MR enhanced signal was localized throughout the kidney. 
Meanwhile, the RBC-GD-PLGA treated mouse exhibit the MR signal enhancement confined 
within abdominal aorta with the ability to delineate carotid arteries and superficial blood vessels 
of the head including anterior facial, posterior facial, transverse facial, and superficial temporal 
veins. Most importantly, the mouse treated RBC-Gd-PLGA exhibit a significantly higher contrast 
in heart and blood vessels when compared to that of Magnevist treated mouse while the Gd3+ 
injected a dose of RBC-Gd-PLGA is 2 times smaller than that of Magnevist. After 15 mins post 
injection, the MR signal of Magnevist at heart cannot be visualized anymore while MR signal at 
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Figure 5.8 In vivo time-dependent T1 weighted magnetic resonance image of mice after 
contrast agent injection. (A) 3D reconstruction of images acquired at injection using maximum 
intensity projection with pre and post contrast subtraction. (B) Time-dependent 3D reconstruction 
using maximum intensity projection without post contrast subtraction. 
 
bladder significantly increases as evident in time-dependent 3D reconstruction using maximum 
intensity projection without post contrast subtraction presented in Figure 5.8B. As the circulating 
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time increase, the MR signal at the bladder of a mouse treated with Magnevist continues to increase 
while the MRI signal of the abdominal area completely disappeared. The time-dependent MR 
images obtained from a mouse injected with Magnevist further confirms the rapid renal 
accumulation and elimination of Magnevist. On the other hand, due to the ability to stay within 
the vasculature system, RBC-Gd-PLGA gives a distinguishable contrast between the blood vessel 
and surrounding tissue with the superior long-lasting contrast enhancement observed at heart.  
5.4  Conclusion 
In conclusion, a biomimetic gadolinium-based contrast agent nanoplatform was designed and 
fabricated to provide an excellent T1 contrast enhancement by harnessing biocompatibility and in 
vivo longevity properties of red blood cell. The optimal packing density of GdL on the surface of 
nanoconstruct facilitate the relaxivity enhancement due to the confinement effect leading to the 
increase in local magnetization that water proton experience while maintaining available space for 
water assessment. Meanwhile, the proteins on the RBC membrane serve as water attraction points 
and provide a biological identity to ensure the survival of nanoplatforms in biological condition. 
Given the outstanding MRI performance, stability, biocompatibility, and prolong resident time, 
the use of RBC-Gd-PLGA allow particle tracking in vivo with a significant reduction in Gd3+ 
concentration, thereby providing a safer and more effective way for medical imaging. In addition, 
with the facile chemistry of polymer core could offer new opportunities for additional 
functionalization and drug loading, RBC-Gd-PLGA has potential applications as multifunctional 
agents for both diagnosis and treatment. 
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Chapter 6 - Summary and Future Outlook 
Nanoparticle (NP)-based therapeutics involve the ability to engineer novel nanoscale 
platforms that can combine different functionalities in a single setting such as targeting, therapy, 
and diagnosis. In this dissertation, two approaches have been put forth, viz. chemistry and biology, 
to engineer different nanoconstructs with an ability to deliver drug and/or contrast agent to cancer.  
In the chemistry, various conjugations including small molecules, ligand binding, and 
isolation and detection were used to assemble the component of the nanoparticulate system. 
Similarly, in the biological approach, characteristic properties of cell membranes such as signature 
protein markers were isolated and hybridized with synthetic components to engineer biomimetic 
nanoconstructs. Engineered biomimetic nanoconstructs were extensively studied and evaluated for 
their biological functions. 
While the extensively researched synthetic nanoparticles in literature offer the opportunity 
for targeted drug delivery to cancer, the major challenges include rapid systemic elimination, 
protein opsonization, cellular degradation, toxicity, and non-specific uptake, limit the therapeutic 
effectiveness. Similarly, cell-based drug delivery systems, where the cell is used as a delivery 
vehicle, have also been studied widely with the hope that natural properties of the cell could be 
utilized for targeted drug delivery. However, the stress due to the payload in the vehicle cell and 
its survival due to toxic payloads remain major concerns. The aim of this dissertation is to take 
advantages of synthetic and biological systems to overcome their respective shortcomings to study 
the nanoparticle design parameters and drug delivery potentials. 
The major advantage of the nanoconstructs presented herein are their abilities to stealth 
(nanoconstructs present in Chapter 2 to 5) and communicate with endogenous cells 
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(nanoconstructs present in Chapter 4 and 5). Due to the unique surface properties acquired from 
cells, for example, immune cells, diseased sites are recognized while preventing rapid elimination 
and nonspecific distribution of the active agent to a wide range of tissues and organs. While 
promising data were obtained indicating the opportunities of these nanoconstructs, challenges from 
design consideration to the practical application still require further investigations such as organ-
specific toxicity, immunogenicity, and therapeutic effectiveness, which are out of the scope of this 
dissertation. Finally, broad vision contributing to the process of transforming the nanocarriers from 
“bench to bedside” should be taken into account from the beginning stage of the development, 
these include feasible manufacture processes, large-scale synthesis, and fulfillment of the clinical 
requirements.  
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Figure A.1 Synthesis scheme of ALE conjugate lipid reaction along with 1HNMR of ALE-Lipid 
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Figure A.2. Physicochemical properties of superparamagnetic iron oxide nanoparticles 
(SPIONs). (A) Dynamic light scattering showing size distribution of SPIONs. (B) Transmission 
electron micrograph showing morphology of SPIONs.  
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Table A.1 Physicochemical properties of HNCs with different SPIONs input (n=6) and 
SPIONs loaded control PEGylated NPs 
 
 
 
 
 
  
Amount of SPIONs input 
(µg/mL)
10 25 50 100 150
SPION loaded 
PEGylated NPs
Hydrodynamic size (nm) 80.5 ± 6.1 82.8 ± 5.2 79.9 ± 4.5 82.5 ± 8 83.4 ± 3.2 86.8 ± 3.8
PDI 0.214 ± 0.122 0.266 ± 0.166 0.270 ± 0.071 0.214 ± 0.034 0.282 ± 0.101 0.146 ± 6  
PDI width (nm) 33.7 ± 7.1 32.71 ± 4.3 40.5 ± 5 37.4 ± 2.3 39.5 ± 5.9 33.2 ± 6
Zeta potential (mV) -35.3 ± 0.68 -36.4 ± 1.01 -34.6 ± 0.52 -33.4 ± 0.95 -34.9 ± 1.2 -49.9 ± 5.7
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Figure A.3. Stability of different formulation of HNC in ionic condition (PBS)   
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Figure A.4. MR decay curve of 4 different kinds of SPIOs nanocluster at 0.1, 2, and 0.5 mM 
measured at TR=1500 ms. Water was used as control 
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Figure A.5. Confocal images of K7M2 cells incubated with RhB labeled HNC for 3h, at 37ºC. 
The cell nuclei were stained by DAPI (blue).  
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Figure A.6. Cellular uptake of HNC quantified by ICP-MS. PEGylated NPs were used as control 
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Figure A.7. (A) Ex vivo MR images of tumor bearing mouse at different z-plane after IV injection 
of SPIONs loaded PEGylated NPs (control NPs). (B) Histogram of signal intensity distribution 
obtained from ImageJ indicating that HNC produces darker contrast than SPIONs loaded 
PEGylated NPs. 
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Appendix B - Supporting information of Chapter 4 
 
Figure B.1 Confocal laser scanning micrograph of cellular uptake of BNc in MCF-7 cells after 
3h of incubation, immunostained with FITC-anti-CD 56. 
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Figure B.2 Ex vivo MRI images of MCF-7 tumor bearing mouse. 
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Mathematical analysis and description of method 
Here, transfer rate constants 𝑘23 and 𝑘32 illustrate the reversible transfer of nanodrug between two 
compartments. We can write the kinematic equations in the following form 
1
𝑉2
 
𝑑𝐶2
𝑑𝑡
=
−𝑘23𝐶2
𝑉2
+
𝑘32𝐶3
𝑉3
−
𝑘𝑒𝑙𝐶2
𝑉2
 
1
𝑉3
 
𝑑𝐶3
𝑑𝑡
=
−𝑘32𝐶3
𝑉3
+
𝑘23𝐶2
𝑉2
 
(1) 
 
where 𝐶2 is the concentration of nanodrug in compartment 2 (blood compartment), 𝐶3 is the 
concentration of nanodrug in compartment 3 (tissue), and 𝑉2 and 𝑉3 are the volumes of 
compartment two and three, respectively. At time 𝑡 = 0, we have the following boundary 
conditions for the above equations 
𝐶2 =
𝐷𝑜𝑠𝑒
𝑉2
            and           𝐶3 = 0 
After solving model (1), it follows that 
𝐶2 =
𝐷𝑜𝑠𝑒
𝑉2(𝐵 − 𝐴)
[(𝑘32 − 𝐴)𝑒
−𝐴𝑡 − (𝑘32 − 𝐵)𝑒
−𝐵𝑡] 
𝐶3 =
𝐷𝑜𝑠𝑒 𝑘23
𝑉2(𝐴 − 𝐵)
[𝑒−𝐵𝑡 − 𝑒−𝐴𝑡] 
where  
𝐴 =
1
2
[(𝑘23 + 𝑘32 + 𝑘𝑒𝑙) − (√(𝑘23 + 𝑘32 − 𝑘𝑒𝑙)2 − 4𝑘32𝑘𝑒𝑙)] 
𝐵 =
1
2
[(𝑘23 + 𝑘32 + 𝑘𝑒𝑙) + (√(𝑘23 + 𝑘32 − 𝑘𝑒𝑙)2 − 4𝑘32𝑘𝑒𝑙)] 
𝐴 and 𝐵 are first-order constants for the rapid distribution phase and slow elimination phase, 
respectively, which depend upon constant rates 𝑘23, 𝑘32 and 𝑘𝑒𝑙 and 𝐷𝑜𝑠𝑒 defines i.v. bolus dose. 
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One may write the following mathematical relationships between the constants 𝐴 and 𝐵 and 
transfer rate constants 𝑘23 , 𝑘32 and 𝑘𝑒𝑙 , 
𝐴 + 𝐵 = 𝑘23 + 𝑘32 + 𝑘𝑒𝑙 
𝐴𝐵 = 𝑘32𝑘𝑒𝑙 
To find the transfer rate constants for bicompartmental model (1), we suppose that the 
concentration of drug in second compartment follows the subsequent form 
𝐶2 = Distribution +  Elimination 
As a result, we have 
𝐶2 = 𝛼𝑒
−𝐴𝑡 + 𝛽𝑒−𝐵𝑡 
where, 𝛼 and 𝛽 are the constants for two exponential terms related to distribution and elimination, 
respectively. In this case, as the initial decline due to the distribution is faster than the final decline 
due to the elimination of drug, we set the first term to zero. We the have 
𝐶2 = 𝛽𝑒
−𝐵𝑡 
Transferring it into a natural logarithm format gives 
log 𝐶2 = log 𝛽 −  𝐵𝑡 
We can then estimate the pharmacokinetic parameters, 𝑘23 , 𝑘32 and 𝑘𝑒𝑙. 
From above we can easily find the biological half-time for the slop of the terminal phase 𝐵 
𝑡1
2
=
log (2)
𝐵
 
which is the duration of action of a drug losing half of its concentration for pharmacologic or 
physiologic activity. Plasma half-life of elimination or half-life of the terminal phase is presented 
as a pharmacokinetic parameter even more than other pharmacokinetic parameters [1]. Needless 
to say, defining half-life in units of time is of great advantage for this parameter. Based on different 
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studies, the clearance is the most important pharmacokinetic parameter while it has the units of 
flow, which is difficult to conceive [2].  
We cannot use the half-life for the persistence of drug in body which is why it is required to 
estimate the mean residence time (MRT) [3]. The residence time of each drug molecule in body is 
different from another. Some molecules have longer residence time than others. MRT may be 
calculated by the integration of total residence time of molecules in the body divided by the number 
of molecules [4].  
𝑀𝑅𝑇 =
∑ 𝑄𝑖 ∗ 𝑡𝑖
∑ 𝑄𝑖
 
where, 𝑡𝑖 is the residence time for molecules and 𝑄𝑖 is the number of molecules. As a result, MRT 
provides the average time for a molecule remaining in the body. As we can assume that each 
molecule that enters the body will eventually leave the body, we substitute the summation of 
molecules with the amount of dose and we then rewrite the denominator of the above formula with 
the following equality: 
∑ 𝑄𝑖 = ∫ 𝑑𝐴(𝑡)
𝐷𝑜𝑠𝑒
0
= 𝐷𝑜𝑠𝑒 
For a drug with a linear kinetic, we can find the average time that a drug molecule spends in the 
body by the following formula: 
𝑀𝑅𝑇 =
∫ 𝑡𝐶(𝑡)𝑑𝑡
∞
0
∫ 𝐶(𝑡)𝑑𝑡
∞
0
=
𝐴𝑈𝑀𝐶
𝐴𝑈𝐶
 
where 𝐴𝑈𝑀𝐶 is the area under the moment curve and 𝐴𝑈𝐶 is the area under the curve. In 
mathematical perspective, the following relations is used to find 𝐴𝑈𝑀𝐶 and 𝐴𝑈𝐶: 
𝐴𝑈𝑀𝐶 = ∫ 𝑡𝐶(𝑡)𝑑𝑡
∞
0
          and          𝐴𝑈𝐶 = ∫ 𝐶(𝑡)𝑑𝑡
∞
0
 
In general, if we consider Bolus IV injection for drug administration we can write  
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𝐶(𝑡) = 𝑝1𝑒
−𝑞1𝑡 + 𝑝2𝑒
−𝑞2𝑡 + ⋯ + 𝑝𝑛𝑒
−𝑞𝑛𝑡 
where 𝐶(0) = 𝑝1 + 𝑝2 + ⋯ + 𝑝𝑛. According to the above formulas for area, it follows that: 
𝐴𝑈𝑀𝐶 = ∫ 𝑡𝐶(𝑡)𝑑𝑡
∞
0
=
𝑝1
𝑞12
 + ⋯ +
𝑝𝑛
𝑞𝑛2
 
𝐴𝑈𝐶 = ∫ 𝐶(𝑡)𝑑𝑡
∞
0
=
𝑝1
𝑞1
 + ⋯ +
𝑝𝑛
𝑞𝑛
 
As a result, the mean residence time is given bye 
𝑀𝑅𝑇 =
𝐴𝑈𝑀𝐶
𝐴𝑈𝐶
=
𝑝1
𝑞12
 + ⋯ +
𝑝𝑛
𝑞𝑛2
𝑝1
𝑞1
 + ⋯ +
𝑝𝑛
𝑞𝑛
 
Therefore, to calculate mean residence time, we should calculate the above ratio. 
Clearance is another important concept that is required calculating [5]. The clearance is used to 
evaluation of the process of drug elimination by the all organs or by an individual organ. In general, 
liver metabolism and or excretion by kidney are two factors which have important roles in the drug 
elimination. The clearance is the most important pharmacokinetic parameter as it is the only way 
to understand the average drug concentration after IV injection of a given dose [6]. To find the 
plasma clearance, we used the following formula that is based on the relation between the rate of 
elimination and volume of distribution: 
Clearance = 𝐶𝑙 = 𝑉𝑑 𝐾𝑒 
where 𝑉𝑑 is the volume of distribution and 𝐾𝑒 is the rate of elimination. To better illustration, 𝑉𝑑 
is a known pharmacokinetic parameter that relates the amount of drug in the body or organ for a 
given dose to the concentration of drug measured in the biological fluid [7]. As a result, 𝑉𝑑 may 
be rewritten in terms of the administrated dose and concentration by the following form, 
𝑉𝑑 =
𝐷𝑜𝑠𝑒
𝐶
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where 𝐷𝑜𝑠𝑒 is the given dose and 𝐶 is the concentration of drug in the body or each organ. The 
rate of elimination, 𝐾𝑒, can be also defined based on the following formula 
𝐾𝑒 = 𝐵 =
ln (2)
𝑡1
2
 
Main results 
Bicompartmental model (1) provides a useful in vitro model to study drug absorption, distribution 
and elimination in blood, tumor and tissue.  We simulated the process of drug distribution and 
elimination from blood to tissue and conversely from tissue to circulation system. According to 
pharmacokinetics and biodistribution of PLG-NK and NKsomes, we calculated the half-life, 𝐴𝑈𝐶, 
𝑉𝑑 , 𝐶𝑙 and 𝑀𝑅𝑇 from 0 to 48h. Table B.1 shows the 95% confidence interval with the mean for 
each parameter using the following quanitity 
?̅? ± 𝑘∗ ×
SEM
√𝑛 
  
where ?̅? represents the mean value, 𝑘∗ denotes the multiplier number, SEM shows the standard 
error of the mean, and 𝑛 is the sample size. 𝐴𝑈𝐶 is calculated using the numerical integration 
technique called Newton-Cotes formula (Butt, 2009) applied to the Composite Simpson’s rule of 
radioactivity concentrations (%ID/ml blood) versus time curve from 0 to 48h and extrapolation 
from 48h to infinity.  
One-way analysis of variance (ANOVA) was used to assess statistically significant differences 
(p<0.05) between the tissue and tumor biodistributions. Using the ANOVA test, we compare the 
means of tissue and tumor biodistributions for the same drug distribution in each organ using the 
F- test.  
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Table B.1 Parameters of pharmacokinetics and biodistribution of PLG-NK NPs. 
Formulation 
𝒕𝟏
𝟐
(𝒉) 𝐀𝐔𝐂𝐨−∞(%ID.h/mL) Vd Cl(mL/h) MRT(h) 
PLG-NK 9.51 1068.8 3.85 0.28 13.61 
 
We used a bicompartmental pharmacokinetic model to study drug disposition in each organ. 
According to the data collected at different time points with three replications, and via the 
equations governing on the concentration of second compartment (blood compartment), we fitted 
our experimental data to bicompartmental model (1) in Supporting Figure B.3. Experimental data 
was quantitatively analyzed using several Toolboxes in MATLAB® 2017a such as Statistics and 
Machine Learning Toolbox, Global Optimization and Curve Fitting. Using these Toolboxes, we 
were able to estimate the goodness-of-fit statistics in this structure with scale (Normalize) and 
robust fitting options.  In Supporting Figure B.3, the red dots with error-bars represent the 
biodistribution of NPs over the course of distribution and blue solid curves show the model fit 
using equation (1).   
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Figure B.3 Model fit to the percentage injected dose using two compartmental model for 
PLGA-NK. 
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Appendix C - Supporting information of Chapter 5 
 
 
Figure C.1 Synthesis of DSPE-DOTA-Gd and its corresponding molecular analysis  
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Figure C.2 Optimize coating RBC coating condition based on RBC membrane protein 
concentration  
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Figure C.3 Stability of RBC-PLGA and RBC-Gd-PLGA under physiological condition (pH 
7.4) 
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Figure C.4 TEM analysis for core diameter and shell thickness of RBC-Gd-PLGA  
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Figure C.5 Stability of RBC-PLGA and RBC-Gd-PLGA under physiological condition (pH 
7.4) 
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Table C.1 In vitro macrophage uptake study of PEGylated, PLGA and RBC-Gd-PLGA NPs 
after 0.5, 1.5, 3, and 6hr incubations analyzed using one-way ANOVA with Turkey’s multiple 
comparison post-test  
 
Incubation 
time 
Tukey's Multiple Comparison 
Test 
Mean 
Diff. 
q 
Significant 
(P < 0.05) 
95% CI of 
diff 
0.5 hr 
PEGylated NPs vs PLGA -3916 15.07 Yes -4789 to -3044 
PEGylated NPs vs RBC-Gd-PLGA 1832 6.632 Yes 905.3 to 2759 
PLGA vs RBC-Gd-PLGA 5749 21.61 Yes 4856 to 6641 
1.5 hr 
PEGylated NPs vs PLGA -3732 13.50 Yes -4660 to -2805 
PEGylated NPs vs RBC-Gd-PLGA 2093 7.841 Yes 1198 to 2989 
PLGA vs RBC-Gd-PLGA 5826 19.09 Yes 4802 to 6849 
3 hr 
PEGylated NPs vs PLGA 446.1 1.250 No -751.5 to 1644 
PEGylated NPs vs RBC-Gd-PLGA 3014 8.475 Yes 1821 to 4208 
PLGA vs RBC-Gd-PLGA 2568 7.755 Yes 1457 to 3679 
6 hr 
PEGylated NPs vs PLGA 3721 7.707 Yes 2101 to 5340 
PEGylated NPs vs RBC-Gd-PLGA 2959 7.089 Yes 1559 to 4360 
PLGA vs RBC-Gd-PLGA -761.2 1.538 No -2421 to 899.0 
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Table C.2 T1 relaxation time of RBC-Gd-PLGA 
Concentration of GdL in sample 
Amount of GdL input 
400ug 200ug 100 ug 50 ug 
Water 4083.12 4083.12 4083.12 4083.12 
12.5 μg 2164.39 1820.79 5080.49 8681.91 
25 μg 1727.13 1306.24 3851.96 5075.60 
50 μg 1163.18 663.99 2257.88 3391.79 
100 μg 571.43 200.62 1051.05 1757.09 
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Figure C.6 Plasma RBC-Gd-PLGA concentrations in natural logarithmic scale with linear 
components of a two-compartment model after an intravenous bolus dose. 
 
  
Central Peripheral
Bolus IV
k12
k21
k10
y = -0.1308x + 2.043
R² = 0.9927
y = -0.0602x + 1.0944
R² = 0.9815
y = -0.2124x + 1.5615
R² = 0.9833
-4
-3
-2
-1
0
1
2
3
0 10 20 30 40 50 60 70 80
ln
(μ
g
/m
L
)
Time (h)
Distribution phase
Elimination phase
Residual line
164 
Table C.3 Pharmacokinetic parameters of RBC-Gd-PLGA calculated based on two 
compartment model using method of residuals. 
Pharmacokinetic parameters Two-compartment model Equations 
Elimination phase 
  
β (h
-1
) 0.06 Slope of red line 
B
0
 
(μg/mL) 3.12 
𝐵0 =
𝐶𝑡
𝑒−𝛽𝑡
 
t
1/2β
 
(h) 11.6 
𝑡1/2𝛽 =
ln (2)
𝛽
=
0.693
𝛽
 
Distribution phase 
  
α (h
-1
) 0.21 Slope for C
p
 (residual)
*
 
A
0
 
(μg/mL) 4.88 
𝐴0 =
𝐶𝑝(𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙)
𝑒−𝛼𝑡
 
t
1/2α
 
(h) 3.27 
𝑡1/2𝛼 =
ln (2)
𝛼
=
0.693
𝛼
 
Concentration at time zero 
  
C
0
 (μg/mL) 8.00 𝐶0 = 𝐴0 + 𝐵0 
Rate constant 
  
k
21
 
(h
-1
) 0.12 𝑘21 =
𝐴 × 𝛽 + 𝐵 × 𝛼
𝐴 + 𝐵
 
k
10
 
(h
-1
) 0.11 𝑘10 =
𝛼 × 𝛽
𝑘21
 
k
10
 
(h
-1
) 0.05 𝑘12 = (𝛼 + 𝛽) − (𝑘21 + 𝑘10) 
Volume of distribution 
  
V
c
 
(mL) 2.00 
𝑉𝑐 =
𝐷
𝐶0
=
𝐷
𝐴0 + 𝐵0
 
V
p
 
(mL) 0.77 
𝑉𝑝 =
𝑉𝑐 × 𝑘12
𝑘21
 
V
dss
 (mL) 2.78  𝑉𝑠𝑠𝑑 = 𝑉𝑝 + 𝑉𝑐 
Area under the curve 
  
AUC (µg.h/mL) 75.02 
𝐴𝑈𝐶 =
𝐴
𝛼
+
𝐵
𝛽
 
Clearance total 
  
Cl
total 
(mL/h) 0.21 
𝐶𝑙𝑡𝑜𝑡𝑎𝑙 =
𝐷
𝐴𝑈𝐶
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Appendix D - List of Abbreviation 
Name Abbreviation 
1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide DiR 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl) 
(sodium salt) 
16:0 Succinyl PE 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine DSPE 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (sodium salt) 
DSPE-PEG-COOH 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride EDC 
2-(N-morpholino)ethanesulfonic acid MES 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide MTT 
4′,6-diamidino-2-phenylindole DAPI 
Alendronic acid ALE 
Alendronic acid conjugated lipid ALE-lipid 
Alpha Minimum Essential Medium α-MEM 
Analysis of variance ANOVA 
Area under the curve AUC 
Bicinchoninic acid assay BCA 
Biomimetic nanoconstruct BNc 
Carbon dioxide CO2 
Chromium Cr 
Circulation half-life t1/2 
Clearance CLSM 
Coefficient factor R2 
Computed Tomography CT 
Confocal Laser Scanning Microscope CLSM 
Contrast-enhanced magnetic resonance imaging ceMRI 
Deterium oxide D2O 
Deuterated chloroform CDCl3 
Dimethyl sulfoxide DMSO 
Doxorubicin DOX 
Dulbecco's Modified Eagle Medium DMEM 
Dynamic Light Scattering DLS 
Echo time TE 
Elimination rate Kel 
Enhanced Permeability and Retention effect EPR effect 
Fast slow angle shot FLASH 
Fetal bovine serum FBS 
Field of view FOV 
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Fluorescein isothiocyanate FITC 
Fluorescence resonance energy transfer FRET 
Fluorescence-activated cell sorting FACS 
Food and Drug Administration FDA 
Fourier-transform infrared spectroscopy FT-IR 
Gadobenate dimeglumine Gd-BOPTA 
Gadofosveset trisodium MS325 
Gadolinium Gd 
Gadolinium (III) acetate hydrate Gd(OAc)3 
Gadolinium based contrast agent GBCA 
Gadolinium lipid Gd-lipid or Gd-L 
Gadopentetate dimeglumine Gd-DTPA 
Gadoxetic acid disodium Gd-EOB-DTPA 
Glyceraldehyde 3-phosphate dehydrogenase GAPDH 
Glycophorin A GPA 
Half maximal inhibitory concentration IC50 
Hematoxylin and eosin H&E 
Horseradish peroxidase HPR 
Hybrid nanoconstruct HNC 
Hydrocloric acid HCl 
Hydroxyapatite Hap 
Immunoglobulin G IgG 
Inductively coupled plasma mass spectrometry ICP-MS 
Injected dose ID 
Institutional Animal Care and Use Committee IACUC 
Institutional Biosafety Committee IBC 
Interleukin IL 
Iron Fe 
Limit of detection LOD 
Lipopolysaccharides LPS 
Longitudinal relaxation time T1 
Longitudinal relaxivity r1 
L-α-Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) 
(Ammonium Salt) (Egg-Transphosphatidylated, Chicken) 
Egg Liss Rhod PE 
Magnetic Resonance MR 
Magnetic Resonance Imaging MRI 
Manganese Mn 
Mean resident time MRT 
Molecular weight Mw 
Molecular weight cut off MWCO 
Mononuclear phagocyte system MPS 
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Nanoparticle NP 
Natural killer cell NK cell 
Natural killer cell membrane NKM 
Near-infrared NIR 
Nephrogenic systemic fibrosis NSF 
N-hydroxysuccinimide NHS 
N-Hydroxysuccinimidyl ester activated 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTA-NHS 
Nitric acid HNO3 
Phosphate buffered saline PBS 
Poly(lactic-co-glycolic acid) PLGA 
Polydispersity index PDI 
Polyethylene glycol PEG 
Polyethylene glycolated PEGylated 
Positron Emission Tomography PET 
Pressure of oxygen pO2 
Proton nuclear magnetic resonance H-NMR 
Receptor activator of nuclear factor κB RANK 
Receptor activator of nuclear factor κB ligand RANKL 
Red blood cell RBC 
Red blood cell membrane RBC-M 
Red blood cell membrane coated paramagnetic polymeric 
nanoparticles 
RBC-Gd-PLGA NPs 
Repetition time TR 
Reticuloendothelial system RES 
Rhodamine dye RhB 
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis SDS-PAGE 
Superparamagnetic iron oxide nanoparticle SPION 
Targeted nanoparticle TNP 
Transmission Electron Micrograph TEM 
Transverse relaxation time T2 
Transverse relaxivity r2 
Triethylamine TEA 
Tris-buffered saline with Tween 20 TBST 
Tumor Necrosis Factor TNF 
Tumor to blood T/B 
Type I transforming growth factor (TGF)-β receptor TβR-I 
Ultraviolet–visible spectroscopy UV-Vis 
United State of America USA 
Volume of distribution Vd 
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TERMS AND CONDITIONS 
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. 
or one of its group companies (each a"Wiley Company") or handled on behalf of a society 
with which a Wiley Company has exclusive publishing rights in relation to a particular work 
(collectively "WILEY"). By clicking "accept" in connection with completing this licensing 
transaction, you agree that the following terms and conditions apply to this transaction (along 
with the billing and payment terms and conditions established by the Copyright Clearance 
Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened 
your RightsLink account (these are available at any time at    
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Terms and Conditions 
 The materials you have requested permission to reproduce or reuse (the "Wiley 
Materials") are protected by copyright.  
 You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-
alone basis), non-transferable, worldwide, limited license to reproduce the Wiley 
Materials for the purpose specified in the licensing process. This license, and any 
CONTENT (PDF or image file) purchased as part of your order, is for a one-
time use only and limited to any maximum distribution number specified in the 
license. The first instance of republication or reuse granted by this license must be 
completed within two years of the date of the grant of this license (although copies 
prepared before the end date may be distributed thereafter). The Wiley Materials 
shall not be used in any other manner or for any other purpose, beyond what is 
granted in the license. Permission is granted subject to an appropriate 
acknowledgement given to the author, title of the material/book/journal and the 
publisher. You shall also duplicate the copyright notice that appears in the Wiley 
publication in your use of the Wiley Material. Permission is also granted on the 
understanding that nowhere in the text is a previously published source 
acknowledged for all or part of this Wiley Material. Any third party content is 
expressly excluded from this permission. 
 With respect to the Wiley Materials, all rights are reserved. Except as expressly 
granted by the terms of the license, no part of the Wiley Materials may be copied, 
modified, adapted (except for minor reformatting required by the new Publication), 
translated, reproduced, transferred or distributed, in any form or by any means, and 
no derivative works may be made based on the Wiley Materials without the prior 
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permission of the respective copyright owner.For STM Signatory Publishers 
clearing permission under the terms of the STM Permissions Guidelines only, 
the terms of the license are extended to include subsequent editions and for 
editions in other languages, provided such editions are for the work as a whole 
in situ and does not involve the separate exploitation of the permitted figures or 
extracts,You may not alter, remove or suppress in any manner any copyright, 
trademark or other notices displayed by the Wiley Materials. You may not license, 
rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials 
on a stand-alone basis, or any of the rights granted to you hereunder to any other 
person. 
 The Wiley Materials and all of the intellectual property rights therein shall at all times 
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or 
their respective licensors, and your interest therein is only that of having possession 
of and the right to reproduce the Wiley Materials pursuant to Section 2 herein during 
the continuance of this Agreement. You agree that you own no right, title or interest 
in or to the Wiley Materials or any of the intellectual property rights therein. You 
shall have no rights hereunder other than the license as provided for above in Section 
2. No right, license or interest to any trademark, trade name, service mark or other 
branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree 
that you shall not assert any such right, license or interest with respect thereto 
 NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, 
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS 
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE 
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED 
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY 
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, 
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES 
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED 
BY YOU.  
 WILEY shall have the right to terminate this Agreement immediately upon breach 
of this Agreement by you. 
 You shall indemnify, defend and hold harmless WILEY, its Licensors and their 
respective directors, officers, agents and employees, from and against any actual or 
threatened claims, demands, causes of action or proceedings arising from any breach 
of this Agreement by you. 
 IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR 
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY 
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN 
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR 
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, 
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WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT 
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, 
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND 
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY 
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY 
LIMITED REMEDY PROVIDED HEREIN.  
 Should any provision of this Agreement be held by a court of competent jurisdiction 
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to 
achieve as nearly as possible the same economic effect as the original provision, and 
the legality, validity and enforceability of the remaining provisions of this Agreement 
shall not be affected or impaired thereby.  
 The failure of either party to enforce any term or condition of this Agreement shall 
not constitute a waiver of either party's right to enforce each and every term and 
condition of this Agreement. No breach under this agreement shall be deemed waived 
or excused by either party unless such waiver or consent is in writing signed by the 
party granting such waiver or consent. The waiver by or consent of a party to a breach 
of any provision of this Agreement shall not operate or be construed as a waiver of 
or consent to any other or subsequent breach by such other party.  
 This Agreement may not be assigned (including by operation of law or otherwise) 
by you without WILEY's prior written consent. 
 Any fee required for this permission shall be non-refundable after thirty (30) days 
from receipt by the CCC. 
 These terms and conditions together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between you 
and WILEY concerning this licensing transaction and (in the absence of fraud) 
supersedes all prior agreements and representations of the parties, oral or written. 
This Agreement may not be amended except in writing signed by both parties. This 
Agreement shall be binding upon and inure to the benefit of the parties' successors, 
legal representatives, and authorized assigns.  
 In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC's Billing and Payment terms and conditions, 
these terms and conditions shall prevail. 
 WILEY expressly reserves all rights not specifically granted in the combination of 
(i) the license details provided by you and accepted in the course of this licensing 
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms 
and conditions. 
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 This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process. 
 This Agreement shall be governed by and construed in accordance with the laws of 
the State of New York, USA, without regards to such state's conflict of law rules. 
Any legal action, suit or proceeding arising out of or relating to these Terms and 
Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction of 
such court, waives any objection to venue in such court and consents to service of 
process by registered or certified mail, return receipt requested, at the last known 
address of such party. 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription 
journals offering Online Open. Although most of the fully Open Access journals publish 
open access articles under the terms of the Creative Commons Attribution (CC BY) License 
only, the subscription journals and a few of the Open Access Journals offer a choice of 
Creative Commons Licenses. The license type is clearly identified on the article. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and 
transmit an article, adapt the article and make commercial use of the article. The CC-BY 
license permits commercial and non- 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use, 
distribution and reproduction in any medium, provided the original work is properly cited 
and is not used for commercial purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) 
permits use, distribution and reproduction in any medium, provided the original work is 
properly cited, is not used for commercial purposes and no modifications or adaptations are 
made. (see below) 
Use by commercial "for-profit" organizations 
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Use of Wiley Open Access articles for commercial, promotional, or marketing purposes 
requires further explicit permission from Wiley and will be subject to a fee. 
Further details can be found on Wiley Online Library  
http://olabout.wiley.com/WileyCDA/Section/id-410895.html 
 
